
==== Front
Transl Psychiatry
Transl Psychiatry
Translational Psychiatry
2158-3188
Nature Publishing Group UK London

39231927
3055
10.1038/s41398-024-03055-y
Perspective
Epigenetic mechanisms of rapid-acting antidepressants
http://orcid.org/0000-0002-7261-5659
Inserra Antonio antonio.inserra@mail.mcgill.ca

14
http://orcid.org/0009-0006-8112-3978
Campanale Antonella 1
Rezai Tamim 1
http://orcid.org/0000-0002-3610-2928
Romualdi Patrizia 2
http://orcid.org/0000-0002-3128-6377
Rubino Tiziana 3
1 https://ror.org/01pxwe438 grid.14709.3b 0000 0004 1936 8649 Department of Psychiatry, McGill University, Montreal, QC Canada
2 https://ror.org/01111rn36 grid.6292.f 0000 0004 1757 1758 Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy
3 https://ror.org/00s409261 grid.18147.3b 0000 0001 2172 4807 Department of Biotechnology and Life Sciences and Neuroscience Center, University of Insubria, Varese, Italy
4 grid.412297.b 0000 0001 0648 9933 Present Address: Behavioral Neuroscience Laboratory, University of South Santa Catarina (UNISUL), Tubarão, Brazil., Tubarão, Brazil
4 9 2024
4 9 2024
2024
14 35921 12 2023
19 8 2024
21 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Background

Rapid-acting antidepressants (RAADs), including dissociative anesthetics, psychedelics, and empathogens, elicit rapid and sustained therapeutic improvements in psychiatric disorders by purportedly modulating neuroplasticity, neurotransmission, and immunity. These outcomes may be mediated by, or result in, an acute and/or sustained entrainment of epigenetic processes, which remodel chromatin structure and alter DNA accessibility to regulate gene expression.

Methods

In this perspective, we present an overview of the known mechanisms, knowledge gaps, and future directions surrounding the epigenetic effects of RAADs, with a focus on the regulation of stress-responsive DNA and brain regions, and on the comparison with conventional antidepressants.

Main body

Preliminary correlative evidence indicates that administration of RAADs is accompanied by epigenetic effects which are similar to those elicited by conventional antidepressants. These include changes in DNA methylation, post-translational modifications of histones, and differential regulation of non-coding RNAs in stress-responsive chromatin areas involved in neurotrophism, neurotransmission, and immunomodulation, in stress-responsive brain regions. Whether these epigenetic changes causally contribute to the therapeutic effects of RAADs, are a consequence thereof, or are unrelated, remains unknown. Moreover, the potential cell type-specificity and mechanisms involved are yet to be fully elucidated. Candidate mechanisms include neuronal activity- and serotonin and Tropomyosine Receptor Kinase B (TRKB) signaling-mediated epigenetic changes, and direct interaction with DNA, histones, or chromatin remodeling complexes.

Conclusion

Correlative evidence suggests that epigenetic changes induced by RAADs accompany therapeutic and side effects, although causation, mechanisms, and cell type-specificity remain largely unknown. Addressing these research gaps may lead to the development of novel neuroepigenetics-based precision therapeutics.

Subject terms

Epigenetics and plasticity
Pharmacology
https://doi.org/10.13039/501100007202 Gouvernement du Canada | Instituts de Recherche en Santé du Canada | CIHR Skin Research Training Centre (Skin Research Training Centre) https://doi.org/10.13039/100008240 Fonds de Recherche du Québec-Société et Culture (FRQSC) Quebec Autism Research Training Programissue-copyright-statement© Springer Nature Limited 2024
==== Body
pmcIntroduction

Chromatin is a plastic entity, which adapts to external stimuli such as a changing environment and stress [1, 2]. This feature shapes the endogenous response to a changing environment via long-term modulation of gene expression [3, 4]. Psychosocial stress causes an epigenetic remodeling of stress-responsive DNA and chromatin regions, and associated histone proteins in susceptible brain areas such as the ventral hippocampus [1, 5], amygdala [6], nucleus accumbens (NAc) [7], and the prefrontal cortex (PFC) [8] – dorsal raphe nucleus loop [9–11]. Similarly, and in an opposite fashion, a remodeling of chromatin regions involved with synaptic plasticity, neurotransmission, neurogenesis, and neuroinflammation is required in infralimbic and prelimbic neurons to elicit antidepressant effects [1, 9–13]. Hence, drugs which directly or indirectly affect the epigenetic control of chromatin regions linked to neurotransmission, neurogenesis, and neuroinflammation, represent promising epigenetics-based therapeutics.

Rapid-acting antidepressants (referred herein as RAADs) are being investigated as novel therapeutics in psychiatry [14–16]. These compounds are generally classified as serotonin (5-HT)2A receptor agonists such as psilocybin, lysergic acid diethylamide (LSD), N, N-Dimethyltryptamine (DMT) and 2,5-Dimethoxy-4-iodoamphetamine (DOI) [14]; N-Methyl-D-Aspartate (NMDA) antagonists such as ketamine [17]; and empathogens such as 3,4-methylenedioxymethamphetamine (MDMA), which act mainly through neurotransmitter transporters [18]. The long-term improvements in psychiatric symptoms and neuropsychological function elicited by RAADs [19–24] are accompanied by enduring serotonergic (such as a peripheral increase of serotonin -5-HT- platelets uptake sites in long-term Ayahuasca users) [25], and neuromorphological changes (such as thinner precuneus and posterior cingulate cortex and thicker anterior cingulate cortex in long-term Ayahuasca users) [26], which suggest the entrainment of epigenetic mechanisms.

Preliminary evidence indicates that the therapeutic effects of RAADs, akin to conventional antidepressants, are accompanied by a remodeling of DNA methylation, histone post-translational modifications (PTMs), and non-coding RNAs (ncRNAs) dynamics in stress-responsive brain areas. Interestingly, repeated, binge, or high-dose administration of RAADs elicit side effects mediated by overlapping yet opposite epigenetic mechanisms, such as hippocampal apoptosis, reduced neurotrophic signaling, increased neuroinflammation, and cognitive impairments (see Involvement of Epigenetic Mechanisms in Potential Side Effects Elicited by RAADs). These effects, contrasting with those of clinically relevant doses and resembling stress-induced epigenetic responses, underscore the importance of identifying the optimal dosages and regimens for clinical RAADs applications to maximize desirable epigenetic outcomes and minimize undesirable ones.

Epigenetic Control in Stress-Related Disorders, and the Effects of Conventional and Rapid-Acting Antidepressants

DNA methylation, stress, and rapid-acting antidepressants

DNA methylation consists in the reversible addition of methyl groups to cytosines in CpG dinucleotides by DNA methyltransferases (DNMTs). This modification generally modulates transcription by inhibiting the binding of transcription factors or recruiting proteins involved in gene repression [27]. Stress and psychosocial trauma modulate the methylation status of CpG dinucleotides in DNA sequences involved with the stress response, and synaptic and neuronal plasticity [28–43]. For example, the methylation status of genes encoding the glucocorticoid receptor, arginin-vasopressin, and the brain-derived neurotrophic factor (BDNF) can be modulated by early-life adversities as early as 1 day after birth [28–43] and specific cell types such as astrocytes carryover the epigenetic marks of stress [35, 44]. Epigenetically-active compounds with DNA demethylase activity [45] have antidepressant effects [46, 47], confirming that the methylation state and the associated psychiatric symptoms can be reversed pharmacologically [48]. Stressors also affect the regulation of DNA-methylating enzymes such as DNMT3a and 3b [49] in stress-susceptible brain areas such as the PFC and hippocampus [35, 44, 50]. Therefore, stress exposure is physically “remembered” in specific cell types and brain areas, causing altered gene expression and ultimately lasting effects on behavior. The most studied example of epigenetic programming by stress, and its normalization by antidepressants, is the BDNF gene. Prenatal and life adversities decrease the promoter IV-mediated BDNF expression via increasing its methylation [36, 43, 49, 51–58], and psychiatric disorders largely share increased BDNF promoter methylation, which can be reversed by conventional antidepressants [36, 54–61].

Like conventional antidepressants, but only requiring one or few administrations, ketamine restores some of the stress-induced aberrant DNA methylation, including on the BDNF gene (Fig. 1 and Table 1). Delving into the molecular mechanisms, ketamine induces a Extracellular Signal-Regulated Kinase 1 (ERK1) / nuclear receptor binding protein 1 (NRBP1)-mediated microglial decrease of methyl-CpG binding protein 2 (MeCP2), which upregulates the cAMP response-binding protein (CREB)-mediated BDNF exon IV transcription [62]. The enhancement of fear extinction elicited by ketamine is also accompanied by demethylation of PFC and hippocampal BDNF exon IV, and increased BDNF transcription [49]. Similarly, fluoxetine dissociates the MeCP2–CREB complex from BDNF promoter IV through the protein kinase A (PKA)-mediated phosphorylation of MeCP2, thus increasing BDNF transcription [55]. Resembling chronic imipramine’s effects in the PFC [50], acute ketamine reversed the nerve injury-induced increase in the hippocampal DNMT1, 3a, and 3b. It also restored the decrease in hippocampal total BDNF and BDNF exon I transcription and protein levels [52]. In rodents, chronic fluoxetine, imipramine, and desipramine blunted the stress-induced increase in hippocampal DNA methylation, and restored the decrease elicited in the PFC [50, 63, 64]. Antidepressant use increased the peripheral methylation level of the 5-HT transporter [65], and the interleukin (IL)-6 gene [66], as well as telomerase activity in individuals with PTSD [67]. While it has been speculated that RAADs such as psilocybin might increase telomerase activity and telomere length, this hypothesis remains to be tested [68].Fig. 1 Converging epigenetic mechanisms of rapid-acting and conventional antidepressants.

Abbreviations: 5-HTRs, Serotonin Receptors; SIGMAR1, Sigma-1 Receptor; SERT, Serotonin Transporter; NET, Norepinephrine Transporter; TRKB, Tropomyosin Receptor Kinase B; BDNF, Brain-Derived Neurotrophic Factor; NMDA, N-Methyl-D-Aspartate; PLC, Phospholipase C; IP3, Inositol trisphosphate; DAG, Diacylglycerol; MAPK, Mitogen-Activated Protein Kinase; ERK, Extracellular Signal-Regulated Kinase; PI3K, Phosphoinositide 3-Kinase; Akt, AKT Serine/Threonine Kinase 1; PKC, Protein Kinase C; GSK-3, Glycogen Synthase Kinase 3; NF-kB, Nuclear Factor Kappa-B; CaMKs, Calcium Calmodulin Dependent Protein Kinases; Wnt, Proto-Oncogene Wnt-1; JAK, Janus Kinase; STAT, Signal Transducer and Activator of Transcription; PLCγ, Phospholipase C Gamma 1; SSRI, Selective Serotonin Reuptake Inhibitors; SNRI, Serotonin-Norepinephrine Reuptake Inhibitors; MAOI, Monoamine Oxidase Inhibitors; H3, Histone 3; H4, Histone 4; H3K4, Histone 3 Lysine 4; H3K9, Histone 3 Lysine 9; H3K12, Histone 3 Lysine 12; H3K27, Histone 3 Lysine 27; PKA, Protein Kinase A; Mecp2, Methyl-Cpg Binding Protein 2; CREB, cAMP Response Element-Binding Protein; G9a, Histone Methyltransferase G9a; HDAC, Histone Deacetylase; DNMT, DNA Methyltransferase; lncRNA, Long non-Coding RNA; circRNA, Circular RNA; miRNA, micro RNA; NR3C1, Glucocorticoid Receptor; CRH31, Corticotropin Releasing Hormone; PTSD, Post-Traumatic Stress Disorder; LSD, lysergic acid diethylamide.

Table 1 Effects of rapid-acting antidepressant on DNA methylation, histone post-translational modifications, and ncRNAs.

STUDIES ON THE EPIGENETIC EFFECTS OF KETAMINE IN HUMANS	
Main findings	Significance	Ref.	
The extent of decreases of the lncRNA FEDORA predicts the decrease in depression symptoms severity following a single ketamine administration in female (but not male) individuals with major depressive disorder (MDD)	The lncRNA FEDORA could be used as a marker of therapeutic response to ketamine in individuals who identify as female	[167]	
An infusion of ketamine in individuals with treatment-resistant depression 24 hours after the first administration does not affect whole blood miRNA levels	Ketamine does not affect blood miRNA 24 hours after administration in individuals with treatment-resistant depression. The discrepancy from clinical findings might be due to the relatively small sample size, the fact that the samples were collected 24 hours after the first infusion, or the fact that whole blood was analyzed. Rapid-acting antidepressants might elicit cell type-specific miRNome fingerprints not detectable in whole blood	[162]	
Deceased individuals that tested positive for ketamine have an acceleration in the mitochondrial epigenetic age of the nucleus accumbens and PFC	Ketamine abuse might accelerate the mitochondrial DNA epigenetic age	[216]	
In clinical studies in individuals with neuropathic pain, ketamine differentially modulated miRNAs expression in responders and non-responders. The responder status could be predicted based on the lower pretreatment level of miR-548d-5p, which targets the UGT1A1 (UDP Glucuronosyltransferase Family 1 Member A1) gene	Ketamine elicits miRNA changes in individuals with neuropathic pain. Specific miRNAs could predict the therapeutic response to rapid-acting antidepressants	[160]	
Poor responders to ketamine have considerable downregulation of circulating miR-605. Downregulating miR-605 leads to increased CXCL5 (C-X-C Motif Chemokine Ligand 5), and increased inflammation	miR-605-mediated regulation of CXCL5 predicted the treatment response to ketamine in complex pain regional syndrome	[161]	
STUDIES ON THE EPIGENETIC EFFECTS OF KETAMINE IN ANIMALS	
Studies on the Effects of Ketamine on DNA Methylation in Animals	
Main findings	Significance	Ref.	
Ketamine enhances fear extinction via decreasing the stress-induced hypermethylation of Bdnf (Brain-Derived Neurotrophic Factor) exon IV (involved with traumatic memory extinction). This effect is accompanied by increased exon IV and IX transcription in the medial prefrontal cortex (PFC) and hippocampus	The therapeutic effects of ketamine in post-traumatic stress disorder (PTSD), depression, and suicidality might be mediated at least partially by decreased BDNF promoter methylation leading to increased expression in the PFC and hippocampus	[49]	
Ketamine elicits antidepressant-like effects via activating cAMP Responsive Element Binding Protein 5 (CREB)-mediated BDNF exon VI transcription, putatively in the PFC microglia. Ketamine decreases the levels of methyl-CpG binding protein 2 (MeCP2), a transcriptional repressor of BDNF	The synaptogenic and antidepressant effects of ketamine might be mediated at least partially via the epigenetic regulation of CREB-BDNF exon IV transcription in the PFC microglia	[62]	
Ketamine reverses the increase in chronic pain-induced hippocampal mRNA and protein levels of the DNA methyltransferase (DNMT) 1, 3a, and 3b. Ketamine restores the chronic pain-induced decrease in total BDNF and BDNF exon I transcription and protein level. Ketamine normalizes the pain-induced increase in pro-BDNF mRNA and protein levels	The therapeutic effects of ketamine in chronic pain-induced depressive states might be mediated by a DNMT-mediated restoration of BDNF expression	[52]	
Studies on the Effects of Ketamine on Histone Post-Translational Modifications in Animals	
Main findings	Significance	Ref.	
Ketamine normalizes the stress-induced enhancement of adult nucleus accumbens histone deacetylase (HDAC) activity in a model of early-life stress, similarly to imipramine. Ketamine has no effect on PFC, hippocampal, and amygdalar HDAC activity	The therapeutic effects of ketamine on the pathophysiological sequelae of early-life stress might be partially mediated by a reduction of the stress-induced enhanced accumbal HDAC activity	[7]	
Ketamine enhances HDAC5 phosphorylation at the sites S259 and S498 in a Ca²⁺ /Calmodulin-Dependent Protein Kinase II (CaMKII)- and Polycystic Kidney Disease (PKD)-dependent fashion in hippocampal neurons, leading to the cytoplasmic export of HDAC5, histones H3 and H4 acetylation, Myocyte Enhancer Factor 2 (MEF2)-mediated transcription, and Eukaryotic Translation Initiation Factor 4E Binding Protein (eIF4EBP) and CREB activation. Ketamine elicits a sustained ( > 24 h) increase of HDAC5 phosphorylation in the hippocampus, and a sustained transcriptional modulation of MEF2-target genes (Activity Regulated Cytoskeleton Associated Protein -Arc-, Nuclear Receptor Subfamily 4 Group A Member 1 -Nurr77-, KLF Transcription Factor 6 -Klf6-, and Early Growth response 1 (Egr1). Blocking HDAC5 phosphorylation nullifies the antidepressant-like effects of ketamine	Ketamine-induced, AMPA-mediated enhanced hippocampal HDAC5 phosphorylation upregulates the cytoplasmic export of HDAC5 and this step is required to elicit antidepressant-like effects in rodents	[97]	
Ketamine downregulates the increased HDAC1 and HDAC5 protein expressions in the hippocampus of rats elicited by Diisopropyl Fluorophosphate, and increases BDNF levels and dendritic spine density. Ketamine restores the decreased H3K9 acetylation of the BDNF promoter IV elicited by Diisopropyl Fluorophosphate	Ketamine elicits pro-histone acetylating effects and restores neuroplasticity in a mouse model of Gulf War Illness	[95]	
Ketamine increases hippocampal BDNF promoter IV activity via HDAC5 phosphorylation at S259 and S498		
High-dose ketamine has a prophylactic effect on the stress-induced increase in hippocampal histone H3 lysine 9 (H3K9) methylation	Ketamine and potentially other rapid-acting antidepressants might have prophylactic effects against stress-induced epigenetic changes	[96]	
Studies on the Effects of Ketamine on Non-Coding RNAs in Animals	
Main findings	Significance	Ref.	
Ketamine increases miR-98-5p, but not miR-23a-5p and miR-3968 in the PFC and hippocampus of chronically stressed mice. miR-98-5p inhibition nullifies the antidepressant-like effects of ketamine	miR-98-5p upregulation is required for the antidepressant-like effects of ketamine	[143]	
Ketamine modulates several hippocampal miRNAs, eliciting a decrease in miR-206 and miR-181a-5p (involved in apoptosis), and an increase in miR-132-3p and miR-29a-3p (involved in N-Methyl-D-Aspartate -NMDA- mediated neuronal survival and neurite remodeling).

These effects are accompanied by a dose-dependent increase of BDNF levels in vivo and in vitro, and decreased apoptosis and electrical currents in hippocampal neuronal cultures

	Ketamine-induced miRNA modulation decreases neuronal apoptosis and modulates the electrophysiological properties of hippocampal pyramidal neurons. The modulation of miR-206 by ketamine might be involved in its antidepressant effects	[147]	
Ketamine and stress modulate hippocampal miRNAs (such as miR-598-5p, miR-451, miR-217, miR-203, miR-211, miR-152, miR-1, and miR-204) linked to pathways such as cAMP responsive element binding protein 5 (CREB5), GABAA, and muscarinic cholinergic receptor 5. Antidepressant effects of ketamine and electroconvulsive therapy converge on common molecular pathways (such as hippocampal miR-598-5p upregulation and miR-451 downregulation)	Ketamine and other antidepressant strategies modulate hippocampal miRNA pathways such as miR-451 which could be exploited in antidepressants drug-discovery	[124]	
Ketamine administered to mice 6 hours prior to lypopolysaccharide (LPS) elicits prophylactic effects, putatively through normalizing the LPS-perturbed PFC expression of miR-149 (increased by LPS), and miR-7688-5p (decreased by LPS), and their target gene nuclear factor Nfatc4 (activated T cells 4, decreased by LPS). The expression level of miR-149 in the PFC negatively correlated to the relative abundance of the gut microbial genus Alloprevotella, while miR-7668-5p was positively correlated to the relative abundance of the latter, and negatively correlated to the relative abundance of Lactobacilllus	Ketamine elicits prophylactic effects in the PFC in response to a systemic inflammatory challenge.

The PFC levels of selected miRNA affected by ketamine correlate to the abundance of specific gut microbiome taxa

	[152]	
Ketamine increases the hippocampal (but not PFC) transcription of a cluster of miRNAs (764-5p, 1912-3p, 1264-3p, 1298-5p, and 448-3p) hosted in the 5-HT2C gene locus through Glycogen Synthase Kinase 3 (GSK-3). These effects on miRNA expression are not detected following acute or repeated treatment with the selective serotonin (5-HT) reuptake inhibitor (SSRI) fluoxetine. Blocking miR-448-3- decreases the antidepressant-like effect of ketamine	Hippocampal GSK-3-miR-448-3p signaling is required for the antidepressant-like effects of ketamine. Ketamine elicits a rapid and sustained modulation of hippocampal miRNA which is not shared with acute or repeated fluoxetine treatment and may contribute to its capacity to elicit antidepressant effects in individuals that do not respond to classical treatment	[150]	
Ketamine increases miR-29b-3p expression and restores its expression in stressed mice selectively in the PFC, but not the hippocampus or the hypothalamus. While the miR-29b-3p target gene Glutamate Metabotropic Receptor 4 (GRM4) gradually declines following ketamine administration, the levels of miR-29b-3p increase. miR-29b-3p overexpression increases the high-voltage-activated current type in primary neuron cells, and promotes cell survival and cytodendritic growth	The brain area-specific effects of ketamine on miRNAs and their target genes (such as miR-29b-3p and GRM4) might be involved in its antidepressant effects.The synaptic-potentiating and neurotrophic properties of ketamine might be mediated by specific miRNAs in specific brain areas	[142]	
Ketamine prophylactic treatment in chronically stressed mice affects the level of 32 miRNAs in the PFC; the miRNA with the most significant change (decrease) following ketamine is miR-132-5p, which targets the BDNF and Transforming Growth Factor Beta 1 (TGF-β1) genes, which are involved in the antidepressant effects of ketamine. Ketamine rescues the stress-induced decrease of BDNF and TGF-β1. Ketamine decreases the expression of Methyl-CpG Binding Protein 2 (MeCP2) in the PFC	Ketamine-induced miR-132-5p in the PFC and its resulting effects on gene expression plays an important role in the prophylactic antidepressant effects of ketamine, potentially through its regulatory effects on the expression of BDNF, TGF-β1, and MeCP2 in the PFC	[144]	
Acute ketamine administration increases the PFC levels of miR-219a-5p, miR-7a-5p, miR-181b-5p and miR-148a-3p and decreases the levels of miR-128-3p. These miRNAs target genes involved with transcription, protein ubiquitination, and protein phosphorylation	Ketamine affects PFC miRNAs involved with transcription, and protein ubiquitination and phosphorylation in the PFC	[151]	
Repeated ketamine increases the hippocampal expression of the circRNAs 003460, 014900, 006565, 013109, and decreases circRNA-005442. The predicted downstream effects converge on calcium signaling, G protein signaling, protein phosphorylation, Mammalian Target of Rapamycin (mTOR) signaling, transcription, alternative splicing, and neuroplasticity	Ketamine modulates hippocampal circRNAs, and these effects might be involved in its antidepressant and neurotrophic effects	[164]	
Ketamine decreases miR-214-3p and Glutathione Peroxidase 4 (GPX4) levels. miR-214-3p inhibition relieves the decreased GPX4 expression. Ectopic expression of long non-coding Pvt1 Oncogene (lncPVT1) reverses the suppressed GPX4 levels caused by ketamine. Ketamine elicits ferropoptosis	Ketamine might have hepatic antineoplastic effects at least partially through lncRNA PVT1/miR-214-3p/GPX4 signaling and ferropoptosis	[263]	
STUDIES ON THE DELETERIOUS EPIGENETIC EFFECTS OF KETAMINE IN ANIMALS	
Main findings	Significance	Ref.	
Repeated ketamine during early gestation decreases the cardiac histone H3K9 acetylation level at the Modulator Of VRAC Current 1 (Mlc2) promoter by increasing histone deacetylase activity, cardiac HDAC3 level, and the binding of HDAC3 at the Mlc2 promoter. This leads to cardiac enlargement, ventricular chamber enlargement, ventricular wall thinning, vacuolar degeneration of cardiomyocytes, reduced systolic function, and decreased expression level of several cardiomyogenesis-related genes	Repeated ketamine during early pregnancy elicits deleterious effects in the cardiac physiology of the offspring through its modulation of histone acetylation activity	[218]	
Ketamine abuse induces Ten-Eleven-Translocation (TET) methylcytosine dioxygenase-mediated hypomethylation of NF-κB CpG promoter sites in cyclooxygenase 2 (COX2) promoters, upregulating COX-2. Ketamine upregulates (permissive) H3K4m3, and downregulates (repressive) H3K27me3 and H3K36me3 at NF-κB responsive COX-2 promoter sites, leading to ulcerative colitis	Epigenetic-mediated inflammatory dysfunction is involved in ketamine abuse-induced ulcerative cystitis. Low-dose ketamine might have a modulatory role over the epigenetic-mediated inflammatory control	[208]	
Repeated high-dose ketamine leads to an upregulation of the circRNA circ-SFMBT2 which sponges and downregulates miR-224-5p, leading to increased Metadherin (MTDH) expression	circ-SFMBT2/miR-224-5p/MTDH signaling might be involved in the inflammatory dysfunction underlying ketamine-induced cystitis	[212]	
In rats with ketamine-induced conditioned place preference (CPP), thirty-four hippocampal miRNAs were differentially expressed, including a strong downregulation of miR-331-5p, which targets the NR4A2 (Nuclear Receptor Subfamily 4 Group A Member 2) gene, and an increased expression of NR4A2, p-CREB, and BDNF	Hippocampal miRNAs might be involved in the rewarding and drug-seeking effects elicited by repeated ketamine exposure	[225]	
Successful ketamine-induced CPP downregulates 122 miRNAs in the rat serum exosomes involved in processes such as nervous system development, neuron generation and differentiation, apoptotic processes, and pathways such as SNARE interaction, Protein Kinase CGMP-Dependent (PKG) signaling, and dopaminergic and GABAergic synapse. The downregulated miRNAs include miR-128-3p, 133a-3p, 152-3p, 181a-5p, 192-3p, 194-5p, 218b, 22-5p, 362-3p, 674-3p	Repeated ketamine exposure and CPP is accompanied by changes in serum exosomes miRNAs in rats	[231]	
Repeated high-dose ketamine decreases miR-15a-3p, miR-15b-3p, and miR-16-1-3p expression in the PFC. Repeated high-dose ketamine decreases miR-16-1 in the hippocampus and Dopamine Receptor D1 (DRD1) levels in the PFC and hippocampus. These neurobiological changes are associated with schizophrenia-like behavior	Ketamine abuse may elicit maladaptive miRNAs expression in the PFC leading to schizophrenia-like behavior	[242]	
Repeated high dose ketamine decreases miR-199a-5p expression and increases that of its target gene Hypoxia Inducible Factor 1 Subunit Alpha (HIF-1α). The regimen induces learning and memory impairment in neonatal rats through the regulation of the miR-199a-5p - HIF-1α pathways. Exposure to ketamine in neonatal rats induces learning and memory impairments. Exposure to ketamine impairs spatial learning memory ability by up-regulating HIF-1α expression	Repeated ketamine administration to neonates elicits cognitive and memory impairments through the miR-199a5p - HIF-1α pathway	[239]	
miR-34c is upregulated in the hippocampus following repeated high-dose ketamine in neonatal rats. miR-34c knockdown increases the levels of BCL2 Apoptosis Regulator (Bcl-2), phospho-Protein Kinase C (PKC), and phospho-Mitogen-Activated Protein Kinase 1 (ERK). miR-34c knockdown ameliorates the ketamine-induced hippocampal toxicity Repeated high-dose ketamine elicits neurotoxicity in the CA1 region of the hippocampus	Repeated ketamine administration in the neonatal period elicits hippocampal neurotoxicity at least partially through miR-34c upregulation	[236]	
miR-34a overexpression reverses the neurological and cognitive deficits, histopathological brain changes, and exacerbation of circulating proinflammatory cytokines elicited by repeated high-dose ketamine in rats	Repeated high-dose ketamine elicits neurotoxic and proinflammatory changes which can be counteracted by miR-34a overexpression	[213]	
Repeated high-dose ketamine decreases miR-214 and increases Phosphatase And Tensin Homolog (PTEN) expression in the hippocampus. Repeated high-dose ketamine elicits cognitive deficits in rats	Repeated high-dose ketamine elicits cognitive deficits in rats which might be due to decreased miR-214 and increased PTEN hippocampal expression	[240]	
Repeated high-dose ketamine in the neonatal period downregulates hippocampal miR-137, leading to apoptosis in hippocampal CA1 neurons and significant long-term memory dysfunction. miR-137 overexpression protects against hippocampal neurodegeneration and memory loss	miR-137 is involved in the neonatal, repeated high dose ketamine-induced hippocampal neurodegeneration and memory loss	[238]	
Chronic ketamine administration induces bladder fibrosis and bladder upregulation of 14 and downregulation of 9 miRNAs. Moreover, chronic ketamine administration leads to the upregulation of 37 and downregulation of 34 lncRNAs in the bladder. Additionally, the treatment leads to 14 downregulated and 54 upregulated circRNAs	The ketamine abuse-induced bladder fibrosis is accompanied by changes in ncRNAs in the bladder	[211]	
Repeated ketamine administration increases histone deacetylase and DNA methyltransferase activity in the PFC and striatum, but not the hippocampus, eliciting hyperlocomotion and altered exploratory activity. Repeated ketamine administration decreases Nerve Growth Factor (NGF) and Glial Cell Derived Neurotrophic Factor (GDNF) in the striatum	Repeated ketamine administration elicits histone deacetylation and DNA methylation, effects opposite to those elicited by clinically relevant doses	[235]	
STUDIES ON THE DELETERIOUS EPIGENETIC EFFECTS OF KETAMINE IN VITRO	
Main findings	Significance	Ref.	
Ketamine dose-dependently inhibits the expression of HDAC6 and its nuclear import. Ketamine decreases dendritic growth, dendrite branches, and dendritic spine density in medium spiny neurons in a time- and concentration-dependent manner	Ketamine elicits neurotoxic effects in in vitro GABAergic neurons through HDAC6 inhibition	[248]	
In PC12 neuronal cells, ketamine dose-dependently decreases the expression of the neuroprotective miR-429. This effect is accompanied by an increase in caspase 3 and reactive oxygen species (ROS) activity, and a dose-dependent increase in the miR-429 target BAG Cochaperone 5 (BAG5), expression. miR-429 overexpression is sufficient to attenuate the neurotoxic action	Ketamine elicits a dose-dependent neurotoxic effect in the PC12 neuronal cell line, mediated by its inhibitory effects on miR-429. Specific miRNAs are responsible for the in vitro neurotoxic effects of ketamine	[210]	
Ketamine downregulates miR-22 in PC12 cells and upregulates BAG Cochaperone 5 (BAG5) in a dose-dependent manner. Lipoxin A4 methyl ester decreases these effects, attenuating neurotoxicity	Ketamine elicits a dose-dependent neurotoxic effect in PC12 cells, mediated by its effects on the miR-22/BAG5	[249]	
Ketamine at higher doses increases miR-375 expression and decreases cell viability, neurite outgrowth, and BDNF levels, while increasing ROS production in human embryonic stem cell-derived neurons. miR-375 inhibition ameliorates these effects	Ketamine elicits dose-dependent neurotoxic effects in human embryonic stem cell-derived neurons, mediated partly by its inhibitory effects on miR-375. Specific miRNAs are involved in the in vitro neurotoxic effects of ketamine at higher doses	[215]	
Ketamine exposure in CA1 hippocampal cell cultures increases miR-124 expression. miR-124 inhibition partially decreases the ketamine-induced neurotoxicity and upregulates the expression of AMPA, phospho-Glutamate Ionotropic Receptor AMPA Type Subunit 1 (GluR1), p-PKC, and p-ERK. Repeated high-dose ketamine in young mice leads to memory impairments during adulthood, and these effects are partially normalized by miR-124 antagonism	The neurotoxic effects elicited by higher dose ketamine in hippocampal cell culture and young mice might be mediated by miR-124 upregulation, which results in decreased AMPA, p-GluR1, p-PKC, and p-ERK hippocampal levels	[237]	
Ketamine elicits a dose-dependent miR-107 (an upstream regulator of BDNF). Ketamine induces apoptosis and neurite degeneration in embryonic stem cells-derived neurons. miR-107 downregulation attenuates these effects	Ketamine elicits neurotoxic effects in embryonic stem cells-derived neurons at least partially through miR-107 signaling	[247]	
Ketamine decreases the expression of the lncRNA Long Intergenic Non-Protein Coding RNA 641 (LINC00641), leading to increased neuronal apoptosis. Downregulation of LINC00641 results in an increase in its target miR-497-5p and a decrease in BDNF expression, which is repressed by miR-497-5p inhibition. LINC00641 improves ketamine-induced neuronal injury by activating the TRKB/Phosphoinositide 3-kinases (PI3K)/Protein Kinase B (Akt) signaling pathway	The neurotoxic effects of high-dose ketamine in vitro might be mediated by LINC00641/miR-497-5p/BDNF signaling	[214]	
Ketamine elicits lncRNA SPRY4 Intronic Transcript 1 (SPRY4-IT1) upregulation, dose-dependent apoptosis, and neurite degeneration in human embryonic stem cells-induced neurons. Lentivirus-mediated SPRY4-IT1 downregulation protects against ketamine neurotoxicity. Enhancer Of Zeste 2 Polycomb Repressive Complex 2 Subunit (EZH2) expression is positively correlated with SPRY4-IT1 in hESC-induced neurons. EZH2 overexpression markedly reverses the protective effects of SPRY4-IT1 knockdown on ketamine neurotoxicity	The lncRNA SPRY4-IT1 is involved in the neurotoxicity elicited by ketamine in human embryonic stem cell-derived neurons, possibly through the regulation on EZH2 gene	[250]	
Repeated ketamine upregulates miR-206 expression. Repeated ketamine downregulates KCNQ1 Opposite Strand/Antisense Transcript 1 (KCNQ1OT1) and BDNF expression. Repeated ketamine induces hippocampal apoptosis in rats, and the apoptosis of PC-12 cells	The KCNQ1OT1/miR-206/BDNF axis may represent a regulatory mechanism mediating ketamine-induced neural injury	[243]	
Ketamine increases the expression of the BDNF antisense RNA (BDNF-AS) and decreases that of BDNF in mouse embryonic neural stem cells-derived neurons, leading to apoptosis. BDNF-AS downregulation activates Neurotrophic Receptor Tyrosine Kinase 2 (TRKB) signaling, protects against the ketamine-induced apoptosis and promotes neurite outgrowth	The neurotoxic effects of ketamine in vitro might be mediated by a modulation of BDNF-AS	[251]	
Repeated high-dose ketamine upregulates hippocampal miR-34a, which targets the Fibroblast Growth Factor Receptor 1 (FGR1) gene, and elicits apoptosis in hippocampal CA1 neurons. Inhibition of miR-34 decreases these effects	Repeated high-dose ketamine elicits hippocampal damage at least partially through miR-34a-FGR1 signaling	[241]	
Ketamine downregulates the lncRNA Small Nucleolar RNA Host Gene 16 (SNHG16), and it induces apoptosis and oxidative stress in human embryonic stem cell-derived neurons. SNHG16 overexpression attenuates the ketamine-induced neurotoxicity. Neuronal Differentiation 1 (NeuroD1) gene inhibition reverses the protective effect of SNHG16 on ketamine-induced neurotoxicity	Ketamine elicits neuronal damage at least partially through downregulation of the lncRNA SNHG16	[246]	
STUDIES ON THE EPIGENETIC EFFECTS OF LSD IN ANIMALS	
Main findings	Significance	Ref.	
Repeated LSD modulated DNA methylation in 635 CpG sites of the mouse PFC, and the expression level of 181 proteins. Gene signaling pathways affected are involved in nervous system development, axon guidance, synaptic plasticity, quantity and cell viability of neurons, and protein translation	LSD affects the DNA methylation, and gene and protein expression related to neurotropic-, neurotrophic- and neuroplasticity signaling	[69]	
Acute LSD increases histone acetylation in the midbrain and cortex, but not cerebellum of rabbits. RNA production is also increased	Acute LSD induces histone acetylation in the cortex and midbrain, which increases gene expression	[98]	
LSD decreases the interaction between nucleic acids and proteins	LSD might directly bind DNA or histone proteins, affecting chromatin structure	[268]	
d-LSD binds to helical DNA (less so to denaturated DNA or RNA) with max 1 molecule per base moiety	LSD might directly bind chromatin, altering its structure, and affecting its functioning	[199]	
LSD causes structural changes to the DNA double-helix conformation, possibly through intercalating DNA	LSD might cause the dissociation of DNA from histones through neutralizing the phosphate anions on the DNA double-helix backbone	[197]	
LSD and tryptamines bind to DNA	LSD and tryptamines might directly interact with chromatin, affecting gene expression	[198]	
A racemic mixture of l-LSD and d-LSD leads to LSD-DNA Binding. l-LSD but not d-LSD may bind to DNA directly	LSD might directly bind DNA	[197]	
STUDIES ON THE EPIGENETIC EFFECTS OF MDMA IN HUMANS	
Main findings	Significance	Ref.	
The increase in methylation level of one CpG site (cg08276280) in the corticotropin-releasing factor receptor 1 gene and one (cg01391283) within the glucocorticoid receptor gene in saliva samples correlates with symptom reduction in individuals with severe PTSD receiving MDMA-assisted psychotherapy	A modulation of DNA methylation in stress-responsive genomic regions might be involved in the therapeutic effects of MDMA-assisted psychotherapy in individuals with severe PTSD	[83]	
STUDIES ON THE DELETERIOUS EPIGENETIC EFFECTS OF MDMA IN ANIMALS	
Main findings	Significance	Ref.	
Acute MDMA increases me3H3K4 (permissive) at the promoters of nociceptin/orphaninFQ (pN/OFQ)-NOP and dynorphin (DYN)-KOP DNA regions. Acute MDMA increases acH3K9 (permissive) and decreases me2H3K9 (repressive) at the pDYN (coupled to transcriptional upregulation). Acute and repeated MDMA decrease acH3K9 (permissive) at the pN/OFQ promoter (coupled to transcriptional downregulation)	Acute and repeated MDMA administration upregulates the DYN system and downregulates the N/OFQ system via modulating histone PTMs in promoter DNA regions in the nucleus accumbens	[232]	
Chronic MDMA leads to cardiac gene promoters hypermethylation and circadian-related gene expression changes, coupled to cardiac hypertrophy and progressive damage	MDMA abuse affects cardiac DNA methylation, and this might be involved in cardiotoxicity	[217]	
STUDIES ON THE EPIGENETIC EFFECTS OF AYAHUASCA IN HUMANS	
Main findings	Significance	Ref.	
Repeated Ayahuasca in ceremonial settings affects the methylation level of 5 CpG sites located in the BDNF promoter (more so in individuals with greater childhood trauma) but does not affect the methylation level of one CpG site within the FKBP Prolyl Isomerase 5 (FKBP5) gene. These effects are accompanied by decreases in anxiety and depression detectable for up to 6 months	Repeated Ayahuasca administration in ceremonial settings elicits sustained antidepressant and anxiolytic effects which are accompanied by DNA methylation changes in the regulatory region of the BDNF gene	[79]	
Hypothesis- Ayahuasca might contribute to fear extinction learning and memory reconsolidation via a Sigma-1 receptor-mediated epigenetic mechanism	Ayahuasca might modulate epigenetics processes, and these effects might be involved in the therapeutic effects of Ayahuasca over traumatic memories, fear extinction, and memory reconsolidation	[80]	
STUDIES ON THE EPIGENETIC EFFECTS OF 2,5-DIMETHOXY-4-IODOAMPHETAMINE (DOI) IN ANIMALS	
Main findings	Significance	Ref.	
DOI affects the acetylation level of the transcriptional enhancer histone H3K27 in neuronal cells of the mouse PFC with highly specific spatio-temporal dynamics and for up to 7 days post-administration. These changes result in transcriptomics shifts, and a structural (5-HT2A-mediated) and functional modulation of synaptic plasticity, and decreased depressive-like behavior	A single DOI administration elicits long-lasting acetylation and transcriptional changes which are accompanied by long-lasting structural and functional modulation of synaptic plasticity	[107]	
STUDIES ON THE EPIGENETIC EFFECTS OF Β-CARBOLINES	
Main findings	Significance	Ref.	
β-carbolines directly interact with DNA in vitro with affinity harmine>harmalol>harmaline>tryptoline	β-carbolines might affect chromatin compaction via direct interaction or via interacting with chromatin-remodeling complexes	[196]	
STUDIES ON THE EPIGENETIC EFFECTS OF PSILOCYBIN	
Main findings	Significance	Ref.	
Psilocybin at the dose of 10 mg/kg increases oxidative DNA damage in the PFC and hippocampus	Higher-than clinically-relevant doses of psilocybin elicit DNA damage in the PFC	[260]	
Hypothesis- Psilocybin might affect genetic aging via epigenetic regulation of telomere length	Psilocybin might affect epigenetics processes involved with aging, preventing telomere degradation	[68]	

Amongst psychedelics, preliminary evidence indicates that LSD and Ayahuasca affect DNA methylation (Fig. 1 and Table 1). Repeated LSD largely increased the methylation level of 635 CpG sites in the PFC of adult male mice receiving a prosocial, anxiolytic, and synaptoplastic repeated regimen of LSD [69–72]. The genes interested were involved with neurotropic-, neurotrophic-, and neuroplasticity-related signaling. Proteomics profiling and qRT-PCR validation suggested specificity and functional significance of the changes observed in DNA methylation [69]. Given that cytosine methylation can affect the likelihood of mutations [73, 74] future studies are warranted to investigate the potential effects of the increased DNA methylation elicited by LSD on genomic stability and mutation rates. Despite the fact that the use of RAADs has been associated with decreased likelihood of suicide [75, 76], DNA hypermethylation is also observed in the blood of individuals who attempted suicide [77] and in the PFC of suicide completers [78]. Hence, future studies are required to better characterize the relationships between the epigenetic effects elicited by psychedelics and suicidality. Participation in a ceremonial Ayahuasca retreat in the Amazon consisting of multiple administrations increased the saliva methylation level of 5 CpG sites within the Sigma-1 receptor gene promoter (in a greater fashion in individuals with greater childhood trauma), but did not affect the methylation level of one CpG site within the FKBP5 gene, which is involved with trauma and the stress response [79]. These changes were accompanied by improved depression and anxiety scores for up to 6 months [79]. While they are preliminary findings, previous biochemical and neurostructural evidence supports the existence of epigenetic mechanisms accompanying the regular consumption of Ayahuasca: increased platelets 5-HT uptake sites [25], thinner precuneus and posterior cingulate cortex, and thicker anterior cingulate cortex [26] were identified in long term Ayahuasca users. Speculations exist that Ayahuasca might extinguish the fear response via an epigenetic mechanism mediated by the DMT-activated Sigma-1 receptor [80], although this hypothesis remains to be tested. The β-carbolines contained in the Ayahuasca brew might also inhibit histone deacetylase activity, given that engineered derivatives containing β-carbolines motifs are potent HDACs inhibitors [81, 82]. However, no studies have insofar investigated the epigenetic effects elicited by β-carboline, or those elicited by the combination of β-carboline with DMT-containing plants (as in the case of Ayahuasca).

MDMA-assisted psychotherapy led to peripheral epigenetic changes correlated to therapeutic improvement [83]. The increase in saliva methylation level of one CpG site (cg08276280) in the corticotropin-releasing factor receptor 1 gene and one (cg01391283) within the glucocorticoid receptor gene was correlated with symptom reduction in individuals with severe PTSD receiving MDMA-assisted psychotherapy [83]. Further studies should characterize the epigenetic effects of psychotherapy coupled to RAADs, and if those treatments synergistically or additively interact to produce determinate epigenetic outcomes. Putative prophylactic or acute effects of RAADs on attenuating stress-induced DNA methylation changes remain to be elucidated.

Histone post-translational modifications, stress, and RAADs

Histones form protein cores around which DNA wraps. Stress and antidepressants affect histone post-translational modifications (PTMs) such as acetylation, methylation, and phosphorylation in stress-responsive chromatin areas, altering chromatin accessibility and transcription. For example, stress elicits hypoacetylation of hippocampal histone 3 (H3) at BDNF III and IV promoters, and increases the levels of histone deacetylases (HDACs) including HDAC5 and Sirtuin 2, ultimately decreasing BDNF expression [1, 84]. Indeed, specific HDACs such as HDAC2 and HDAC5, which are critical regulators of adult neurogenesis [85] and cognition [86], are altered in depression [87].

Some of the aberrant PTMs dynamics elicited by stress are restored by chronic administration of conventional antidepressants such as fluoxetine, paroxetine, reboxetine, citalopram, imipramine and mirtazapine. These drugs rescue the H3-H4 (i.e., H3 lysine (K)9 and H3K27) hypoacetylation of the BDNF promoters, reverse the stress-induced decrease in BDNF transcription and protein level, promote HDAC5 phosphorylation and nuclear export, and attenuate the stress-induced increase in HDACs in stress-susceptible brain areas [1, 55, 84, 88–92]. Delving into the mechanisms, fluoxetine was shown to disassociate the MeCP2-CREB-BDNF promoter IV complex via Protein Kinase A (PKA)- mediated phosphorylation of MeCP2, leading to CREB-mediated BDNF transcription [55]. Fluoxetine also inhibited the binding of delta-FosB to the Calcium/calmodulin-dependent protein kinase IIa (CaMKIIa) promoter by reducing its acetylation and increasing its H3K9 dimethylation, ultimately decreasing CaMKIIa expression in the NAc [93]. Eight-week escitalopram treatment in individuals with depression decreased H3K27 histone trimethylation, and these changes were negatively correlated with increased BDNF levels [58]. Importantly, the stress-induced hippocampal BDNF promoter-associated H3K9 hypoacetylation and HDAC2 overexpression can also be restored by non-pharmacological strategies such as acupuncture [94].

The epigenetic outcomes elicited by a single administration of ketamine largely overlap those elicited by chronic conventional antidepressants. Indeed, one or few ketamine administrations are sufficient to reverse the stress-induced histone hypoacetylation and downregulated neurotrophic-related transcription (Fig. 1 and Table 1). In a mouse model of Gulf War Illness, ketamine decreased the hippocampal HDAC1 and HDAC5 levels and increased the H3K9 acetylation of BDNF promoter IV, restoring BDNF levels and neuroplasticity [95]. Similarly, in rats exposed to early life adversities, ketamine decreased the depressive-like behaviors and restored NAc HDAC activity [7]. Moreover, high-dose ketamine had a prophylactic effect on attenuating the stress-induced increase in hippocampal H3K9 methylation [96]. Similarly to conventional antidepressants, ketamine increases HDAC5 phosphorylation and nuclear export, resulting in enhanced H3-H4 acetylation. This triggers the myocyte enhancer factor 2-mediated transcription of the plasticity-related genes Eukaryotic Translation Initiation Factor 4E Binding Protein 1 (eIF4EBP1) and CREB, and their target genes, and ultimately the onset of antidepressant-like effects [97].

Psychedelics such as LSD and DOI also have histone-acetylating properties, which might be involved in their therapeutic effects (Fig. 1 and Table 1). Early studies reported that LSD acutely increases histone acetylation in the midbrain and cortex, but not the cerebellum of rabbits [98]. The increased histone acetylation activity elicited by LSD suggests gene activation, and indeed, LSD activates the transcription [99] of immediate early genes and genes involved with synaptic potentiation and neurotropism in the hippocampus, cortex, midbrain [100], and brainstem [99]. Given that enhancing hippocampal and PFC histone acetylation ameliorates fear extinction [101] and the consolidation of cued fear extinction [102] via a permissive effect over transcription [101], the increased histone acetylation elicited by LSD could be involved in its therapeutic action for alcohol addiction, and distress associated with a life-threatening condition [103–106].

A single administration of the LSD analog DOI also elicited a sustained modulation of the acetylation level of the transcriptional enhancer histone H3K27 in neurons of the mouse PFC [107]. This sustained effect had highly specific spatio-temporal dynamics, was accompanied by neurotrophic-related transcriptional shifts, and was associated to enhanced synaptic plasticity and antidepressant-like activity [107]. Lastly, the recently identified histone PTMs serotonylation and dopaminylation [108–110] might potentially be involved in the therapeutic effects of psychedelics, although further investigations are required. Together, the therapeutic effects of RAADs, similarly to conventional antidepressants, are accompanied by PTMs opposite to those elicited by stress, leading to increased accessibility of genes involved with neurotrophic signaling and antidepressant response.

Non-coding RNAs, stress, and RAADs

Non-coding RNAs (ncRNAs) are portions of the genome which are transcribed but not translated, with roles in tissue-specific selective or cooperative regulation of splicing, transcription, and translation [111–114]. ncRNAs, including stress-responsive ones, are intricately linked to neuroplasticity, psychiatric disorders, and suicide, offering potential as biomarkers and therapeutics for psychiatric disorders [115–122]. Early-life and chronic stressors affect the PFC, amygdalar and hippocampal regulatory RNA network, influencing neurotransmission, neuroplasticity, neurogenesis, and behavior [118, 123–127]. Among these networks, microRNAs (miRNAs), approximately 22 nucleotides in length, stand out for their tissue-specific regulation of a significant proportion of protein-coding genes expression by binding mRNA untranslated regions. Dysregulated miRNA dynamics are observed in depression and suicide, with studies pinpointing alterations in the PFC and hippocampus during depressive states [121, 122, 128, 129]. Conventional antidepressants influence miRNA expression patterns. For instance, miRNAs such as miR-16, miR-124, miR-132, and miR-135 are implicated in antidepressant response, with drugs like fluoxetine and venlafaxine, imipramine, sertraline, and citalopram modulating their expression, as well as the expression of miR-18a, miR-34a, miR-326, miR-1202 and miR-1971 [117, 130–141].

RAADs such as ketamine also alter miRNA pathways, with PFC miR-29b-3p, miR-98-5p, and miR-132-5p playing important roles in mediating the upregulation of BDNF leading to ketamine’s antidepressant-like effects (Fig. 1 and Table 1) [142–144]. In preclinical studies, ketamine modulated some of the stress-dysregulated hippocampal miRNAs (i.e., miR-598), which are also regulated by other antidepressant strategies such as fluoxetine and electroconvulsive therapy (ECT) [124]. Ketamine also decreased miR-451 levels and increased those of the RNA-binding protein hur-6, a de-repressor miRNA “sponge” for deleterious miRNAs involved in inflammatory responses [124, 145, 146]. ECT and ketamine in rodents exposed to early-life adversities affected 43 common miRNA targets, 7 of which were reversals of stress-induced changes. Interestingly, ketamine rescued some of the stress-induced miRNAs alterations which were not reversed by fluoxetine [124], suggesting that some of the epigenetic mechanisms engaged by conventional and RAADs diverge. A three-day ketamine regimen upregulated 23 miRNAs and downregulated 15 including miR-206 [147] (a negative modulator of BDNF) in vivo and in vitro, while increasing BDNF and decreasing apoptosis [147–149]. Ketamine time-dependently modulated the transcription of a cluster of hippocampal (but not PFC) miRNAs (764-5p, 1912-3p, 1264-3p, 1298-5p, and 448-3p) which are hosted in the 5-HT2C gene locus, mediated by the inhibition of glycogen synthase kinase 3 [150]. Acutely, ketamine increased the prefrontal level of miR-148a-3p and decreased miR-128-3p, miRNAs involved with the ubiquitin proteasome system [151]. Ketamine also elicited immunomodulatory prophylactic effects in lipopolysaccharide (LPS)-treated mice through miR-149 [152], indicating that some of the immunomodulatory effects of ketamine involved in its antidepressant effects [153] might be mediated by ncRNAs.

Similarly to what observed with conventional antidepressants [140, 154–159] the miRNome might predict the therapeutic response elicited by RAADs. For example, the non-responder status to ketamine was predicted by lower pretreatment level of miR-548d-5p and miR-605 in individuals with neuropathic pain [160, 161]. However, in a study in individuals with treatment-resistant depression receiving a ketamine infusion, no significant effects on whole blood miRNA levels were detected 24 hours after [162]. Further studies are required to identify miRNAs that can predict favorable treatment outcome in response to RAADs to increase therapeutic precision.

Circular RNAs (circRNAs), ncRNAs generated by back-splicing, have extensive complementarity to target mRNAs and can encode proteins or increase the expression of the target gene(s) [163]. A regimen of repeated ketamine in rats increased the hippocampal expression of 4, and decreased the expression of 1 circRNA, with predicted downstream effects on genes involved in calcium signaling, G protein signaling, protein phosphorylation, Mammalian Target of Rapamycin (mTOR) signaling, transcription, alternative splicing, and neuroplasticity [164]. Long non-coding RNAs (lncRNAs) are a class of ncRNAs longer than 200 nucleotides with brain area-specific expression patterns involved with neural differentiation and plasticity [165]. lncRNA dynamics are stress- and antidepressant-responsive, are altered in several neuropsychiatric disorders including Major Depressive Disorder (MDD), and might predict the antidepressant response [118, 127, 166]. For example, greater decreases of the lncRNA FEDORA predicted the decrease in depression severity following ketamine in individuals identifying as female who experience MDD [167].

Potential mechanisms of rapid-acting antidepressants-induced epigenetic changes

Neuronal activity-mediated epigenetic effects

One mechanism through which psychedelics might affect the epigenetic regulation of neurotrophic-related gene expression is via neuronal activity-induced modification of chromatin structure and accessibility. The membrane depolarization of cortical neurons results in chromatin remodeling and enhanced BDNF gene accessibility via a) decreased methylation of BDNF promoter III and IV [168, 169], b) H3K4 dimethylation of BDNF promoter IV, and c) HDAC1 and mammalian Switch-independent 3 A promoter dissociation [169]. Additionally, upon neuronal depolarization, CaMKII-mediated phosphorylation and release of the methyl-binding protein MeCP2 from the BDNF promoter III permits BDNF promoter III-dependent transcription, causing dendritic plasticity in neurons [168, 170]. Additionally, the ketamine-induced loss of somatostatin-expressing interneurons dendritic inhibition leads to heightened synaptic calcium transients in the dendritic spines of pyramidal neurons in the PFC. This process might play a role in the epigenetic effects observed following ketamine administration through altered calcium signaling, leading to increased activity-dependent synaptic plasticity [171–173]. DOI activates specific subsets of 5-HT2A- and metabotropic glutamate receptor 2 (mGlu2)-expressing glutamatergic neurons and interneurons, as well as astrocytes of deep-layer prefrontal and somatosensory cortices, the claustrum, and the insula [174], and this activation might be involved in the sustained epigenetic and antidepressant-like effects elicited [107]. A single administration of DOI induced prolonged alterations in the acetylation level of neuronal transcriptional enhancers, causing sustained effects over axonogenesis, synapse organization, assembly, and function, and receptor internalization and activity [107]. Despite this preliminary correlative evidence, given that physiological neuronal activation itself can profoundly modulate the epigenetic landscape de novo [175], this calls into questions whether the epigenetic effects elicited by RAADs are causally involved in the therapeutic effects, or neuronal activity-driven changes. Future studies are encouraged to address this research question.

5-HT receptors signaling-mediated epigenetic effects

Psychedelics might activate similar epigenetic mechanisms to those activated by endogenous 5-HT signaling through various 5-HT receptors. 5-HT triggers a transient remodeling of chromatin structure mediated by 5-HT1A and BDNF-TRKB signaling which decreases HDAC5 expression, and increases cortical H3K9 acetylation of the BDNF promoter and BDNF levels, reinstating plasticity in the adult nervous system [176]. 5-HT signaling also induces changes in the methylation status of the promoter of CREB2, a plasticity-related transcription factor involved in long-term facilitation [177, 178]. The properties of psychedelics resemble those of 5-HT: they interact with 5-HT receptors such as the 5-HT1A and 5-HT2A receptors, triggering biased signaling and the transcription of genes involved in neurotransmission, neuroplasticity, and neuroimmunomodulation [14–16]. Given that these 5-HT receptors are fundamentally involved in governing cortical circuits mediating cognitive and executive functions [179, 180], the activation of these receptors by RAADs might result in specific epigenomic fingerprints and chromatin architecture changes, ultimately leading to structural and functional synaptic changes. The epigenetic effects elicited in discrete cell types through activation of 5-HT receptors, might alter circuit and network activities, putatively mediating therapeutic improvement at the circuit-, network-, and system-levels.

TRKB signaling-mediated epigenetic effects

Like classical antidepressants [181], a mechanism that might mediate the epigenetic effects of RAADs is the activation of endogenous BDNF signaling through direct binding to and activation of the TRKB receptor [182–185]. Activation of TRKB signaling results in the activation of other cascades such as the CaMKII, RAS/MAPK and phosphoinositide 3 kinase pathways [14, 17, 186–188]. Moreover, TRKB signaling leads to altered chromatin structure of the BDNF gene, and transcriptional upregulation of the BDNF gene and its downstream effector target AKT Serine/Threonine Kinase 1 (Akt)-mTOR. These events ultimately cause an increase in neuroplasticity, synaptic potentiation, and antidepressant effects. The outcome is the reopening of a period of structural and functional plasticity within the CNS that can be harnessed therapeutically [182–184, 189, 190]. Supporting a fundamental role of the reopening of critical periods of plasticity, RAADs lead to the degradation of the extracellular matrix in the NAc, creating the prerequisites to enable metaplasticity [190]. Whether epigenetic mechanisms are involved in this process remains unknown.

Interestingly, the epigenetic changes elicited by LSD resemble those observed during critical periods of neurodevelopment and synaptic plasticity, thus seemingly re-creating in the adult nervous system the epigenetic correlates observed during neurodevelopment and learning [69]. Indeed, CCAAT enhancer binding protein beta (CEBP2), a co-activator and target gene of CREB, was a “top-hit” in the PFC in terms of differential DNA methylation following repeated LSD [69]. In accordance, CEBP2 together with several other neuroplasticity-related genes is dose-dependently transcriptionally modulated in the PFC following psilocybin administration [191]. Accordingly, a single administration of psilocybin following chronic stress during adolescence in rats was sufficient to normalize depressive-like and cognitive-like behaviors [192]. Lastly, given that (i) psychedelics interact with TRKB, 5-HT2A, and mGlu2 receptors, that (ii) TRKB interacts with the 5-HT2A [193] and the mGlu2 [194] receptors, and that (iii) the latter two receptors interact with each other [195], these interactions may be functionally relevant from an epigenetic standpoint.

Direct interaction with DNA, histones, or chromatin remodeling complexes

Another intriguing mechanism supported by several lines of evidence is that RAADs may directly interact with DNA, histones, or chromatin remodeling complexes, thus acting as direct epigenetic modulators. Indeed, the β-carbolines contained in the brew Ayahuasca directly interact with DNA in vitro [196], and early studies observed that LSD directly binds DNA or histone proteins [197–199]. For psychedelics to interact with DNA or histones in vivo, they would first need to reach the intracellular space and the nucleus. Indeed, membrane permeability is essential for the neuroplastic effects of psychedelics, and ligand-bound 5-HT2A receptors are internalized in vivo and in vitro [200–203]. Additionally, neurotrophic factors are uptaken and transported to the cell body through retrograde axonal transport. Given that RAADs bind the TRKB receptor [186], they might similarly be internalized by nerve terminals. In support of this hypothesis, DMT is internalized via a three-step process requiring active transport: 1) it is actively transported across the blood-brain barrier, 2) acts as a 5-HT transporter substrate on the neuronal plasma membrane, and 3) it is internalized by neuronal cells, and stored into synaptic vesicles by the neuronal vesicle monoamine transporter 2 for up to 1 week [204–206]. Whether the sequestered DMT in synaptic vesicles or the DMT-activated Sigma-1 receptor interact with DNA or chromatin remodeling complexes remains to be assessed [206, 207]. Recently, it was reported that 5-HT can covalently bind to glutamine 5 on the trimethylated H3K4 histone, eliciting a permissive transcriptional influence that modulates the interaction of histone PTMs with chromatin readers during neuronal differentiation [109]. Due to the structural similarity of 5-HTergic psychedelics to 5-HT, it remains to be assessed whether they modulate the relationship between histone PTMs and chromatin readers.

The mechanisms discussed here are not necessarily mutually exclusive and may be part of a series of events responsible for reopening a period of neurodevelopmental-like neuroplasticity, providing a neurobiological substrate that can be harnessed therapeutically. Achieving this seems to require appropriate support and integration before, during, and following psychedelic-assisted psychotherapy. Given that the different mechanisms modulating chromatin structure and DNA accessibility may interact with one another, deciphering the “psychedelic epigenome” represents a new frontier in psychiatry.

Involvement of epigenetic mechanisms in the potential side effects elicited by RAADs

While preliminary evidence suggests that the epigenetic effects induced by RAADs may contribute to therapeutic improvement, uncertainties persist regarding side effects. Studies have documented epigenetic alterations following the abuse of RAADs, which appear antithetical to those elicited by clinically relevant doses, yet similar to those elicited by stress. These changes are reminiscent of neuronal, immune and cardiac dysfunction. Most of the potential epigenetic-mediated side effects associated with RAADs were observed following repeated administration of higher doses of ketamine during gestation, lactation, and the neonatal period (Table 1).

Immune-related side effects

High or repeated doses of ketamine may cause side effects through the epigenetic modulation of immune function, via (i) upregulation of permissive H3K4 trimethylation, (ii) downregulation of repressive H3K27 and H3K36 trimethylation, and (iii) DNA hypomethylation at nuclear factor-κB (NF-κB)-responsive promoters [208, 209], as well as iv) modulation of proinflammatory, neurotoxic, and oxidative signaling through RNA regulatory pathways [152, 210–216]. Repeated MDMA administration also causes epigenetic marks reminiscent of immune dysfunction such as hypermethylation of the Terminal Nucleotidyltransferase 5B gene, a chaperone involved with cyclooxygenase 2 maturation [217]. Future studies are warranted to further investigate potential epigenetics-mediated immune side effects arising from repeated use and abuse of RAADs.

Cardiac hypertrophy

In a model of ketamine abuse during early gestation, ketamine decreased the acetylation level of cardiac histone H3K9 at the Myosin Light Chain 2 promoter by increasing HDAC3 level and histone deacetylase activity. These effects were accompanied by altered expression of several genes related to cardiomyogenesis, resulting in enlarged heart and ventricular chamber, thinner ventricular wall, degeneration of cardiomyocytes, and reduced systolic function [218]. Repeated MDMA exposure also led to hypermethylation of cardiac DNA promoter regions resulting in cardiac hypertrophy and progressive damage [217]. Given the concern surrounding the potential impact of RAADs on cardiovascular function through cardiac 5-HT receptors [219], future investigations are recommended to explore potential deleterious effects at clinically relevant doses and regimens.

Deleterious gestational and transgenerational effects

While few studies have assessed the transgenerational effects of RAADs, maternal intake during pregnancy and lactation may similarly to conventional antidepressants lead to epigenetic modifications and altered anxiety and depressive-like behavior in the offspring [56, 220–222]. For example, ketamine abuse during gestation impacts the epigenetic make-up of the fetus, and can result in impaired neurocognitive function in the offspring [218, 223]. Similarly, sociability, emotional behavior, and increased PFC dopamine levels are observed in the offspring of rats following repeated Ayahuasca administration during pregnancy and lactation [224].

Potential for addiction

While there is general consensus that psychedelics have low potential for addiction, psychological dependence or reinforcing effects, the NMDA antagonist ketamine [225, 226] and the empathogen MDMA [227, 228] have been associated with drug-seeking behaviors accompanied by epigenetic changes, similarly to drugs of abuse [229, 230]. For instance, one study found that ketamine-induced conditioned place preference resulted in differential expression of 34 hippocampal miRNAs [225], while another study showed that the conditioned place preference was accompanied by altered expression of serum exosomal miRNAs associated with processes such as nervous system development, neuron generation and differentiation, and apoptosis [231]. Acute and repeated MDMA exposure altered histone PTMs in the NAc promoter regions of the opioid-related nociceptin/orphaninFQ (N/OFQ)- Nociceptin Receptor (NOP) and dynorphin (DYN)- Kappa-Opioid Receptor (KOP) systems [232]. Specifically, acute MDMA increased the H3K4 methylation at N/OFQ and DYN promoters, while increasing H3K9 acetylation and decreasing H3K9 dymethylation at the DYN promoter. Acute and repeated MDMA also decreased H3K9 acetylation at the N/OFQ promoter [232]. These opioidergic effects could have direct implications for the therapeutic effects of MDMA on trauma [233], and for MDMA’s potential for addiction and neurotoxicity [234]. Considering the known involvement of epigenetics and transcriptional changes in addiction, it is prudent to investigate through cell-type and brain area-specific approaches whether epigenetic mechanisms may play a role in putative addictive, or anti-addictive, properties of RAADs.

Neurotoxicity

Several studies have reported neurotoxic effects of RAADs arising from repeated administration or higher doses. While such effects are not triggered in vivo by clinically relevant doses, this knowledge remains relevant from a harm-reduction perspective. Repeated ketamine increased histone deacetylase and DNMT activity, in an opposite fashion to the homolog changes elicited by clinically-relevant doses [235]. Additionally, repeated high-dose ketamine in young mice led to neurotoxicity, neuronal degeneration and memory impairments during adulthood, at least partially through miR-34c [236], miR-124 [237], miR-137 [238], and miR-199a-5p [239] signaling. In adolescent rats, repeated ketamine high-doses elicited hippocampal apoptosis and cognitive impairments, putatively mediated by hippocampal miR-214 downregulation/ Phosphatase And Tensin Homolog upregulation [240] and miR-34a upregulation/ Fibroblast Growth Factor Receptor 1 downregulation [241]. Repeated high-dose ketamine also elicited schizophrenia-like behavior accompanied by modulation of the miRNome and neurotrophic-related gene expression in the PFC and hippocampus [242, 243]. In vitro studies corroborate the neurotoxic effects of ketamine at higher doses through epigenetic mechanisms involving HDAC6, miR-22, miR-124, miR-497-5p, the lncRNAs SPRY4-IT1, LINC00641, and SNHG16, and the BDNF antisense RNA [214, 215, 237, 244–251]. Together, future research exploring the neurotoxic effects of RAADs abuse through epigenetic changes is encouraged.

Cancer

Several of the epigenetic effects elicited by RAADs involve signaling cascades related to cell growth, proliferation, and cancer, such as mTOR and BDNF [252, 253]. Therefore, epigenetic changes in these genes might induce or affect the progression of cancer. Considering that psychedelic-assisted psychotherapy is a promising treatment to attenuate psychological and existential distress in individuals facing a life-threatening conditions such as cancer, it is important to assess the neoplastic potential of RAADs [254–256]. If RAADs affected DNA methylation and other epigenetic mechanisms indiscriminately, for example by increasing or decreasing global DNA methylation aspecifically, this could pose a risk factor by causing genomic instability or repressing the transcription of tumor-suppressor genes [257–259]. A recent study reported oxidative DNA damage following the administration of higher-than clinically-relevant doses of psilocybin in the PFC and hippocampus [260]. Early reports suggested that ingesting or being exposed in utero to psychedelics such as LSD might be mutagenic and cause chromosomal damage and potential delayed mutations in the offspring (reviewed in [261]). However, subsequent experimental and epidemiological studies failed to replicate the findings, even in long-term psychedelic users [261, 262]. One investigation found that ketamine elicited ferropoptosis, and may thus elicit anti-neoplastic effects through the lncRNA Pvt1 oncogene /miR-214-3p signaling [263]. Given this evidence, further studies are warranted to investigate the potential of RAADs to induce, accelerate, or perhaps counteract, cancer.

Conclusion

Preliminary correlative evidence indicates that the epigenetic mechanisms engaged by RAADs converge, like conventional antidepressants, on permissive mechanisms over chromatin areas involved in neuroplasticity within stress-vulnerable brain regions. Importantly, these epigenetic changes counteract those induced by psychosocial stress, early-life adversities, and substance abuse. Yet, the abuse of RAADs triggers epigenetic marks resembling those elicited by stress.

Significant knowledge gaps remain, such as the mechanistic relationship between RAADs and epigenetic effects, the timing of onset of these epigenetic changes and their duration, the mechanisms responsible, cell type specificity, the role of metabolites, and the effects of “microdosing” (the ingestion of 1/10th–1/20th of a “large” dose). The polypharmacological nature of RAADs implies that each compound, dose, and regimen may uniquely affect the epigenetic control of gene expression, with potential indications or contraindications for various psychiatric disorders. Understanding how the subjective experience and environment modulate the epigenetic effects accompanying the administration of RAADs is an area ripe for exploration. Determining the potential modulation by the environment on the epigenetic effects of psychedelics could inform ongoing clinical investigations and expand our understanding of epigenetics. Brain area- and cell type-specific methods, facilitated by techniques like cell-sorting approaches and single-cell omics approaches, could address these questions [264, 265]. Identifying predictors [266] and modulators (i.e., set and setting, placebo effect) [267] of epigenetic responses accompanying RAADs administration could lead to improved therapeutic precision and efficacy.

While the epigenetic outcomes may causally contribute to therapeutic benefits, causative investigations lack. Given that epigenetic changes are observed in all cell types under disparate conditions (for example following neuronal activity or neurotoxic stimuli), the observed epigenetic changes could be secondary to behavioral changes induced by psychedelics. The potential epigenetic-mediated side effects, such as immune-related effects, cardiac hypertrophy, gestational and transgenerational effects, and cancer, also require further investigation. Future studies addressing these knowledge gaps could lead the way for developing novel neuroepigenetics-based precision therapeutics.

Competing interests

Antonio Inserra has received postdoctoral fellowships from the CIHR (Canadian Institutes of Health Research), FRQS (Fonds de Recherche Santé du Québec), and the Canadian Neurodevelopmental Research Training Platform (CanRT). Antonella Campanale has received Graduate Excellence Awards form the Faculty of Medicine of McGill University. Tamim Rezai, Patrizia Romualdi, and Tiziana Rubino have no biomedical financial interests or potential conflicts of interest.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

These authors contributed equally: Patrizia Romualdi, Tiziana Rubino.
==== Refs
References

1. Tsankova NM Berton O Renthal W Kumar A Neve RL Nestler EJ Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action Nat Neurosci 2006 9 519 25 10.1038/nn1659 16501568
Tsankova NM, Berton O, Renthal W, Kumar A, Neve RL, Nestler EJ. Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat Neurosci. 2006;9:519–25. 10.1038/nn1659.16501568 10.1038/nn1659
2. McGowan PO Sasaki A D’Alessio AC Dymov S Labonté B Szyf M Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse Nat Neurosci 2009 12 342 8 10.1038/nn.2270 19234457
McGowan PO, Sasaki A, D’Alessio AC, Dymov S, Labonté B, Szyf M, et al. Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse. Nat Neurosci. 2009;12:342–8. 10.1038/nn.2270.19234457 10.1038/nn.2270
3. Szyf M The early life social environment and DNA methylation Epigenetics 2011 6 971 8 10.4161/epi.6.8.16793 21772123
Szyf M. The early life social environment and DNA methylation. Epigenetics. 2011;6:971–8. 10.4161/epi.6.8.16793.21772123 10.4161/epi.6.8.16793
4. Stajic D Jansen LET Empirical evidence for epigenetic inheritance driving evolutionary adaptation Philos Trans R Soc B: Biol Sci 2021 376 20200121 10.1098/rstb.2020.0121
Stajic D, Jansen LET. Empirical evidence for epigenetic inheritance driving evolutionary adaptation. Philos Trans R Soc B: Biol Sci. 2021;376:20200121. 10.1098/rstb.2020.0121.10.1098/rstb.2020.0121
5. Floriou-Servou A von Ziegler L Stalder L Sturman O Privitera M Rassi A Distinct proteomic, transcriptomic, and epigenetic stress responses in dorsal and ventral hippocampus Biol Psychiatry 2018 84 531 41 10.1016/j.biopsych.2018.02.003 29605177
Floriou-Servou A, von Ziegler L, Stalder L, Sturman O, Privitera M, Rassi A, et al. Distinct proteomic, transcriptomic, and epigenetic stress responses in dorsal and ventral hippocampus. Biol Psychiatry. 2018;84:531–41. 10.1016/j.biopsych.2018.02.003.29605177 10.1016/j.biopsych.2018.02.003
6. van Marle HJF Hermans EJ Qin S Fernández G From specificity to sensitivity: how acute stress affects amygdala processing of biologically salient stimuli Biol Psychiatry 2009 66 649 55 10.1016/j.biopsych.2009.05.014 19596123
van Marle HJF, Hermans EJ, Qin S, Fernández G. From specificity to sensitivity: how acute stress affects amygdala processing of biologically salient stimuli. Biol Psychiatry. 2009;66:649–55. 10.1016/j.biopsych.2009.05.014.19596123 10.1016/j.biopsych.2009.05.014
7. Reus GZ Abelaira HM dos Santos MA Carlessi AS Tomaz DB Neotti MV Ketamine and imipramine in the nucleus accumbens regulate histone deacetylation induced by maternal deprivation and are critical for associated behaviors Behav Brain Res 2013 256 451 6 10.1016/j.bbr.2013.08.041 24004850
Reus GZ, Abelaira HM, dos Santos MA, Carlessi AS, Tomaz DB, Neotti MV, et al. Ketamine and imipramine in the nucleus accumbens regulate histone deacetylation induced by maternal deprivation and are critical for associated behaviors. Behav Brain Res. 2013;256:451–6. 10.1016/j.bbr.2013.08.041.24004850 10.1016/j.bbr.2013.08.041
8. Chen ES Ernst C Turecki G The epigenetic effects of antidepressant treatment on human prefrontal cortex BDNF expression Int J Neuropsychopharmacol 2011 14 427 9 10.1017/S1461145710001422 21134314
Chen ES, Ernst C, Turecki G. The epigenetic effects of antidepressant treatment on human prefrontal cortex BDNF expression. Int J Neuropsychopharmacol. 2011;14:427–9. 10.1017/S1461145710001422.21134314 10.1017/S1461145710001422
9. Amat J Baratta MV Paul E Bland ST Watkins LR Maier SF Medial prefrontal cortex determines how stressor controllability affects behavior and dorsal raphe nucleus Nat Neurosci 2005 8 365 71 10.1038/nn1399 15696163
Amat J, Baratta MV, Paul E, Bland ST, Watkins LR, Maier SF. Medial prefrontal cortex determines how stressor controllability affects behavior and dorsal raphe nucleus. Nat Neurosci. 2005;8:365–71.15696163 10.1038/nn1399
10. Vialou V Feng J Robison AJ Nestler EJ Epigenetic mechanisms of depression and antidepressant action Annu Rev Pharm Toxicol 2013 53 59 87 10.1146/annurev-pharmtox-010611-134540
Vialou V, Feng J, Robison AJ, Nestler EJ. Epigenetic mechanisms of depression and antidepressant action. Annu Rev Pharm Toxicol. 2013;53:59–87. 10.1146/annurev-pharmtox-010611-134540.10.1146/annurev-pharmtox-010611-134540
11. Labonte B Suderman M Maussion G Navaro L Yerko V Mahar I Genome-wide epigenetic regulation by early-life trauma Arch Gen Psychiatry 2012 69 722 31 10.1001/archgenpsychiatry.2011.2287 22752237
Labonte B, Suderman M, Maussion G, Navaro L, Yerko V, Mahar I, et al. Genome-wide epigenetic regulation by early-life trauma. Arch Gen Psychiatry. 2012;69:722–31. 10.1001/archgenpsychiatry.2011.2287.22752237 10.1001/archgenpsychiatry.2011.2287
12. Lim DA Huang Y-C Swigut T Mirick AL Garcia-Verdugo JM Wysocka J Chromatin remodelling factor Mll1 is essential for neurogenesis from postnatal neural stem cells Nature 2009 458 529 33 10.1038/nature07726 19212323
Lim DA, Huang Y-C, Swigut T, Mirick AL, Garcia-Verdugo JM, Wysocka J, et al. Chromatin remodelling factor Mll1 is essential for neurogenesis from postnatal neural stem cells. Nature. 2009;458:529–33. 10.1038/nature07726.19212323 10.1038/nature07726
13. Borrelli E Nestler EJ Allis CD Sassone-Corsi P Decoding the epigenetic language of neuronal plasticity Neuron 2008 60 961 74 10.1016/j.neuron.2008.10.012 19109904
Borrelli E, Nestler EJ, Allis CD, Sassone-Corsi P. Decoding the epigenetic language of neuronal plasticity. Neuron. 2008;60:961–74. 10.1016/j.neuron.2008.10.012.19109904 10.1016/j.neuron.2008.10.012
14. Inserra A De Gregorio D Gobbi G Psychedelics in psychiatry: neuroplastic, immunomodulatory, and neurotransmitter mechanisms Pharm Rev 2021 73 202 77 10.1124/pharmrev.120.000056 33328244
Inserra A, De Gregorio D, Gobbi G. Psychedelics in psychiatry: neuroplastic, immunomodulatory, and neurotransmitter mechanisms. Pharm Rev. 2021;73:202–77. 10.1124/pharmrev.120.000056.33328244 10.1124/pharmrev.120.000056
15. Vollenweider FX Preller KH Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders Nat Rev Neurosci 2020 21 611 24 10.1038/s41583-020-0367-2 32929261
Vollenweider FX, Preller KH. Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders. Nat Rev Neurosci. 2020;21:611–24. 10.1038/s41583-020-0367-2.32929261 10.1038/s41583-020-0367-2
16. Nichols DE Psychedelics Pharm Rev 2016 68 264 355 10.1124/pr.115.011478 26841800
Nichols DE. Psychedelics. Pharm Rev. 2016;68:264–355. 10.1124/pr.115.011478.26841800 10.1124/pr.115.011478
17. Krystal JH, Kavalali ET, Monteggia LM. Ketamine and rapid antidepressant action: new treatments and novel synaptic signaling mechanisms. Neuropsychopharmacology 2023. 10.1038/s41386-023-01629-w
18. Rudnick, G, Wall, SC. The molecular mechanism of “ecstasy” [3,4-methylenedioxy-methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release. Proc Natl Acad Sci USA. 1992;89:1817–21.
19. Johnson MW Garcia-Romeu A Griffiths RR Long-term follow-up of psilocybin-facilitated smoking cessation Am J Drug Alcohol Abus 2017 43 55 60 10.3109/00952990.2016.1170135
Johnson MW, Garcia-Romeu A, Griffiths RR. Long-term follow-up of psilocybin-facilitated smoking cessation. Am J Drug Alcohol Abus. 2017;43:55–60. 10.3109/00952990.2016.1170135.10.3109/00952990.2016.1170135
20. Murphy-Beiner A, Soar K. Ayahuasca’s ‘afterglow’: improved mindfulness and cognitive flexibility in ayahuasca drinkers. Psychopharmacology (Berl) 2020. 10.1007/s00213-019-05445-3
21. Zeifman RJ Palhano-Fontes F Hallak J Arcoverde E Maia-Oliveira JP Araujo DB The Impact of Ayahuasca on Suicidality: Results From a Randomized Controlled Trial Front Pharm 2019 10 1325 10.3389/fphar.2019.01325
Zeifman RJ, Palhano-Fontes F, Hallak J, Arcoverde E, Maia-Oliveira JP, Araujo DB. The Impact of Ayahuasca on Suicidality: Results From a Randomized Controlled Trial. Front Pharm. 2019;10:1325. 10.3389/fphar.2019.01325.10.3389/fphar.2019.01325
22. Kuypers KP Riba J de la Fuente Revenga M Barker S Theunissen EL Ramaekers JG Ayahuasca enhances creative divergent thinking while decreasing conventional convergent thinking Psychopharmacol (Berl) 2016 233 3395 403 10.1007/s00213-016-4377-8
Kuypers KP, Riba J, de la Fuente Revenga M, Barker S, Theunissen EL, Ramaekers JG. Ayahuasca enhances creative divergent thinking while decreasing conventional convergent thinking. Psychopharmacol (Berl). 2016;233:3395–403. 10.1007/s00213-016-4377-8.10.1007/s00213-016-4377-8
23. Davis AK Barsuglia JP Lancelotta R Grant RM Renn E The epidemiology of 5-methoxy- N, N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption J Psychopharmacol 2018 32 779 92 10.1177/0269881118769063 29708042
Davis AK, Barsuglia JP, Lancelotta R, Grant RM, Renn E. The epidemiology of 5-methoxy- N, N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption. J Psychopharmacol. 2018;32:779–92. 10.1177/0269881118769063.29708042 10.1177/0269881118769063
24. Garcia-Romeu A Griffiths RR Johnson MW Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction Curr Drug Abus Rev 2014 7 157 64 10.2174/1874473708666150107121331
Garcia-Romeu A, Griffiths RR, Johnson MW. Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Curr Drug Abus Rev. 2014;7:157–64. 10.2174/1874473708666150107121331.10.2174/1874473708666150107121331
25. Callaway JC Airaksinen MM McKenna DJ Brito GS Grob CS Platelet serotonin uptake sites increased in drinkers of ayahuasca Psychopharmacol (Berl) 1994 116 385 7 10.1007/bf02245347
Callaway JC, Airaksinen MM, McKenna DJ, Brito GS, Grob CS. Platelet serotonin uptake sites increased in drinkers of ayahuasca. Psychopharmacol (Berl). 1994;116:385–7. 10.1007/bf02245347.10.1007/bf02245347
26. Bouso JC Palhano-Fontes F Rodríguez-Fornells A Ribeiro S Sanches R Crippa JAS Long-term use of psychedelic drugs is associated with differences in brain structure and personality in humans Eur Neuropsychopharmacol 2015 25 483 92 10.1016/j.euroneuro.2015.01.008 25637267
Bouso JC, Palhano-Fontes F, Rodríguez-Fornells A, Ribeiro S, Sanches R, Crippa JAS, et al. Long-term use of psychedelic drugs is associated with differences in brain structure and personality in humans. Eur Neuropsychopharmacol. 2015;25:483–92. 10.1016/j.euroneuro.2015.01.008.25637267 10.1016/j.euroneuro.2015.01.008
27. Robertson KD DNA methylation and human disease Nat Rev Genet 2005 6 597 610 10.1038/nrg1655 16136652
Robertson KD. DNA methylation and human disease. Nat Rev Genet. 2005;6:597–610. 10.1038/nrg1655.16136652 10.1038/nrg1655
28. Weaver ICG Diorio J Seckl JR Szyf M Meaney MJ Early Environmental Regulation of Hippocampal Glucocorticoid Receptor Gene Expression: Characterization of Intracellular Mediators and Potential Genomic Target Sites Ann N. Y Acad Sci 2004 1024 182 212 10.1196/annals.1321.099 15265782
Weaver ICG, Diorio J, Seckl JR, Szyf M, Meaney MJ. Early Environmental Regulation of Hippocampal Glucocorticoid Receptor Gene Expression: Characterization of Intracellular Mediators and Potential Genomic Target Sites. Ann N. Y Acad Sci. 2004;1024:182–212. 10.1196/annals.1321.099.15265782 10.1196/annals.1321.099
29. Kundakovic M Gudsnuk K Herbstman JB Tang D Perera FP Champagne FA DNA methylation of BDNF as a biomarker of early-life adversity Proc Natl Acad Sci USA 2015 112 6807 13 10.1073/pnas.1408355111 25385582
Kundakovic M, Gudsnuk K, Herbstman JB, Tang D, Perera FP, Champagne FA. DNA methylation of BDNF as a biomarker of early-life adversity. Proc Natl Acad Sci USA. 2015;112:6807–13. 10.1073/pnas.1408355111.25385582 10.1073/pnas.1408355111
30. Murgatroyd C Patchev AV Wu Y Micale V Bockmuhl Y Fischer D Dynamic DNA methylation programs persistent adverse effects of early-life stress Nat Neurosci 2009 12 1559 66 10.1038/nn.2436 19898468
Murgatroyd C, Patchev AV, Wu Y, Micale V, Bockmuhl Y, Fischer D, et al. Dynamic DNA methylation programs persistent adverse effects of early-life stress. Nat Neurosci. 2009;12:1559–66. 10.1038/nn.2436.19898468 10.1038/nn.2436
31. Kangaspeska S Stride B Metivier R Polycarpou-Schwarz M Ibberson D Carmouche RP Transient cyclical methylation of promoter DNA Nature 2008 452 112 5 10.1038/nature06640 18322535
Kangaspeska S, Stride B, Metivier R, Polycarpou-Schwarz M, Ibberson D, Carmouche RP, et al. Transient cyclical methylation of promoter DNA. Nature. 2008;452:112–5. 10.1038/nature06640.18322535 10.1038/nature06640
32. Labonté B Suderman M Maussion G Lopez JP Navarro-Sánchez L Yerko V Genome-wide methylation changes in the brains of suicide completers Am J Psychiatry 2013 170 511 20 10.1176/appi.ajp.2012.12050627 23511308
Labonté B, Suderman M, Maussion G, Lopez JP, Navarro-Sánchez L, Yerko V, et al. Genome-wide methylation changes in the brains of suicide completers. Am J Psychiatry. 2013;170:511–20. 10.1176/appi.ajp.2012.12050627.23511308 10.1176/appi.ajp.2012.12050627
33. Provencal N Suderman MJ Guillemin C Massart R Ruggiero A Wang D The signature of maternal rearing in the methylome in rhesus macaque prefrontal cortex and T cells J Neurosci 2012 32 15626 42 10.1523/JNEUROSCI.1470-12.2012 23115197
Provencal N, Suderman MJ, Guillemin C, Massart R, Ruggiero A, Wang D, et al. The signature of maternal rearing in the methylome in rhesus macaque prefrontal cortex and T cells. J Neurosci. 2012;32:15626–42. 10.1523/JNEUROSCI.1470-12.2012.23115197 10.1523/JNEUROSCI.1470-12.2012
34. McGowan PO Sasaki A Huang TCT Unterberger A Suderman M Ernst C Promoter-wide hypermethylation of the ribosomal RNA gene promoter in the suicide brain PLoS ONE 2008 3 e2085 10.1371/journal.pone.0002085 18461137
McGowan PO, Sasaki A, Huang TCT, Unterberger A, Suderman M, Ernst C, et al. Promoter-wide hypermethylation of the ribosomal RNA gene promoter in the suicide brain. PLoS ONE. 2008;3:e2085. 10.1371/journal.pone.0002085.18461137 10.1371/journal.pone.0002085
35. Ernst C Deleva V Deng X Sequeira A Pomarenski A Klempan T Alternative Splicing, Methylation State, and Expression Profile of Tropomyosin-Related Kinase B in the Frontal Cortex of Suicide Completers Arch Gen Psychiatry 2009 66 22 32 10.1001/archpsyc.66.1.22 19124685
Ernst C, Deleva V, Deng X, Sequeira A, Pomarenski A, Klempan T, et al. Alternative Splicing, Methylation State, and Expression Profile of Tropomyosin-Related Kinase B in the Frontal Cortex of Suicide Completers. Arch Gen Psychiatry. 2009;66:22–32. 10.1001/archpsyc.66.1.22.19124685 10.1001/archpsyc.66.1.22
36. Kang H-J Kim J-M Lee J-Y Kim S-Y Bae K-Y Kim S-W BDNF promoter methylation and suicidal behavior in depressive patients J Affect Disord 2013 151 679 85 10.1016/j.jad.2013.08.001 23992681
Kang H-J, Kim J-M, Lee J-Y, Kim S-Y, Bae K-Y, Kim S-W, et al. BDNF promoter methylation and suicidal behavior in depressive patients. J Affect Disord. 2013;151:679–85. 10.1016/j.jad.2013.08.001.23992681 10.1016/j.jad.2013.08.001
37. Kang H-J Kim J-M Bae K-Y Kim S-W Shin I-S Kim H-R Longitudinal associations between BDNF promoter methylation and late-life depression Neurobiol Aging 2015 36 1764.e1761 1764.e1767 10.1016/j.neurobiolaging.2014.12.035
Kang H-J, Kim J-M, Bae K-Y, Kim S-W, Shin I-S, Kim H-R, et al. Longitudinal associations between BDNF promoter methylation and late-life depression. Neurobiol Aging. 2015;36:1764.e1761–1764.e1767. 10.1016/j.neurobiolaging.2014.12.035.10.1016/j.neurobiolaging.2014.12.035
38. Januar V Ancelin ML Ritchie K Saffery R Ryan J BDNF promoter methylation and genetic variation in late-life depression Transl Psychiatry 2015 5 e619 10.1038/tp.2015.114 26285129
Januar V, Ancelin ML, Ritchie K, Saffery R, Ryan J. BDNF promoter methylation and genetic variation in late-life depression. Transl Psychiatry. 2015;5:e619. 10.1038/tp.2015.114.26285129 10.1038/tp.2015.114
39. Kang HJ Kim JM Kim SY Kim SW Shin IS Kim HR A longitudinal study of BDNF promoter methylation and depression in breast cancer Psychiatry Investig 2015 12 523 31 10.4306/pi.2015.12.4.523 26508964
Kang HJ, Kim JM, Kim SY, Kim SW, Shin IS, Kim HR, et al. A longitudinal study of BDNF promoter methylation and depression in breast cancer. Psychiatry Investig. 2015;12:523–31. 10.4306/pi.2015.12.4.523.26508964 10.4306/pi.2015.12.4.523
40. Kim J-M Stewart R Kang H-J Kim S-Y Kim S-W Shin I-S A longitudinal study of BDNF promoter methylation and genotype with poststroke depression J Affect Disord 2013 149 93 99 10.1016/j.jad.2013.01.008 23399480
Kim J-M, Stewart R, Kang H-J, Kim S-Y, Kim S-W, Shin I-S, et al. A longitudinal study of BDNF promoter methylation and genotype with poststroke depression. J Affect Disord. 2013;149:93–99. 10.1016/j.jad.2013.01.008.23399480 10.1016/j.jad.2013.01.008
41. Ferrer A Labad J Salvat-Pujol N Barrachina M Costas J Urretavizcaya M BDNF genetic variants and methylation: effects on cognition in major depressive disorder Transl Psychiatry 2019 9 265 10.1038/s41398-019-0601-8 31636250
Ferrer A, Labad J, Salvat-Pujol N, Barrachina M, Costas J, Urretavizcaya M, et al. BDNF genetic variants and methylation: effects on cognition in major depressive disorder. Transl Psychiatry. 2019;9:265. 10.1038/s41398-019-0601-8.31636250 10.1038/s41398-019-0601-8
42. Ikegame T Bundo M Murata Y Kasai K Kato T Iwamoto K DNA methylation of the BDNF gene and its relevance to psychiatric disorders J Hum Genet 2013 58 434 8 10.1038/jhg.2013.65 23739121
Ikegame T, Bundo M, Murata Y, Kasai K, Kato T, Iwamoto K. DNA methylation of the BDNF gene and its relevance to psychiatric disorders. J Hum Genet. 2013;58:434–8. 10.1038/jhg.2013.65.23739121 10.1038/jhg.2013.65
43. Roth TL Lubin FD Funk AJ Sweatt JD Lasting epigenetic influence of early-life adversity on the BDNF gene Biol Psychiatry 2009 65 760 9 10.1016/j.biopsych.2008.11.028 19150054
Roth TL, Lubin FD, Funk AJ, Sweatt JD. Lasting epigenetic influence of early-life adversity on the BDNF gene. Biol Psychiatry. 2009;65:760–9. 10.1016/j.biopsych.2008.11.028.19150054 10.1016/j.biopsych.2008.11.028
44. Nagy C Suderman M Yang J Szyf M Mechawar N Ernst C Astrocytic abnormalities and global DNA methylation patterns in depression and suicide Mol Psychiatry 2015 20 320 8 10.1038/mp.2014.21 24662927
Nagy C, Suderman M, Yang J, Szyf M, Mechawar N, Ernst C, et al. Astrocytic abnormalities and global DNA methylation patterns in depression and suicide. Mol Psychiatry. 2015;20:320–8. 10.1038/mp.2014.21.24662927 10.1038/mp.2014.21
45. Detich N Bovenzi V Szyf M Valproate induces replication-independent active DNA demethylation J Biol Chem 2003 278 27586 92 10.1074/jbc.M303740200 12748177
Detich N, Bovenzi V, Szyf M. Valproate induces replication-independent active DNA demethylation. J Biol Chem. 2003;278:27586–92. 10.1074/jbc.M303740200.12748177 10.1074/jbc.M303740200
46. Lima IVA Almeida-Santos AF Ferreira-Vieira TH Aguiar DC Ribeiro FM Campos AC Antidepressant-like effect of valproic acid-possible involvement of PI3K/Akt/mTOR pathway Behav Brain Res 2017 329 166 71 10.1016/j.bbr.2017.04.015 28408298
Lima IVA, Almeida-Santos AF, Ferreira-Vieira TH, Aguiar DC, Ribeiro FM, Campos AC, et al. Antidepressant-like effect of valproic acid-possible involvement of PI3K/Akt/mTOR pathway. Behav Brain Res. 2017;329:166–71. 10.1016/j.bbr.2017.04.015.28408298 10.1016/j.bbr.2017.04.015
47. Ghabrash MF Comai S Tabaka J Saint-Laurent M Booij L Gobbi G Valproate augmentation in a subgroup of patients with treatment-resistant unipolar depression World J Biol Psychiatry 2016 17 165 70 10.3109/15622975.2015.1073856 26444701
Ghabrash MF, Comai S, Tabaka J, Saint-Laurent M, Booij L, Gobbi G. Valproate augmentation in a subgroup of patients with treatment-resistant unipolar depression. World J Biol Psychiatry. 2016;17:165–70. 10.3109/15622975.2015.1073856.26444701 10.3109/15622975.2015.1073856
48. Ramchandani S Bhattacharya SK Cervoni N Szyf M DNA methylation is a reversible biological signal Proc Natl Acad Sci USA. 1999 96 6107 12 10.1073/pnas.96.11.6107 10339549
Ramchandani S, Bhattacharya SK, Cervoni N, Szyf M. DNA methylation is a reversible biological signal. Proc Natl Acad Sci USA. 1999;96:6107–12. 10.1073/pnas.96.11.6107.10339549 10.1073/pnas.96.11.6107
49. Ju LS Yang JJ Lei L Xia JY Luo D Ji MH The combination of long-term ketamine and extinction training contributes to fear erasure by Bdnf methylation Front Cell Neurosci 2017 11 100 10.3389/fncel.2017.00100 28473755
Ju LS, Yang JJ, Lei L, Xia JY, Luo D, Ji MH, et al. The combination of long-term ketamine and extinction training contributes to fear erasure by Bdnf methylation. Front Cell Neurosci. 2017;11:100. 10.3389/fncel.2017.00100.28473755 10.3389/fncel.2017.00100
50. Sales AJ Joca SRL Antidepressant administration modulates stress-induced DNA methylation and DNA methyltransferase expression in rat prefrontal cortex and hippocampus Behavioural Brain Res 2018 343 8 15 10.1016/j.bbr.2018.01.022
Sales AJ, Joca SRL. Antidepressant administration modulates stress-induced DNA methylation and DNA methyltransferase expression in rat prefrontal cortex and hippocampus. Behavioural Brain Res. 2018;343:8–15. 10.1016/j.bbr.2018.01.022.10.1016/j.bbr.2018.01.022
51. Sakata K Duke S Lack of BDNF expression through promoter IV disturbs expression of monoamine genes in the frontal cortex and hippocampus Neuroscience 2014 260 265 75 10.1016/j.neuroscience.2013.12.013 24345476
Sakata K, Duke S. Lack of BDNF expression through promoter IV disturbs expression of monoamine genes in the frontal cortex and hippocampus. Neuroscience. 2014;260:265–75.24345476 10.1016/j.neuroscience.2013.12.013
52. Liu R Wu X-M He X Wang R-Z Yin X-Y Zhou F Contribution of DNA methyltransferases to spared nerve injury induced depression partially through epigenetically repressing Bdnf in hippocampus: reversal by ketamine Pharm Biochem Behav 2021 200 173079 10.1016/j.pbb.2020.173079
Liu R, Wu X-M, He X, Wang R-Z, Yin X-Y, Zhou F, et al. Contribution of DNA methyltransferases to spared nerve injury induced depression partially through epigenetically repressing Bdnf in hippocampus: reversal by ketamine. Pharm Biochem Behav. 2021;200:173079. 10.1016/j.pbb.2020.173079.10.1016/j.pbb.2020.173079
53. Xu H Wang J Zhang K Zhao M Ellenbroek B Shao F Effects of adolescent social stress and antidepressant treatment on cognitive inflexibility and Bdnf epigenetic modifications in the mPFC of adult mice Psychoneuroendocrinology 2018 88 92 101 10.1016/j.psyneuen.2017.11.013 29195162
Xu H, Wang J, Zhang K, Zhao M, Ellenbroek B, Shao F, et al. Effects of adolescent social stress and antidepressant treatment on cognitive inflexibility and Bdnf epigenetic modifications in the mPFC of adult mice. Psychoneuroendocrinology. 2018;88:92–101. 10.1016/j.psyneuen.2017.11.013.29195162 10.1016/j.psyneuen.2017.11.013
54. Wang P Zhang C Lv Q Bao C Sun H Ma G Association of DNA methylation in BDNF with escitalopram treatment response in depressed Chinese Han patients Eur J Clin Pharm 2018 74 1011 20 10.1007/s00228-018-2463-z
Wang P, Zhang C, Lv Q, Bao C, Sun H, Ma G, et al. Association of DNA methylation in BDNF with escitalopram treatment response in depressed Chinese Han patients. Eur J Clin Pharm. 2018;74:1011–20. 10.1007/s00228-018-2463-z.10.1007/s00228-018-2463-z
55. Jin H-J Pei L Li Y-N Zheng H Yang S Wan Y Alleviative effects of fluoxetine on depressive-like behaviors by epigenetic regulation of BDNF gene transcription in mouse model of post-stroke depression Sci Rep. 2017 7 14926 10.1038/s41598-017-13929-5 29097744
Jin H-J, Pei L, Li Y-N, Zheng H, Yang S, Wan Y, et al. Alleviative effects of fluoxetine on depressive-like behaviors by epigenetic regulation of BDNF gene transcription in mouse model of post-stroke depression. Sci Rep. 2017;7:14926. 10.1038/s41598-017-13929-5.29097744 10.1038/s41598-017-13929-5
56. Boulle F Pawluski JL Homberg JR Machiels B Kroeze Y Kumar N Prenatal stress and early-life exposure to fluoxetine have enduring effects on anxiety and hippocampal BDNF gene expression in adult male offspring Dev Psychobiol. 2016 58 427 38 10.1002/dev.21385 26608001
Boulle F, Pawluski JL, Homberg JR, Machiels B, Kroeze Y, Kumar N, et al. Prenatal stress and early-life exposure to fluoxetine have enduring effects on anxiety and hippocampal BDNF gene expression in adult male offspring. Dev Psychobiol. 2016;58:427–38. 10.1002/dev.21385.26608001 10.1002/dev.21385
57. Allen AP Naughton M Dowling J Walsh A Ismail F Shorten G Serum BDNF as a peripheral biomarker of treatment-resistant depression and the rapid antidepressant response: a comparison of ketamine and ECT J Affect Disord 2015 186 306 11 10.1016/j.jad.2015.06.033 26275358
Allen AP, Naughton M, Dowling J, Walsh A, Ismail F, Shorten G, et al. Serum BDNF as a peripheral biomarker of treatment-resistant depression and the rapid antidepressant response: a comparison of ketamine and ECT. J Affect Disord. 2015;186:306–11. 10.1016/j.jad.2015.06.033.26275358 10.1016/j.jad.2015.06.033
58. Lopez JP Mamdani F Labonte B Beaulieu MM Yang JP Berlim MT Epigenetic regulation of BDNF expression according to antidepressant response Mol Psychiatry 2013 18 398 9 10.1038/mp.2012.38 22547115
Lopez JP, Mamdani F, Labonte B, Beaulieu MM, Yang JP, Berlim MT, et al. Epigenetic regulation of BDNF expression according to antidepressant response. Mol Psychiatry. 2013;18:398–9. 10.1038/mp.2012.38.22547115 10.1038/mp.2012.38
59. D’Addario C Dell’Osso B Palazzo MC Benatti B Lietti L Cattaneo E Selective DNA methylation of BDNF promoter in bipolar disorder: differences among patients with BDI and BDII Neuropsychopharmacology 2012 37 1647 55 10.1038/npp.2012.10 22353757
D’Addario C, Dell’Osso B, Palazzo MC, Benatti B, Lietti L, Cattaneo E, et al. Selective DNA methylation of BDNF promoter in bipolar disorder: differences among patients with BDI and BDII. Neuropsychopharmacology. 2012;37:1647–55. 10.1038/npp.2012.10.22353757 10.1038/npp.2012.10
60. D’Addario C Dell’Osso B Galimberti D Palazzo MC Benatti B Di Francesco A Epigenetic modulation of BDNF gene in patients with major depressive disorder Biol Psychiatry 2013 73 e6 e7 10.1016/j.biopsych.2012.07.009 22901293
D’Addario C, Dell’Osso B, Galimberti D, Palazzo MC, Benatti B, Di Francesco A, et al. Epigenetic modulation of BDNF gene in patients with major depressive disorder. Biol Psychiatry. 2013;73:e6–e7. 10.1016/j.biopsych.2012.07.009.22901293 10.1016/j.biopsych.2012.07.009
61. Carlberg L Scheibelreiter J Hassler MR Schloegelhofer M Schmoeger M Ludwig B Brain-derived neurotrophic factor (BDNF)—Epigenetic regulation in unipolar and bipolar affective disorder J Affect Disord 2014 168 399 406 10.1016/j.jad.2014.07.022 25106037
Carlberg L, Scheibelreiter J, Hassler MR, Schloegelhofer M, Schmoeger M, Ludwig B, et al. Brain-derived neurotrophic factor (BDNF)—Epigenetic regulation in unipolar and bipolar affective disorder. J Affect Disord. 2014;168:399–406. 10.1016/j.jad.2014.07.022.25106037 10.1016/j.jad.2014.07.022
62. Yao W Cao Q Luo S He L Yang C Chen J Microglial ERK-NRBP1-CREB-BDNF signaling in sustained antidepressant actions of (R)-ketamine Mol Psychiatry 2022 27 1618 29 10.1038/s41380-021-01377-7 34819637
Yao W, Cao Q, Luo S, He L, Yang C, Chen J, et al. Microglial ERK-NRBP1-CREB-BDNF signaling in sustained antidepressant actions of (R)-ketamine. Mol Psychiatry. 2022;27:1618–29. 10.1038/s41380-021-01377-7.34819637 10.1038/s41380-021-01377-7
63. Joca SRL Sales AJ Effects of DNA methylation inhibitors and conventional antidepressants on mice behaviour and brain DNA methylation levels Acta Neuropsychiatrica 2016 28 11 22 10.1017/neu.2015.40 26112212
Joca SRL, Sales AJ. Effects of DNA methylation inhibitors and conventional antidepressants on mice behaviour and brain DNA methylation levels. Acta Neuropsychiatrica. 2016;28:11–22. 10.1017/neu.2015.40.26112212 10.1017/neu.2015.40
64. Toffoli LV Rodrigues GM Oliveira JF Silva AS Moreira EG Pelosi GG Maternal exposure to fluoxetine during gestation and lactation affects the DNA methylation programming of rat’s offspring: modulation by folic acid supplementation Behav Brain Res 2014 265 142 7 10.1016/j.bbr.2014.02.031 24583191
Toffoli LV, Rodrigues GM, Oliveira JF, Silva AS, Moreira EG, Pelosi GG, et al. Maternal exposure to fluoxetine during gestation and lactation affects the DNA methylation programming of rat’s offspring: modulation by folic acid supplementation. Behav Brain Res. 2014;265:142–7. 10.1016/j.bbr.2014.02.031.24583191 10.1016/j.bbr.2014.02.031
65. Booij L Szyf M Carballedo A Frey EM Morris D Dymov S DNA methylation of the serotonin transporter gene in peripheral cells and stress-related changes in hippocampal volume: a study in depressed patients and healthy controls PLoS ONE 2015 10 e0119061 10.1371/journal.pone.0119061 25781010
Booij L, Szyf M, Carballedo A, Frey EM, Morris D, Dymov S, et al. DNA methylation of the serotonin transporter gene in peripheral cells and stress-related changes in hippocampal volume: a study in depressed patients and healthy controls. PLoS ONE. 2015;10:e0119061. 10.1371/journal.pone.0119061.25781010 10.1371/journal.pone.0119061
66. Ryan J Pilkington L Neuhaus K Ritchie K Ancelin M-L Saffery R Investigating the epigenetic profile of the inflammatory gene IL-6 in late-life depression BMC Psychiatry 2017 17 354 10.1186/s12888-017-1515-8 29070016
Ryan J, Pilkington L, Neuhaus K, Ritchie K, Ancelin M-L, Saffery R. Investigating the epigenetic profile of the inflammatory gene IL-6 in late-life depression. BMC Psychiatry. 2017;17:354. 10.1186/s12888-017-1515-8.29070016 10.1186/s12888-017-1515-8
67. Verhoeven JE Yang R Wolkowitz OM Bersani FS Lindqvist D Mellon SH Epigenetic age in male combat-exposed War Veterans: Associations with Posttraumatic Stress Disorder Status Mol Neuropsychiatry 2018 4 90 9 10.1159/000491431 30397597
Verhoeven JE, Yang R, Wolkowitz OM, Bersani FS, Lindqvist D, Mellon SH, et al. Epigenetic age in male combat-exposed War Veterans: Associations with Posttraumatic Stress Disorder Status. Mol Neuropsychiatry. 2018;4:90–9. 10.1159/000491431.30397597 10.1159/000491431
68. Germann CB The Psilocybin-Telomere Hypothesis: An empirically falsifiable prediction concerning the beneficial neuropsychopharmacological effects of psilocybin on genetic aging Med Hypotheses 2020 134 109406 10.1016/j.mehy.2019.109406 31634774
Germann CB. The Psilocybin-Telomere Hypothesis: An empirically falsifiable prediction concerning the beneficial neuropsychopharmacological effects of psilocybin on genetic aging. Med Hypotheses. 2020;134:109406. 10.1016/j.mehy.2019.109406.31634774 10.1016/j.mehy.2019.109406
69. Inserra A Campanale A Cheishvili D Dymov S Wong A Marcal N Modulation of DNA methylation and protein expression in the prefrontal cortex by repeated administration of D-lysergic acid diethylamide (LSD): Impact on neurotropic, neurotrophic, and neuroplasticity signaling Prog Neuro-Psychopharmacol Biol Psychiatry 2022 119 110594 10.1016/j.pnpbp.2022.110594
Inserra A, Campanale A, Cheishvili D, Dymov S, Wong A, Marcal N, et al. Modulation of DNA methylation and protein expression in the prefrontal cortex by repeated administration of D-lysergic acid diethylamide (LSD): Impact on neurotropic, neurotrophic, and neuroplasticity signaling. Prog Neuro-Psychopharmacol Biol Psychiatry. 2022;119:110594. 10.1016/j.pnpbp.2022.110594.10.1016/j.pnpbp.2022.110594
70. De Gregorio D Popic J Enns JP Inserra A Skalecka A Markopoulos A Lysergic acid diethylamide (LSD) promotes social behavior through mTORC1 in the excitatory neurotransmission Proc Natl Acad Sci USA 2021 118 e2020705118 10.1073/pnas.2020705118 33495318
De Gregorio D, Popic J, Enns JP, Inserra A, Skalecka A, Markopoulos A, et al. Lysergic acid diethylamide (LSD) promotes social behavior through mTORC1 in the excitatory neurotransmission. Proc Natl Acad Sci USA. 2021;118:e2020705118. 10.1073/pnas.2020705118.33495318 10.1073/pnas.2020705118
71. De Gregorio D Inserra A Enns JP Markopoulos A Pileggi M El Rahimy Y Repeated lysergic acid diethylamide (LSD) reverses stress-induced anxiety-like behavior, cortical synaptogenesis deficits and serotonergic neurotransmission decline Neuropsychopharmacology 2022 47 1188 98 10.1038/s41386-022-01301-9 35301424
De Gregorio D, Inserra A, Enns JP, Markopoulos A, Pileggi M, El Rahimy Y, et al. Repeated lysergic acid diethylamide (LSD) reverses stress-induced anxiety-like behavior, cortical synaptogenesis deficits and serotonergic neurotransmission decline. Neuropsychopharmacology. 2022;47:1188–98. 10.1038/s41386-022-01301-9.35301424 10.1038/s41386-022-01301-9
72. Inserra A Giorgini G Lacroix S Bertazzo A Choo J Markopolous A Effects of repeated lysergic acid diethylamide (LSD) on the mouse brain endocannabinoidome and gut microbiome Br J Pharm 2023 180 721 39 10.1111/bph.15977
Inserra A, Giorgini G, Lacroix S, Bertazzo A, Choo J, Markopolous A, et al. Effects of repeated lysergic acid diethylamide (LSD) on the mouse brain endocannabinoidome and gut microbiome. Br J Pharm. 2023;180:721–39. 10.1111/bph.15977.10.1111/bph.15977
73. Hanson HE, Liebl AL. The mutagenic consequences of DNA methylation within and across generations. Epigenomes 2022;6.
74. Supek F Lehner B Hajkova P Warnecke T Hydroxymethylated cytosines are associated with elevated C to G transversion rates PLoS Genet 2014 10 e1004585 10.1371/journal.pgen.1004585 25211471
Supek F, Lehner B, Hajkova P, Warnecke T. Hydroxymethylated cytosines are associated with elevated C to G transversion rates. PLoS Genet. 2014;10:e1004585. 10.1371/journal.pgen.1004585.25211471 10.1371/journal.pgen.1004585
75. Zeifman RJ, Yu D, Singhal N, Wang G, Nayak SM, Weissman CR. Decreases in suicidality following psychedelic therapy: a meta-analysis of individual patient data across clinical trials. J Clin Psychiatry. 2022;83. 10.4088/JCP.21r14057
76. Hendricks PS Thorne CB Clark CB Coombs DW Johnson MW Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population J Psychopharmacol 2015 29 280 8 10.1177/0269881114565653 25586402
Hendricks PS, Thorne CB, Clark CB, Coombs DW, Johnson MW. Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. J Psychopharmacol. 2015;29:280–8. 10.1177/0269881114565653.25586402 10.1177/0269881114565653
77. Murphy TM Mullins N Ryan M Foster T Kelly C McClelland R Genetic variation in DNMT3B and increased global DNA methylation is associated with suicide attempts in psychiatric patients Genes Brain Behav 2013 12 125 32 10.1111/j.1601-183X.2012.00865.x 23025623
Murphy TM, Mullins N, Ryan M, Foster T, Kelly C, McClelland R, et al. Genetic variation in DNMT3B and increased global DNA methylation is associated with suicide attempts in psychiatric patients. Genes Brain Behav. 2013;12:125–32. 10.1111/j.1601-183X.2012.00865.x.23025623 10.1111/j.1601-183X.2012.00865.x
78. Haghighi F Xin Y Chanrion B O’Donnell AH Ge Y Dwork AJ Increased DNA methylation in the suicide brain Dialogues Clin Neurosci 2014 16 430 8 10.31887/DCNS.2014.16.3/jmann 25364291
Haghighi F, Xin Y, Chanrion B, O’Donnell AH, Ge Y, Dwork AJ, et al. Increased DNA methylation in the suicide brain. Dialogues Clin Neurosci. 2014;16:430–8. 10.31887/DCNS.2014.16.3/jmann.25364291 10.31887/DCNS.2014.16.3/jmann
79. Ruffell SGD, Netzband N, Tsang W, Davies M, Butler M, Rucker JJH et al. Ceremonial Ayahuasca in Amazonian retreats—mental health and epigenetic outcomes from a six-month naturalistic study. Front Psychiatry 2021;12. 10.3389/fpsyt.2021.687615
80. Inserra A Hypothesis: The Psychedelic Ayahuasca Heals Traumatic Memories via a Sigma 1 Receptor-Mediated Epigenetic-Mnemonic Process Front Pharm 2018 9 330 10.3389/fphar.2018.00330
Inserra A. Hypothesis: The Psychedelic Ayahuasca Heals Traumatic Memories via a Sigma 1 Receptor-Mediated Epigenetic-Mnemonic Process. Front Pharm. 2018;9:330. 10.3389/fphar.2018.00330.10.3389/fphar.2018.00330
81. Ling Y Feng J Luo L Guo J Peng Y Wang T Design and Synthesis of C3-Substituted β-Carboline-Based Histone Deacetylase Inhibitors with Potent Antitumor Activities ChemMedChem 2017 12 646 51 10.1002/cmdc.201700133 28425177
Ling Y, Feng J, Luo L, Guo J, Peng Y, Wang T, et al. Design and Synthesis of C3-Substituted β-Carboline-Based Histone Deacetylase Inhibitors with Potent Antitumor Activities. ChemMedChem. 2017;12:646–51. 10.1002/cmdc.201700133.28425177 10.1002/cmdc.201700133
82. Leonhardt M Sellmer A Krämer OH Dove S Elz S Kraus B Design and biological evaluation of tetrahydro-β-carboline derivatives as highly potent histone deacetylase 6 (HDAC6) inhibitors Eur J Medicinal Chem 2018 152 329 57 10.1016/j.ejmech.2018.04.046
Leonhardt M, Sellmer A, Krämer OH, Dove S, Elz S, Kraus B, et al. Design and biological evaluation of tetrahydro-β-carboline derivatives as highly potent histone deacetylase 6 (HDAC6) inhibitors. Eur J Medicinal Chem. 2018;152:329–57. 10.1016/j.ejmech.2018.04.046.10.1016/j.ejmech.2018.04.046
83. Lewis, CR, Tafur, J, Spencer, S, Green, JM, Harrison, C, Kelmendi, B, et al. Pilot study suggests DNA methylation of the glucocorticoid receptor gene (NR3C1) is associated with MDMA-assisted therapy treatment response for severe PTSD. Frontiers in Psychiatry 2023;14 10.3389/fpsyt.2023.959590
84. Erburu M Muñoz-Cobo I Domínguez-Andrés J Beltran E Suzuki T Mai A Chronic stress and antidepressant induced changes in Hdac5 and Sirt2 affect synaptic plasticity Eur Neuropsychopharmacol 2015 25 2036 48 10.1016/j.euroneuro.2015.08.016 26433268
Erburu M, Muñoz-Cobo I, Domínguez-Andrés J, Beltran E, Suzuki T, Mai A, et al. Chronic stress and antidepressant induced changes in Hdac5 and Sirt2 affect synaptic plasticity. Eur Neuropsychopharmacol. 2015;25:2036–48. 10.1016/j.euroneuro.2015.08.016.26433268 10.1016/j.euroneuro.2015.08.016
85. Jawerka M Colak D Dimou L Spiller C Lagger S Montgomery RL The specific role of histone deacetylase 2 in adult neurogenesis Neuron Glia Biol 2010 6 93 107 10.1017/S1740925X10000049 20388229
Jawerka M, Colak D, Dimou L, Spiller C, Lagger S, Montgomery RL, et al. The specific role of histone deacetylase 2 in adult neurogenesis. Neuron Glia Biol. 2010;6:93–107. 10.1017/S1740925X10000049.20388229 10.1017/S1740925X10000049
86. Gräff J Rei D Guan J-S Wang W-Y Seo J Hennig KM An epigenetic blockade of cognitive functions in the neurodegenerating brain Nature 2012 483 222 6 10.1038/nature10849 22388814
Gräff J, Rei D, Guan J-S, Wang W-Y, Seo J, Hennig KM, et al. An epigenetic blockade of cognitive functions in the neurodegenerating brain. Nature. 2012;483:222–6. 10.1038/nature10849.22388814 10.1038/nature10849
87. Covington HE 3rd Maze I LaPlant QC Vialou VF Ohnishi YN Antidepressant actions of histone deacetylase inhibitors J Neurosci 2009 29 11451 60 10.1523/JNEUROSCI.1758-09.2009 19759294
Covington HE 3rd, Maze I, LaPlant QC, Vialou VF, Ohnishi YN, et al. Antidepressant actions of histone deacetylase inhibitors. J Neurosci. 2009;29:11451–60. 10.1523/JNEUROSCI.1758-09.2009.19759294 10.1523/JNEUROSCI.1758-09.2009
88. Qiao M Jiang QS Liu YJ Hu XY Wang LJ Zhou QX Antidepressant mechanisms of venlafaxine involving increasing histone acetylation and modulating tyrosine hydroxylase and tryptophan hydroxylase expression in hippocampus of depressive rats Neuroreport 2019 30 255 61 10.1097/wnr.0000000000001191 30640193
Qiao M, Jiang QS, Liu YJ, Hu XY, Wang LJ, Zhou QX, et al. Antidepressant mechanisms of venlafaxine involving increasing histone acetylation and modulating tyrosine hydroxylase and tryptophan hydroxylase expression in hippocampus of depressive rats. Neuroreport. 2019;30:255–61. 10.1097/wnr.0000000000001191.30640193 10.1097/wnr.0000000000001191
89. Nghia NA Hirasawa T Kasai H Obata C Moriishi K Mochizuki K Long-term imipramine treatment increases N-methyl-d-aspartate receptor activity and expression via epigenetic mechanisms Eur J Pharm 2015 752 69 77 10.1016/j.ejphar.2015.02.010
Nghia NA, Hirasawa T, Kasai H, Obata C, Moriishi K, Mochizuki K, et al. Long-term imipramine treatment increases N-methyl-d-aspartate receptor activity and expression via epigenetic mechanisms. Eur J Pharm. 2015;752:69–77. 10.1016/j.ejphar.2015.02.010.10.1016/j.ejphar.2015.02.010
90. El-Saiy KA Sayed RH El-Sahar AE Kandil EA Modulation of histone deacetylase, the ubiquitin proteasome system, and autophagy underlies the neuroprotective effects of venlafaxine in a rotenone-induced Parkinson’s disease model in rats Chem-Biol Interact 2022 354 109841 10.1016/j.cbi.2022.109841 35104487
El-Saiy KA, Sayed RH, El-Sahar AE, Kandil EA. Modulation of histone deacetylase, the ubiquitin proteasome system, and autophagy underlies the neuroprotective effects of venlafaxine in a rotenone-induced Parkinson’s disease model in rats. Chem-Biol Interact. 2022;354:109841. 10.1016/j.cbi.2022.109841.35104487 10.1016/j.cbi.2022.109841
91. Ookubo M Kanai H Aoki H Yamada N Antidepressants and mood stabilizers effects on histone deacetylase expression in C57BL/6 mice: Brain region specific changes J Psychiatr Res 2013 47 1204 14 10.1016/j.jpsychires.2013.05.028 23777937
Ookubo M, Kanai H, Aoki H, Yamada N. Antidepressants and mood stabilizers effects on histone deacetylase expression in C57BL/6 mice: Brain region specific changes. J Psychiatr Res. 2013;47:1204–14. 10.1016/j.jpsychires.2013.05.028.23777937 10.1016/j.jpsychires.2013.05.028
92. Li W Ali T Zheng C Liu Z He K Shah FA Fluoxetine regulates eEF2 activity (phosphorylation) via HDAC1 inhibitory mechanism in an LPS-induced mouse model of depression J Neuroinflammation 2021 18 38 10.1186/s12974-021-02091-5 33526073
Li W, Ali T, Zheng C, Liu Z, He K, Shah FA, et al. Fluoxetine regulates eEF2 activity (phosphorylation) via HDAC1 inhibitory mechanism in an LPS-induced mouse model of depression. J Neuroinflammation. 2021;18:38. 10.1186/s12974-021-02091-5.33526073 10.1186/s12974-021-02091-5
93. Robison AJ Vialou V Sun HS Labonte B Golden SA Dias C Fluoxetine Epigenetically Alters the CaMKIIα Promoter in Nucleus Accumbens to Regulate ΔFosB Binding and Antidepressant Effects Neuropsychopharmacology 2014 39 1178 86 10.1038/npp.2013.319 24240473
Robison AJ, Vialou V, Sun HS, Labonte B, Golden SA, Dias C, et al. Fluoxetine Epigenetically Alters the CaMKIIα Promoter in Nucleus Accumbens to Regulate ΔFosB Binding and Antidepressant Effects. Neuropsychopharmacology. 2014;39:1178–86. 10.1038/npp.2013.319.24240473 10.1038/npp.2013.319
94. Jiang H Zhang X Lu J Meng H Sun Y Yang X Antidepressant-Like Effects of Acupuncture-Insights From DNA Methylation and Histone Modifications of Brain-Derived Neurotrophic Factor Front Psychiatry 2018 9 102 10.3389/fpsyt.2018.00102 29636708
Jiang H, Zhang X, Lu J, Meng H, Sun Y, Yang X, et al. Antidepressant-Like Effects of Acupuncture-Insights From DNA Methylation and Histone Modifications of Brain-Derived Neurotrophic Factor. Front Psychiatry. 2018;9:102. 10.3389/fpsyt.2018.00102.29636708 10.3389/fpsyt.2018.00102
95. Ana R-D Dalia YAS Fay MJ Elisa H Joseph LM Laxmikant SD Ketamine Produces Antidepressant Effects by Inhibiting Histone Deacetylases and Upregulating Hippocampal Brain-Derived Neurotrophic Factor Levels in a Diisopropyl Fluorophosphate–Based Rat Model of Gulf War Illness J Pharm Exp Therapeutics 2024 388 647 10.1124/jpet.123.001824
Ana R-D, Dalia YAS, Fay MJ, Elisa H, Joseph LM, Laxmikant SD. Ketamine Produces Antidepressant Effects by Inhibiting Histone Deacetylases and Upregulating Hippocampal Brain-Derived Neurotrophic Factor Levels in a Diisopropyl Fluorophosphate–Based Rat Model of Gulf War Illness. J Pharm Exp Therapeutics. 2024;388:647. 10.1124/jpet.123.001824.10.1124/jpet.123.001824
96. Levina AS Shiryaeva NV Vaido AI Dyuzhikova NA Effect of NMDA receptor activity on histone H3 methylation and its asymmetry in the hippocampal pyramidal neurons of rats with different excitability thresholds under normal and stress conditions J Evol Biochem Physiol 2013 49 615 23 10.1134/S0022093013060091
Levina AS, Shiryaeva NV, Vaido AI, Dyuzhikova NA. Effect of NMDA receptor activity on histone H3 methylation and its asymmetry in the hippocampal pyramidal neurons of rats with different excitability thresholds under normal and stress conditions. J Evol Biochem Physiol. 2013;49:615–23. 10.1134/S0022093013060091.10.1134/S0022093013060091
97. Choi M Lee SH Wang SE Ko SY Song M Choi JS Ketamine produces antidepressant-like effects through phosphorylation-dependent nuclear export of histone deacetylase 5 (HDAC5) in rats Proc Natl Acad Sci USA 2015 112 15755 60 10.1073/pnas.1513913112 26647181
Choi M, Lee SH, Wang SE, Ko SY, Song M, Choi JS, et al. Ketamine produces antidepressant-like effects through phosphorylation-dependent nuclear export of histone deacetylase 5 (HDAC5) in rats. Proc Natl Acad Sci USA. 2015;112:15755–60. 10.1073/pnas.1513913112.26647181 10.1073/pnas.1513913112
98. Brown I Liew C Lysergic acid diethylamide: effect on histone acetylation in rabbit brain Science 1975 188 1122 3 10.1126/science.1215990 1215990
Brown I, Liew C. Lysergic acid diethylamide: effect on histone acetylation in rabbit brain. Science. 1975;188:1122–3. 10.1126/science.1215990.1215990 10.1126/science.1215990
99. Brown IR RNA synthesis in isolated brian nuclei after administration of d-lysergic acid diethylamide (LSD) in vivo Proc Natl Acad Sci USA 1975 72 837 9 10.1073/pnas.72.3.837 1055380
Brown IR. RNA synthesis in isolated brian nuclei after administration of d-lysergic acid diethylamide (LSD) in vivo. Proc Natl Acad Sci USA. 1975;72:837–9. 10.1073/pnas.72.3.837.1055380 10.1073/pnas.72.3.837
100. Nichols CD Sanders-Bush E A Single Dose of Lysergic Acid Diethylamide Influences Gene Expression Patterns within the Mammalian Brain Neuropsychopharmacology 2002 26 634 42 10.1016/S0893-133X(01)00405-5 11927188
Nichols CD, Sanders-Bush E. A Single Dose of Lysergic Acid Diethylamide Influences Gene Expression Patterns within the Mammalian Brain. Neuropsychopharmacology. 2002;26:634–42. 10.1016/S0893-133X(01)00405-5.11927188 10.1016/S0893-133X(01)00405-5
101. Stafford JM Raybuck JD Ryabinin AE Lattal KM Increasing histone acetylation in the hippocampus-infralimbic network enhances fear extinction Biol Psychiatry 2012 72 25 33 10.1016/j.biopsych.2011.12.012 22290116
Stafford JM, Raybuck JD, Ryabinin AE, Lattal KM. Increasing histone acetylation in the hippocampus-infralimbic network enhances fear extinction. Biol Psychiatry. 2012;72:25–33. 10.1016/j.biopsych.2011.12.012.22290116 10.1016/j.biopsych.2011.12.012
102. Bowers ME Xia B Carreiro S Ressler KJ The Class I HDAC inhibitor RGFP963 enhances consolidation of cued fear extinction Learn Mem 2015 22 225 31 10.1101/lm.036699.114 25776040
Bowers ME, Xia B, Carreiro S, Ressler KJ. The Class I HDAC inhibitor RGFP963 enhances consolidation of cued fear extinction. Learn Mem. 2015;22:225–31. 10.1101/lm.036699.114.25776040 10.1101/lm.036699.114
103. Eisner BG Cohen S Psychotherapy with lysergic acid diethylamide J Nerv Ment Dis 1958 127 528 39 10.1097/00005053-195812000-00006 13621221
Eisner BG, Cohen S. Psychotherapy with lysergic acid diethylamide. J Nerv Ment Dis. 1958;127:528–39. 10.1097/00005053-195812000-00006.13621221 10.1097/00005053-195812000-00006
104. Gasser P Holstein D Michel Y Doblin R Yazar-Klosinski B Passie T Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases J Nerv Ment Dis 2014 202 513 20 10.1097/nmd.0000000000000113 24594678
Gasser P, Holstein D, Michel Y, Doblin R, Yazar-Klosinski B, Passie T, et al. Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Ment Dis. 2014;202:513–20. 10.1097/nmd.0000000000000113.24594678 10.1097/nmd.0000000000000113
105. Spencer AM Permissive Group Therapy with Lysergic Acid Diethylamide Br J Psychiatry 1963 109 37 45 10.1192/bjp.109.458.37 13990011
Spencer AM. Permissive Group Therapy with Lysergic Acid Diethylamide. Br J Psychiatry. 1963;109:37–45. 10.1192/bjp.109.458.37.13990011 10.1192/bjp.109.458.37
106. Bogenschutz MP Forcehimes AA Pommy JA Wilcox CE Barbosa PC Strassman RJ Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study J Psychopharmacol 2015 29 289 99 10.1177/0269881114565144 25586396
Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa PC, Strassman RJ. Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol. 2015;29:289–99. 10.1177/0269881114565144.25586396 10.1177/0269881114565144
107. de la Fuente Revenga M Zhu B Guevara CA Naler LB Saunders JM Zhou Z Prolonged epigenomic and synaptic plasticity alterations following single exposure to a psychedelic in mice Cell Rep. 2021 37 109836 10.1016/j.celrep.2021.109836 34686347
de la Fuente Revenga M, Zhu B, Guevara CA, Naler LB, Saunders JM, Zhou Z, et al. Prolonged epigenomic and synaptic plasticity alterations following single exposure to a psychedelic in mice. Cell Rep. 2021;37:109836. 10.1016/j.celrep.2021.109836.34686347 10.1016/j.celrep.2021.109836
108. Chan JC Maze I Nothing Is Yet Set in (Hi)stone: Novel Post-Translational Modifications Regulating Chromatin Function Trends Biochemical Sci 2020 45 829 44 10.1016/j.tibs.2020.05.009
Chan JC, Maze I. Nothing Is Yet Set in (Hi)stone: Novel Post-Translational Modifications Regulating Chromatin Function. Trends Biochemical Sci. 2020;45:829–44. 10.1016/j.tibs.2020.05.009.10.1016/j.tibs.2020.05.009
109. Farrelly LA Thompson RE Zhao S Lepack AE Lyu Y Bhanu NV Histone serotonylation is a permissive modification that enhances TFIID binding to H3K4me3 Nature 2019 567 535 9 10.1038/s41586-019-1024-7 30867594
Farrelly LA, Thompson RE, Zhao S, Lepack AE, Lyu Y, Bhanu NV, et al. Histone serotonylation is a permissive modification that enhances TFIID binding to H3K4me3. Nature. 2019;567:535–9. 10.1038/s41586-019-1024-7.30867594 10.1038/s41586-019-1024-7
110. Lepack AE Werner CT Stewart AF Fulton SL Zhong P Farrelly LA Dopaminylation of histone H3 in ventral tegmental area regulates cocaine seeking Science 2020 368 197 201 10.1126/science.aaw8806 32273471
Lepack AE, Werner CT, Stewart AF, Fulton SL, Zhong P, Farrelly LA, et al. Dopaminylation of histone H3 in ventral tegmental area regulates cocaine seeking. Science. 2020;368:197–201. 10.1126/science.aaw8806.32273471 10.1126/science.aaw8806
111. Lee I Ajay SS Yook JI Kim HS Hong SH Kim NH New class of microRNA targets containing simultaneous 5’-UTR and 3’-UTR interaction sites Genome Res 2009 19 1175 83 10.1101/gr.089367.108 19336450
Lee I, Ajay SS, Yook JI, Kim HS, Hong SH, Kim NH, et al. New class of microRNA targets containing simultaneous 5’-UTR and 3’-UTR interaction sites. Genome Res. 2009;19:1175–83. 10.1101/gr.089367.108.19336450 10.1101/gr.089367.108
112. Esteller M Non-coding RNAs in human disease Nat Rev Genet 2011 12 861 74 10.1038/nrg3074 22094949
Esteller M. Non-coding RNAs in human disease. Nat Rev Genet. 2011;12:861–74. 10.1038/nrg3074.22094949 10.1038/nrg3074
113. Zhou R Yuan P Wang Y Hunsberger JG Elkahloun A Wei Y Evidence for selective microRNAs and their effectors as common long-term targets for the actions of mood stabilizers Neuropsychopharmacology 2009 34 1395 405 10.1038/npp.2008.131 18704095
Zhou R, Yuan P, Wang Y, Hunsberger JG, Elkahloun A, Wei Y, et al. Evidence for selective microRNAs and their effectors as common long-term targets for the actions of mood stabilizers. Neuropsychopharmacology. 2009;34:1395–405. 10.1038/npp.2008.131.18704095 10.1038/npp.2008.131
114. Daskalakis NP Provost AC Hunter RG Guffanti G Noncoding RNAs: Stress, Glucocorticoids, and Posttraumatic Stress Disorder Biol Psychiatry 2018 83 849 65 10.1016/j.biopsych.2018.01.009 29559087
Daskalakis NP, Provost AC, Hunter RG, Guffanti G. Noncoding RNAs: Stress, Glucocorticoids, and Posttraumatic Stress Disorder. Biol Psychiatry. 2018;83:849–65. 10.1016/j.biopsych.2018.01.009.29559087 10.1016/j.biopsych.2018.01.009
115. Bocchio-Chiavetto L Maffioletti E Bettinsoli P Giovannini C Bignotti S Tardito D Blood microRNA changes in depressed patients during antidepressant treatment Eur Neuropsychopharmacol 2013 23 602 11 10.1016/j.euroneuro.2012.06.013 22925464
Bocchio-Chiavetto L, Maffioletti E, Bettinsoli P, Giovannini C, Bignotti S, Tardito D, et al. Blood microRNA changes in depressed patients during antidepressant treatment. Eur Neuropsychopharmacol. 2013;23:602–11. 10.1016/j.euroneuro.2012.06.013.22925464 10.1016/j.euroneuro.2012.06.013
116. Enatescu VR Papava I Enatescu I Antonescu M Anghel A Seclaman E Circulating Plasma Micro RNAs in Patients with Major Depressive Disorder Treated with Antidepressants: A Pilot Study Psychiatry Investig 2016 13 549 57 10.4306/pi.2016.13.5.549 27757134
Enatescu VR, Papava I, Enatescu I, Antonescu M, Anghel A, Seclaman E, et al. Circulating Plasma Micro RNAs in Patients with Major Depressive Disorder Treated with Antidepressants: A Pilot Study. Psychiatry Investig. 2016;13:549–57. 10.4306/pi.2016.13.5.549.27757134 10.4306/pi.2016.13.5.549
117. Ahmadimanesh M Etemad L Morshedi Rad D Ghahremani MH Mohammadpour AH Jafarzadeh Esfehani R Effect of citalopram and sertraline on the expression of miRNA- 124, 132, and 16 and their protein targets in patients with depression Iran J Basic Med Sci 2023 26 820 9 10.22038/ijbms.2023.66496.14595 37396946
Ahmadimanesh M, Etemad L, Morshedi Rad D, Ghahremani MH, Mohammadpour AH, Jafarzadeh Esfehani R, et al. Effect of citalopram and sertraline on the expression of miRNA- 124, 132, and 16 and their protein targets in patients with depression. Iran J Basic Med Sci. 2023;26:820–9. 10.22038/ijbms.2023.66496.14595.37396946 10.22038/ijbms.2023.66496.14595
118. Barry G Integrating the roles of long and small non-coding RNA in brain function and disease Mol Psychiatry 2014 19 410 6 10.1038/mp.2013.196 24468823
Barry G. Integrating the roles of long and small non-coding RNA in brain function and disease. Mol Psychiatry. 2014;19:410–6. 10.1038/mp.2013.196.24468823 10.1038/mp.2013.196
119. Zhou Y Lutz PE Wang YC Ragoussis J Turecki G Global long non-coding RNA expression in the rostral anterior cingulate cortex of depressed suicides Transl Psychiatry 2018 8 224 10.1038/s41398-018-0267-7 30337518
Zhou Y, Lutz PE, Wang YC, Ragoussis J, Turecki G. Global long non-coding RNA expression in the rostral anterior cingulate cortex of depressed suicides. Transl Psychiatry. 2018;8:224. 10.1038/s41398-018-0267-7.30337518 10.1038/s41398-018-0267-7
120. Maffioletti E Cattaneo A Rosso G Maina G Maj C Gennarelli M Peripheral whole blood microRNA alterations in major depression and bipolar disorder J Affect Disord 2016 200 250 8 10.1016/j.jad.2016.04.021 27152760
Maffioletti E, Cattaneo A, Rosso G, Maina G, Maj C, Gennarelli M, et al. Peripheral whole blood microRNA alterations in major depression and bipolar disorder. J Affect Disord. 2016;200:250–8. 10.1016/j.jad.2016.04.021.27152760 10.1016/j.jad.2016.04.021
121. Roy B Wang Q Palkovits M Faludi G Dwivedi Y Altered miRNA expression network in locus coeruleus of depressed suicide subjects Sci Rep 2017 7 4387 10.1038/s41598-017-04300-9 28663595
Roy B, Wang Q, Palkovits M, Faludi G, Dwivedi Y. Altered miRNA expression network in locus coeruleus of depressed suicide subjects. Sci Rep. 2017;7:4387. 10.1038/s41598-017-04300-9.28663595 10.1038/s41598-017-04300-9
122. Rasheed, M, Asghar, R, Firdoos, S, Ahmad, N, Nazir, A, Ullah, KM, et al. A Systematic Review of Circulatory microRNAs in Major Depressive Disorder: Potential Biomarkers for Disease Prognosis. Int JMol Sci. 2022;23:1294 10.3390/ijms23031294.
123. Meerson A Cacheaux L Goosens KA Sapolsky RM Soreq H Kaufer D Changes in brain MicroRNAs contribute to cholinergic stress reactions J Mol Neurosci 2010 40 47 55 10.1007/s12031-009-9252-1 19711202
Meerson A, Cacheaux L, Goosens KA, Sapolsky RM, Soreq H, Kaufer D. Changes in brain MicroRNAs contribute to cholinergic stress reactions. J Mol Neurosci. 2010;40:47–55. 10.1007/s12031-009-9252-1.19711202 10.1007/s12031-009-9252-1
124. O’Connor RM Grenham S Dinan TG Cryan JF microRNAs as novel antidepressant targets: converging effects of ketamine and electroconvulsive shock therapy in the rat hippocampus Int J Neuropsychopharmacol 2013 16 1885 92 10.1017/s1461145713000448 23684180
O’Connor RM, Grenham S, Dinan TG, Cryan JF. microRNAs as novel antidepressant targets: converging effects of ketamine and electroconvulsive shock therapy in the rat hippocampus. Int J Neuropsychopharmacol. 2013;16:1885–92. 10.1017/s1461145713000448.23684180 10.1017/s1461145713000448
125. Wang SS Mu RH Li CF Dong SQ Geng D Liu Q microRNA-124 targets glucocorticoid receptor and is involved in depression-like behaviors Prog Neuropsychopharmacol Biol Psychiatry 2017 79 417 25 10.1016/j.pnpbp.2017.07.024 28764913
Wang SS, Mu RH, Li CF, Dong SQ, Geng D, Liu Q, et al. microRNA-124 targets glucocorticoid receptor and is involved in depression-like behaviors. Prog Neuropsychopharmacol Biol Psychiatry. 2017;79:417–25. 10.1016/j.pnpbp.2017.07.024.28764913 10.1016/j.pnpbp.2017.07.024
126. Torres-Berrío A Lopez JP Bagot RC Nouel D Dal Bo G Cuesta S DCC Confers Susceptibility to Depression-like Behaviors in Humans and Mice and Is Regulated by miR-218 Biol Psychiatry 2017 81 306 15 10.1016/j.biopsych.2016.08.017 27773352
Torres-Berrío A, Lopez JP, Bagot RC, Nouel D, Dal Bo G, Cuesta S, et al. DCC Confers Susceptibility to Depression-like Behaviors in Humans and Mice and Is Regulated by miR-218. Biol Psychiatry. 2017;81:306–15. 10.1016/j.biopsych.2016.08.017.27773352 10.1016/j.biopsych.2016.08.017
127. Zuo L Tan Y Wang Z Wang KS Zhang X Chen X Long noncoding RNAs in psychiatric disorders Psychiatr Genet 2016 26 109 16 10.1097/ypg.0000000000000129 26974119
Zuo L, Tan Y, Wang Z, Wang KS, Zhang X, Chen X, et al. Long noncoding RNAs in psychiatric disorders. Psychiatr Genet. 2016;26:109–16. 10.1097/ypg.0000000000000129.26974119 10.1097/ypg.0000000000000129
128. Belzeaux R Lin R Turecki G Potential Use of MicroRNA for Monitoring Therapeutic Response to Antidepressants CNS Drugs 2017 31 253 62 10.1007/s40263-017-0418-z 28290081
Belzeaux R, Lin R, Turecki G. Potential Use of MicroRNA for Monitoring Therapeutic Response to Antidepressants. CNS Drugs. 2017;31:253–62. 10.1007/s40263-017-0418-z.28290081 10.1007/s40263-017-0418-z
129. Smalheiser NR Lugli G Rizavi HS Torvik VI Turecki G Dwivedi Y MicroRNA Expression Is Down-Regulated and Reorganized in Prefrontal Cortex of Depressed Suicide Subjects PLOS ONE 2012 7 e33201 10.1371/journal.pone.0033201 22427989
Smalheiser NR, Lugli G, Rizavi HS, Torvik VI, Turecki G, Dwivedi Y. MicroRNA Expression Is Down-Regulated and Reorganized in Prefrontal Cortex of Depressed Suicide Subjects. PLOS ONE. 2012;7:e33201. 10.1371/journal.pone.0033201.22427989 10.1371/journal.pone.0033201
130. Issler O Haramati S Paul ED Maeno H Navon I Zwang R MicroRNA 135 is essential for chronic stress resiliency, antidepressant efficacy, and intact serotonergic activity Neuron 2014 83 344 60 10.1016/j.neuron.2014.05.042 24952960
Issler O, Haramati S, Paul ED, Maeno H, Navon I, Zwang R, et al. MicroRNA 135 is essential for chronic stress resiliency, antidepressant efficacy, and intact serotonergic activity. Neuron. 2014;83:344–60.24952960 10.1016/j.neuron.2014.05.042
131. He S Liu X Jiang K Peng D Hong W Fang Y Alterations of microRNA-124 expression in peripheral blood mononuclear cells in pre- and post-treatment patients with major depressive disorder J Psychiatr Res 2016 78 65 71 10.1016/j.jpsychires.2016.03.015 27078210
He S, Liu X, Jiang K, Peng D, Hong W, Fang Y, et al. Alterations of microRNA-124 expression in peripheral blood mononuclear cells in pre- and post-treatment patients with major depressive disorder. J Psychiatr Res. 2016;78:65–71. 10.1016/j.jpsychires.2016.03.015.27078210 10.1016/j.jpsychires.2016.03.015
132. Guan W, Wu XY, Jin X, Sheng XM, Fan Y. miR-204-5p Plays a Critical Role in the Pathogenesis of Depression and Anti-depression Action of Venlafaxine in the Hippocampus of Mice. Curr Med Chem. 2023. 10.2174/0929867330666230623163315
133. Baudry A Mouillet-Richard S Schneider B Launay JM Kellermann O miR-16 targets the serotonin transporter: a new facet for adaptive responses to antidepressants Science 2010 329 1537 41 10.1126/science.1193692 20847275
Baudry A, Mouillet-Richard S, Schneider B, Launay JM, Kellermann O. miR-16 targets the serotonin transporter: a new facet for adaptive responses to antidepressants. Science. 2010;329:1537–41. 10.1126/science.1193692.20847275 10.1126/science.1193692
134. Roy B Wang Q Dwivedi Y Long noncoding RNA-associated transcriptomic changes in resiliency or susceptibility to depression and response to antidepressant treatment Int J Neuropsychopharmacol 2018 21 461 72 10.1093/ijnp/pyy010 29390069
Roy B, Wang Q, Dwivedi Y. Long noncoding RNA-associated transcriptomic changes in resiliency or susceptibility to depression and response to antidepressant treatment. Int J Neuropsychopharmacol. 2018;21:461–72. 10.1093/ijnp/pyy010.29390069 10.1093/ijnp/pyy010
135. Zhang CL Li YJ Lu S Zhang T Xiao R Luo HR Fluoxetine ameliorates depressive symptoms by regulating lncRNA expression in the mouse hippocampus Zool Res 2021 42 28 42 10.24272/j.issn.2095-8137.2020.294 33420763
Zhang CL, Li YJ, Lu S, Zhang T, Xiao R, Luo HR. Fluoxetine ameliorates depressive symptoms by regulating lncRNA expression in the mouse hippocampus. Zool Res. 2021;42:28–42. 10.24272/j.issn.2095-8137.2020.294.33420763 10.24272/j.issn.2095-8137.2020.294
136. Schmidt U, Herrmann L, Hagl K, Novak B, Huber C, Holsboer F, et al. Therapeutic action of fluoxetine is associated with a reduction in prefrontal cortical miR-1971 expression levels in a mouse model of posttraumatic stress disorder. Front Psychiatry. 2013;4. 10.3389/fpsyt.2013.00066
137. Pan B Liu Y Effects of duloxetine on microRNA expression profile in frontal lobe and hippocampus in a mouse model of depression Int J Clin Exp Pathol 2015 8 15454 61 26823914
Pan B, Liu Y. Effects of duloxetine on microRNA expression profile in frontal lobe and hippocampus in a mouse model of depression. Int J Clin Exp Pathol. 2015;8:15454–61.26823914
138. Lo Iacono L Ielpo D Parisi C Napoli G Accoto A Di Segni M MicroRNA-34a regulates 5-HT2C expression in dorsal raphe and contributes to the anti-depressant-like effect of fluoxetine Neuropharmacology 2021 190 108559 10.1016/j.neuropharm.2021.108559 33845072
Lo Iacono L, Ielpo D, Parisi C, Napoli G, Accoto A, Di Segni M, et al. MicroRNA-34a regulates 5-HT2C expression in dorsal raphe and contributes to the anti-depressant-like effect of fluoxetine. Neuropharmacology. 2021;190:108559. 10.1016/j.neuropharm.2021.108559.33845072 10.1016/j.neuropharm.2021.108559
139. Zhang Y, Wang Y, Wang L, Bai M, Zhang X, Zhu X. Dopamine receptor D2 and associated microRNAs are involved in stress susceptibility and resistance to escitalopram treatment. Int J Neuropsychopharmacol. 2015;18. 10.1093/ijnp/pyv025
140. Lopez JP Pereira F Richard-Devantoy S Berlim M Chachamovich E Fiori LM Co-variation of peripheral levels of miR-1202 and brain activity and connectivity during antidepressant treatment Neuropsychopharmacology 2017 42 2043 51 10.1038/npp.2017.9 28079059
Lopez JP, Pereira F, Richard-Devantoy S, Berlim M, Chachamovich E, Fiori LM, et al. Co-variation of peripheral levels of miR-1202 and brain activity and connectivity during antidepressant treatment. Neuropsychopharmacology. 2017;42:2043–51. 10.1038/npp.2017.9.28079059 10.1038/npp.2017.9
141. Launay JM Mouillet-Richard S Baudry A Pietri M Kellermann O Raphe-mediated signals control the hippocampal response to SRI antidepressants via miR-16 Transl Psychiatry 2011 1 e56 10.1038/tp.2011.54 22833211
Launay JM, Mouillet-Richard S, Baudry A, Pietri M, Kellermann O. Raphe-mediated signals control the hippocampal response to SRI antidepressants via miR-16. Transl Psychiatry. 2011;1:e56. 10.1038/tp.2011.54.22833211 10.1038/tp.2011.54
142. Wan Y-Q Feng J-G Li M Wang M-Z Liu L Liu X Prefrontal cortex miR-29b-3p plays a key role in the antidepressant-like effect of ketamine in rats Exp Mol Med 2018 50 1 14 10.1038/s12276-018-0164-4 30369596
Wan Y-Q, Feng J-G, Li M, Wang M-Z, Liu L, Liu X, et al. Prefrontal cortex miR-29b-3p plays a key role in the antidepressant-like effect of ketamine in rats. Exp Mol Med. 2018;50:1–14. 10.1038/s12276-018-0164-4.30369596 10.1038/s12276-018-0164-4
143. Huang C Wang Y Wu Z Xu J Zhou L Wang D miR-98-5p plays a critical role in depression and antidepressant effect of ketamine Transl Psychiatry 2021 11 454 10.1038/s41398-021-01588-0 34480014
Huang C, Wang Y, Wu Z, Xu J, Zhou L, Wang D, et al. miR-98-5p plays a critical role in depression and antidepressant effect of ketamine. Transl Psychiatry. 2021;11:454. 10.1038/s41398-021-01588-0.34480014 10.1038/s41398-021-01588-0
144. Ma L Wang L Chang L Shan J Qu Y Wang X A key role of miR-132-5p in the prefrontal cortex for persistent prophylactic actions of (R)-ketamine in mice Transl Psychiatry 2022 12 417 10.1038/s41398-022-02192-6 36171191
Ma L, Wang L, Chang L, Shan J, Qu Y, Wang X, et al. A key role of miR-132-5p in the prefrontal cortex for persistent prophylactic actions of (R)-ketamine in mice. Transl Psychiatry. 2022;12:417. 10.1038/s41398-022-02192-6.36171191 10.1038/s41398-022-02192-6
145. De Kock M Loix S Lavand’homme P Ketamine and peripheral inflammation CNS Neurosci Ther 2013 19 403 10 10.1111/cns.12104 23574634
De Kock M, Loix S, Lavand’homme P. Ketamine and peripheral inflammation. CNS Neurosci Ther. 2013;19:403–10. 10.1111/cns.12104.23574634 10.1111/cns.12104
146. Goswami A Mukherjee K Mazumder A Ganguly S Mukherjee I Chakrabarti S MicroRNA exporter HuR clears the internalized pathogens by promoting pro-inflammatory response in infected macrophages EMBO Mol Med 2020 12 e11011 10.15252/emmm.201911011 32031337
Goswami A, Mukherjee K, Mazumder A, Ganguly S, Mukherjee I, Chakrabarti S, et al. MicroRNA exporter HuR clears the internalized pathogens by promoting pro-inflammatory response in infected macrophages. EMBO Mol Med. 2020;12:e11011. 10.15252/emmm.201911011.32031337 10.15252/emmm.201911011
147. Yang X Yang Q Wang X Luo C Wan Y Li J MicroRNA expression profile and functional analysis reveal that miR-206 is a critical novel gene for the expression of BDNF induced by ketamine Neuromolecular Med 2014 16 594 605 10.1007/s12017-014-8312-z 24839168
Yang X, Yang Q, Wang X, Luo C, Wan Y, Li J, et al. MicroRNA expression profile and functional analysis reveal that miR-206 is a critical novel gene for the expression of BDNF induced by ketamine. Neuromolecular Med. 2014;16:594–605. 10.1007/s12017-014-8312-z.24839168 10.1007/s12017-014-8312-z
148. Lepack, AE, Fuchikami, M, Dwyer, JM, Banasr, M, Duman, RS. BDNF release is required for the behavioral actions of ketamine. Int J Neuropsychopharmacol. 2014;18. 10.1093/ijnp/pyu033
149. Nibuya M Morinobu S Duman R Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments J Neurosci 1995 15 7539 47 10.1523/jneurosci.15-11-07539.1995 7472505
Nibuya M, Morinobu S, Duman R. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci. 1995;15:7539–47. 10.1523/jneurosci.15-11-07539.1995.7472505 10.1523/jneurosci.15-11-07539.1995
150. Grieco SF Velmeshev D Magistri M Eldar-Finkelman H Faghihi MA Jope RS Ketamine up-regulates a cluster of intronic miRNAs within the serotonin receptor 2C gene by inhibiting glycogen synthase kinase-3 World J Biol Psychiatry 2017 18 445 56 10.1080/15622975.2016.1224927 27723376
Grieco SF, Velmeshev D, Magistri M, Eldar-Finkelman H, Faghihi MA, Jope RS, et al. Ketamine up-regulates a cluster of intronic miRNAs within the serotonin receptor 2C gene by inhibiting glycogen synthase kinase-3. World J Biol Psychiatry. 2017;18:445–56. 10.1080/15622975.2016.1224927.27723376 10.1080/15622975.2016.1224927
151. Choi Y Kim B Ham S Chung S Maeng S Kim H-S Subanesthetic ketamine rapidly alters medial prefrontal miRNAs involved in ubiquitin-mediated proteolysis PLoS ONE 2021 16 e0256390 10.1371/journal.pone.0256390 34437591
Choi Y, Kim B, Ham S, Chung S, Maeng S, Kim H-S, et al. Subanesthetic ketamine rapidly alters medial prefrontal miRNAs involved in ubiquitin-mediated proteolysis. PLoS ONE. 2021;16:e0256390. 10.1371/journal.pone.0256390.34437591 10.1371/journal.pone.0256390
152. Ma L Wang L Chang L Shan J Qu Y Wang X A role of microRNA-149 in the prefrontal cortex for prophylactic actions of (R)-ketamine in inflammation model Neuropharmacology 2022 219 109250 10.1016/j.neuropharm.2022.109250 36088985
Ma L, Wang L, Chang L, Shan J, Qu Y, Wang X, et al. A role of microRNA-149 in the prefrontal cortex for prophylactic actions of (R)-ketamine in inflammation model. Neuropharmacology. 2022;219:109250. 10.1016/j.neuropharm.2022.109250.36088985 10.1016/j.neuropharm.2022.109250
153. Zhang N, Yao L, Wang P, Liu Z. Immunoregulation and antidepressant effect of ketamine. 12, 218-36 (2021). 10.1515/tnsci-2020-0167
154. Lopez JP Lim R Cruceanu C Crapper L Fasano C Labonte B miR-1202 is a primate-specific and brain-enriched microRNA involved in major depression and antidepressant treatment Nat Med 2014 20 764 8 10.1038/nm.3582 24908571
Lopez JP, Lim R, Cruceanu C, Crapper L, Fasano C, Labonte B, et al. miR-1202 is a primate-specific and brain-enriched microRNA involved in major depression and antidepressant treatment. Nat Med. 2014;20:764–8. 10.1038/nm.3582.24908571 10.1038/nm.3582
155. Lopez JP Fiori LM Cruceanu C Lin R Labonte B Cates HM MicroRNAs 146a/b-5 and 425-3p and 24-3p are markers of antidepressant response and regulate MAPK/Wnt-system genes Nat Commun 2017 8 15497 10.1038/ncomms15497 28530238
Lopez JP, Fiori LM, Cruceanu C, Lin R, Labonte B, Cates HM, et al. MicroRNAs 146a/b-5 and 425-3p and 24-3p are markers of antidepressant response and regulate MAPK/Wnt-system genes. Nat Commun. 2017;8:15497. 10.1038/ncomms15497.28530238 10.1038/ncomms15497
156. Kuang, W-H, Dong Z-Q, Tian L-T, Li J. MicroRNA-451a, microRNA-34a-5p, and microRNA-221-3p as predictors of response to antidepressant treatment. Braz J Med Biol Res. 2018;51.
157. Hung Y-Y, Chou C-K, Yang Y-C, Fu H-C, Loh E-W, Kang H-Y. Exosomal let-7e, miR-21-5p, miR-145, miR-146a and miR-155 in Predicting Antidepressants Response in Patients with Major Depressive Disorder. Biomedicines 9 (2021).
158. Lin C-C Tsai M-C Lee C-T Sun M-H Huang T-L Antidepressant treatment increased serum miR-183 and miR-212 levels in patients with major depressive disorder Psychiatry Res 2018 270 232 7 10.1016/j.psychres.2018.09.025 30269040
Lin C-C, Tsai M-C, Lee C-T, Sun M-H, Huang T-L. Antidepressant treatment increased serum miR-183 and miR-212 levels in patients with major depressive disorder. Psychiatry Res. 2018;270:232–7. 10.1016/j.psychres.2018.09.025.30269040 10.1016/j.psychres.2018.09.025
159. Kato M Ogata H Tahara H Shimamoto A Takekita Y Koshikawa Y Multiple Pre-Treatment miRNAs Levels in Untreated Major Depressive Disorder Patients Predict Early Response to Antidepressants and Interact with Key Pathways Int J Mol Sci 2022 23 3873 10.3390/ijms23073873 35409234
Kato M, Ogata H, Tahara H, Shimamoto A, Takekita Y, Koshikawa Y, et al. Multiple Pre-Treatment miRNAs Levels in Untreated Major Depressive Disorder Patients Predict Early Response to Antidepressants and Interact with Key Pathways. Int J Mol Sci. 2022;23:3873.35409234 10.3390/ijms23073873
160. Douglas SR Shenoda BB Qureshi RA Sacan A Alexander GM Perreault M Analgesic Response to Intravenous Ketamine Is Linked to a Circulating microRNA Signature in Female Patients With Complex Regional Pain Syndrome J Pain 2015 16 814 24 10.1016/j.jpain.2015.05.008 26072390
Douglas SR, Shenoda BB, Qureshi RA, Sacan A, Alexander GM, Perreault M, et al. Analgesic Response to Intravenous Ketamine Is Linked to a Circulating microRNA Signature in Female Patients With Complex Regional Pain Syndrome. J Pain. 2015;16:814–24. 10.1016/j.jpain.2015.05.008.26072390 10.1016/j.jpain.2015.05.008
161. Pande R Parikh A Shenoda B Ramanathan S Alexander GM Schwartzman RJ Hsa-miR-605 regulates the proinflammatory chemokine CXCL5 in complex regional pain syndrome Biomedicine Pharmacother 2021 140 111788 10.1016/j.biopha.2021.111788
Pande R, Parikh A, Shenoda B, Ramanathan S, Alexander GM, Schwartzman RJ, et al. Hsa-miR-605 regulates the proinflammatory chemokine CXCL5 in complex regional pain syndrome. Biomedicine Pharmacother. 2021;140:111788. 10.1016/j.biopha.2021.111788.10.1016/j.biopha.2021.111788
162. Gururajan A Naughton ME Scott KA O’Connor RM Moloney G Clarke G MicroRNAs as biomarkers for major depression: a role for let-7b and let-7c Transl Psychiatry 2016 6 e862 10.1038/tp.2016.131 27483380
Gururajan A, Naughton ME, Scott KA, O’Connor RM, Moloney G, Clarke G, et al. MicroRNAs as biomarkers for major depression: a role for let-7b and let-7c. Transl Psychiatry. 2016;6:e862. 10.1038/tp.2016.131.27483380 10.1038/tp.2016.131
163. Tay Y Rinn J Pandolfi PP The multilayered complexity of ceRNA crosstalk and competition Nature 2014 505 344 52 10.1038/nature12986 24429633
Tay Y, Rinn J, Pandolfi PP. The multilayered complexity of ceRNA crosstalk and competition. Nature. 2014;505:344–52. 10.1038/nature12986.24429633 10.1038/nature12986
164. Mao J Li T Fan D Zhou H Feng J Liu L Abnormal expression of rno_circRNA_014900 and rno_circRNA_005442 induced by ketamine in the rat hippocampus BMC Psychiatry 2020 20 1 10.1186/s12888-019-2374-2 31898506
Mao J, Li T, Fan D, Zhou H, Feng J, Liu L, et al. Abnormal expression of rno_circRNA_014900 and rno_circRNA_005442 induced by ketamine in the rat hippocampus. BMC Psychiatry. 2020;20:1. 10.1186/s12888-019-2374-2.31898506 10.1186/s12888-019-2374-2
165. Briggs JA Wolvetang EJ Mattick JS Rinn JL Barry G Mechanisms of long non-coding RNAs in mammalian nervous system development, plasticity, disease, and evolution Neuron 2015 88 861 77 10.1016/j.neuron.2015.09.045 26637795
Briggs JA, Wolvetang EJ, Mattick JS, Rinn JL, Barry G. Mechanisms of long non-coding RNAs in mammalian nervous system development, plasticity, disease, and evolution. Neuron. 2015;88:861–77.26637795 10.1016/j.neuron.2015.09.045
166. Seki T Yamagata H Uchida S Chen C Kobayashi A Kobayashi M Altered expression of long noncoding RNAs in patients with major depressive disorder J Psychiatr Res 2019 117 92 9 10.1016/j.jpsychires.2019.07.004 31351391
Seki T, Yamagata H, Uchida S, Chen C, Kobayashi A, Kobayashi M, et al. Altered expression of long noncoding RNAs in patients with major depressive disorder. J Psychiatr Res. 2019;117:92–9. 10.1016/j.jpsychires.2019.07.004.31351391 10.1016/j.jpsychires.2019.07.004
167. Issler O, van der Zee YY, Ramakrishnan A, Xia S, Zinsmaier AK, Tan C, et al. The long noncoding RNA FEDORA is a cell type– and sex-specific regulator of depression. Sci Adv. 8, eabn9494. 10.1126/sciadv.abn9494
168. Chen WG Chang Q Lin Y Meissner A West AE Griffith EC Derepression of BDNF transcription involves calcium-dependent phosphorylation of MeCP2 Science 2003 302 885 9 10.1126/science.1086446 14593183
Chen WG, Chang Q, Lin Y, Meissner A, West AE, Griffith EC, et al. Derepression of BDNF transcription involves calcium-dependent phosphorylation of MeCP2. Science. 2003;302:885–9. 10.1126/science.1086446.14593183 10.1126/science.1086446
169. Martinowich K Hattori D Wu H Fouse S He F Hu Y DNA methylation-related chromatin remodeling in activity-dependent Bdnf gene regulation Science 2003 302 890 3 10.1126/science.1090842 14593184
Martinowich K, Hattori D, Wu H, Fouse S, He F, Hu Y, et al. DNA methylation-related chromatin remodeling in activity-dependent Bdnf gene regulation. Science. 2003;302:890–3. 10.1126/science.1090842.14593184 10.1126/science.1090842
170. Zhou Z Hong EJ Cohen S Zhao W-N Ho H-YH Schmidt L Brain-specific phosphorylation of MeCP2 regulates activity-dependent Bdnf transcription, dendritic growth, and spine maturation Neuron 2006 52 255 69 10.1016/j.neuron.2006.09.037 17046689
Zhou Z, Hong EJ, Cohen S, Zhao W-N, Ho H-YH, Schmidt L, et al. Brain-specific phosphorylation of MeCP2 regulates activity-dependent Bdnf transcription, dendritic growth, and spine maturation. Neuron. 2006;52:255–69.17046689 10.1016/j.neuron.2006.09.037
171. Ali F Gerhard DM Sweasy K Pothula S Pittenger C Duman RS Ketamine disinhibits dendrites and enhances calcium signals in prefrontal dendritic spines Nat Commun 2020 11 72 10.1038/s41467-019-13809-8 31911591
Ali F, Gerhard DM, Sweasy K, Pothula S, Pittenger C, Duman RS, et al. Ketamine disinhibits dendrites and enhances calcium signals in prefrontal dendritic spines. Nat Commun. 2020;11:72. 10.1038/s41467-019-13809-8.31911591 10.1038/s41467-019-13809-8
172. Hernández-Oliveras A Zarain-Herzberg A The role of Ca2+-signaling in the regulation of epigenetic mechanisms Cell Calcium 2024 117 102836 10.1016/j.ceca.2023.102836 37988873
Hernández-Oliveras A, Zarain-Herzberg A. The role of Ca2+-signaling in the regulation of epigenetic mechanisms. Cell Calcium. 2024;117:102836. 10.1016/j.ceca.2023.102836.37988873 10.1016/j.ceca.2023.102836
173. Malenka RC Kauer JA Zucker RS Nicoll RA Postsynaptic calcium is sufficient for potentiation of hippocampal synaptic transmission Science 1988 242 81 4 10.1126/science.2845577 2845577
Malenka RC, Kauer JA, Zucker RS, Nicoll RA. Postsynaptic calcium is sufficient for potentiation of hippocampal synaptic transmission. Science. 1988;242:81–4. 10.1126/science.2845577.2845577 10.1126/science.2845577
174. Martin DA Nichols CD Psychedelics recruit multiple cellular types and produce complex transcriptional responses within the brain EBioMedicine 2016 11 262 77 10.1016/j.ebiom.2016.08.049 27649637
Martin DA, Nichols CD. Psychedelics recruit multiple cellular types and produce complex transcriptional responses within the brain. EBioMedicine. 2016;11:262–77. 10.1016/j.ebiom.2016.08.049.27649637 10.1016/j.ebiom.2016.08.049
175. Guo JU Ma DK Mo H Ball MP Jang M-H Bonaguidi MA Neuronal activity modifies the DNA methylation landscape in the adult brain Nat Neurosci 2011 14 1345 51 10.1038/nn.2900 21874013
Guo JU, Ma DK, Mo H, Ball MP, Jang M-H, Bonaguidi MA, et al. Neuronal activity modifies the DNA methylation landscape in the adult brain. Nat Neurosci. 2011;14:1345–51. 10.1038/nn.2900.21874013 10.1038/nn.2900
176. Vetencourt JFM Tiraboschi E Spolidoro M Castrén E Maffei L Serotonin triggers a transient epigenetic mechanism that reinstates adult visual cortex plasticity in rats Eur J Neurosci 2011 33 49 57 10.1111/j.1460-9568.2010.07488.x 21156002
Vetencourt JFM, Tiraboschi E, Spolidoro M, Castrén E, Maffei L. Serotonin triggers a transient epigenetic mechanism that reinstates adult visual cortex plasticity in rats. Eur J Neurosci. 2011;33:49–57. 10.1111/j.1460-9568.2010.07488.x.21156002 10.1111/j.1460-9568.2010.07488.x
177. Rajasethupathy P Antonov I Sheridan R Frey S Sander C Tuschl T A role for neuronal piRNAs in the epigenetic control of memory-related synaptic plasticity Cell 2012 149 693 707 10.1016/j.cell.2012.02.057 22541438
Rajasethupathy P, Antonov I, Sheridan R, Frey S, Sander C, Tuschl T, et al. A role for neuronal piRNAs in the epigenetic control of memory-related synaptic plasticity. Cell. 2012;149:693–707.22541438 10.1016/j.cell.2012.02.057
178. Chen S Cai D Pearce K Sun PY Roberts AC Glanzman DL Reinstatement of long-term memory following erasure of its behavioral and synaptic expression in Aplysia Elife 2014 3 e03896 10.7554/eLife.03896 25402831
Chen S, Cai D, Pearce K, Sun PY, Roberts AC, Glanzman DL. Reinstatement of long-term memory following erasure of its behavioral and synaptic expression in Aplysia. Elife. 2014;3:e03896.25402831 10.7554/eLife.03896
179. Ögren SO Eriksson TM Elvander-Tottie E D’Addario C Ekström JC Svenningsson P The role of 5-HT1A receptors in learning and memory Behav Brain Res 2008 195 54 77 10.1016/j.bbr.2008.02.023 18394726
Ögren SO, Eriksson TM, Elvander-Tottie E, D’Addario C, Ekström JC, Svenningsson P, et al. The role of 5-HT1A receptors in learning and memory. Behav Brain Res. 2008;195:54–77. 10.1016/j.bbr.2008.02.023.18394726 10.1016/j.bbr.2008.02.023
180. Zhang, G, Stackman, RW. The role of serotonin 5-HT2A receptors in memory and cognition. Front. Pharmacol. 2015;6. 10.3389/fphar.2015.00225
181. Rantamäki T Hendolin P Kankaanpää A Mijatovic J Piepponen P Domenici E Pharmacologically diverse antidepressants rapidly activate brain-derived neurotrophic factor receptor TrkB and induce phospholipase-Cγ signaling pathways in mouse brain Neuropsychopharmacology 2007 32 2152 62 10.1038/sj.npp.1301345 17314919
Rantamäki T, Hendolin P, Kankaanpää A, Mijatovic J, Piepponen P, Domenici E, et al. Pharmacologically diverse antidepressants rapidly activate brain-derived neurotrophic factor receptor TrkB and induce phospholipase-Cγ signaling pathways in mouse brain. Neuropsychopharmacology. 2007;32:2152–62. 10.1038/sj.npp.1301345.17314919 10.1038/sj.npp.1301345
182. Huang ZJ Kirkwood A Pizzorusso T Porciatti V Morales B Bear MF BDNF regulates the maturation of inhibition and the critical period of plasticity in mouse visual cortex Cell 1999 98 739 55 10.1016/S0092-8674(00)81509-3 10499792
Huang ZJ, Kirkwood A, Pizzorusso T, Porciatti V, Morales B, Bear MF, et al. BDNF regulates the maturation of inhibition and the critical period of plasticity in mouse visual cortex. Cell. 1999;98:739–55.10499792 10.1016/S0092-8674(00)81509-3
183. Zeng Y Tan M Kohyama J Sneddon M Watson JB Sun YE Epigenetic enhancement of BDNF signaling rescues synaptic plasticity in aging J Neurosci 2011 31 17800 10 10.1523/jneurosci.3878-11.2011 22159096
Zeng Y, Tan M, Kohyama J, Sneddon M, Watson JB, Sun YE, et al. Epigenetic enhancement of BDNF signaling rescues synaptic plasticity in aging. J Neurosci. 2011;31:17800–10. 10.1523/jneurosci.3878-11.2011.22159096 10.1523/jneurosci.3878-11.2011
184. Mikics É Guirado R Umemori J Tóth M Biró L Miskolczi C Social learning requires plasticity enhanced by fluoxetine through prefrontal Bdnf-TrkB signaling to limit aggression induced by post-weaning social isolation Neuropsychopharmacology 2018 43 235 45 10.1038/npp.2017.142 28685757
Mikics É, Guirado R, Umemori J, Tóth M, Biró L, Miskolczi C, et al. Social learning requires plasticity enhanced by fluoxetine through prefrontal Bdnf-TrkB signaling to limit aggression induced by post-weaning social isolation. Neuropsychopharmacology. 2018;43:235–45. 10.1038/npp.2017.142.28685757 10.1038/npp.2017.142
185. Casarotto PC Girych M Fred SM Kovaleva V Moliner R Enkavi G Antidepressant drugs act by directly binding to TRKB neurotrophin receptors Cell 2021 184 1299 1313.e1219 10.1016/j.cell.2021.01.034 33606976
Casarotto PC, Girych M, Fred SM, Kovaleva V, Moliner R, Enkavi G, et al. Antidepressant drugs act by directly binding to TRKB neurotrophin receptors. Cell. 2021;184:1299–1313.e1219. 10.1016/j.cell.2021.01.034.33606976 10.1016/j.cell.2021.01.034
186. Moliner R Girych M Brunello CA Kovaleva V Biojone C Psychedelics promote plasticity by directly binding to BDNF receptor TrkB Nat Neurosci 2023 26 1032 41 10.1038/s41593-023-01316-5 37280397
Moliner, R, Girych M, Brunello CA, Kovaleva V, Biojone C, et al. Psychedelics promote plasticity by directly binding to BDNF receptor TrkB. Nat Neurosci. 2023;26:1032–41. 10.1038/s41593-023-01316-5.37280397 10.1038/s41593-023-01316-5
187. Ly C Greb AC Cameron LP Wong JM Barragan EV Wilson PC Psychedelics promote structural and functional neural plasticity Cell Rep. 2018 23 3170 82 10.1016/j.celrep.2018.05.022 29898390
Ly C, Greb AC, Cameron LP, Wong JM, Barragan EV, Wilson PC, et al. Psychedelics promote structural and functional neural plasticity. Cell Rep. 2018;23:3170–82. 10.1016/j.celrep.2018.05.022.29898390 10.1016/j.celrep.2018.05.022
188. Lin P-Y Ma ZZ Mahgoub M Kavalali ET Monteggia LM A synaptic locus for TrkB signaling underlying ketamine rapid antidepressant action Cell Rep. 2021 36 109513 10.1016/j.celrep.2021.109513 34407417
Lin P-Y, Ma ZZ, Mahgoub M, Kavalali ET, Monteggia LM. A synaptic locus for TrkB signaling underlying ketamine rapid antidepressant action. Cell Rep. 2021;36:109513. 10.1016/j.celrep.2021.109513.34407417 10.1016/j.celrep.2021.109513
189. Autry AE Adachi M Nosyreva E Na ES Los MF Cheng P-F NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses Nature 2011 475 91 5 10.1038/nature10130 21677641
Autry AE, Adachi M, Nosyreva E, Na ES, Los MF, Cheng P-F, et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature. 2011;475:91–5. 10.1038/nature10130.21677641 10.1038/nature10130
190. Nardou R Sawyer E Song YJ Wilkinson M Padovan-Hernandez Y de Deus JL Psychedelics reopen the social reward learning critical period Nature 2023 618 790 8 10.1038/s41586-023-06204-3 37316665
Nardou R, Sawyer E, Song YJ, Wilkinson M, Padovan-Hernandez Y, de Deus JL, et al. Psychedelics reopen the social reward learning critical period. Nature. 2023;618:790–8. 10.1038/s41586-023-06204-3.37316665 10.1038/s41586-023-06204-3
191. Jefsen OH Elfving B Wegener G Müller HK Transcriptional regulation in the rat prefrontal cortex and hippocampus after a single administration of psilocybin J Psychopharmacol 2021 35 483 93 10.1177/0269881120959614 33143539
Jefsen OH, Elfving B, Wegener G, Müller HK. Transcriptional regulation in the rat prefrontal cortex and hippocampus after a single administration of psilocybin. J Psychopharmacol. 2021;35:483–93. 10.1177/0269881120959614.33143539 10.1177/0269881120959614
192. Hibicke M Kramer HM Nichols CD A single administration of psilocybin persistently rescues cognitive deficits caused by adolescent chronic restraint stress without long-term changes in synaptic protein gene expression in a rat experimental system with translational relevance to depression Psychedelic Med 2023 1 54 67 10.1089/psymed.2022.0012
Hibicke M, Kramer HM, Nichols CD. A single administration of psilocybin persistently rescues cognitive deficits caused by adolescent chronic restraint stress without long-term changes in synaptic protein gene expression in a rat experimental system with translational relevance to depression. Psychedelic Med. 2023;1:54–67. 10.1089/psymed.2022.0012.10.1089/psymed.2022.0012
193. Ilchibaeva, T, Tsybko, A, Zeug, A, Müller, FE, Guseva, D, Bischoff, S, et al. Serotonin Receptor 5-HT2A Regulates TrkB Receptor Function in Heteroreceptor Complexes. Cells. 2022;11.
194. Philibert CE, Disdier C, Lafon P-A, Bouyssou A, Oosterlaken M, Galant S, et al. TrkB receptor interacts with mGlu2 receptor and mediates antipsychotic-like effects of mGlu2 receptor activation in the mouse. Sci Adv.;10 eadg1679. 10.1126/sciadv.adg1679
195. Moreno JL Miranda-Azpiazu P García-Bea A Younkin J Cui M Kozlenkov A Allosteric signaling through an mGlu2 and 5-HT2A heteromeric receptor complex and its potential contribution to schizophrenia Sci Signal 2016 9 ra5 10.1126/scisignal.aab0467 26758213
Moreno JL, Miranda-Azpiazu P, García-Bea A, Younkin J, Cui M, Kozlenkov A, et al. Allosteric signaling through an mGlu2 and 5-HT2A heteromeric receptor complex and its potential contribution to schizophrenia. Sci Signal. 2016;9:ra5. 10.1126/scisignal.aab0467.26758213 10.1126/scisignal.aab0467
196. Nafisi S Bonsaii M Maali P Khalilzadeh MA Manouchehri F Beta-carboline alkaloids bind DNA J Photochem Photobio B 2010 100 84 91 10.1016/j.jphotobiol.2010.05.005
Nafisi S, Bonsaii M, Maali P, Khalilzadeh MA, Manouchehri F. Beta-carboline alkaloids bind DNA. J Photochem Photobio B. 2010;100:84–91. 10.1016/j.jphotobiol.2010.05.005.10.1016/j.jphotobiol.2010.05.005
197. Wagner TE In vitro Interaction of LSD with Purified Calf Thymus DNA Nature 1969 222 1170 2 10.1038/2221170b0 5788983
Wagner TE. In vitro Interaction of LSD with Purified Calf Thymus DNA. Nature. 1969;222:1170–2. 10.1038/2221170b0.5788983 10.1038/2221170b0
198. Smythies JR Antun F Binding of tryptamine and allied compounds to nucleic acids Nature 1969 223 1061 3 10.1038/2231061a0 5811902
Smythies JR, Antun F. Binding of tryptamine and allied compounds to nucleic acids. Nature. 1969;223:1061–3. 10.1038/2231061a0.5811902 10.1038/2231061a0
199. Yielding KL Sterglanz H Lysergic acid diethylamide (LSD) binding to deoxyribonucleic acid (DNA) Proc Soc Exp Biol Med 1968 128 1096 8 10.3181/00379727-128-33303
Yielding KL, Sterglanz H. Lysergic acid diethylamide (LSD) binding to deoxyribonucleic acid (DNA). Proc Soc Exp Biol Med. 1968;128:1096–8. 10.3181/00379727-128-33303.10.3181/00379727-128-33303
200. Vargas MV Dunlap LE Dong C Carter SJ Tombari RJ Jami SA Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors Science 2023 379 700 6 10.1126/science.adf0435 36795823
Vargas MV, Dunlap LE, Dong C, Carter SJ, Tombari RJ, Jami SA, et al. Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors. Science. 2023;379:700–6. 10.1126/science.adf0435.36795823 10.1126/science.adf0435
201. Willins DL Berry SA Alsayegh L Backstrom JR Sanders-Bush E Friedman L Clozapine and other 5-hydroxytryptamine-2A receptor antagonists alter the subcellular distribution of 5-hydroxytryptamine-2A receptors in vitro and in vivo Neuroscience 1999 91 599 606 10.1016/s0306-4522(98)00653-8 10366017
Willins DL, Berry SA, Alsayegh L, Backstrom JR, Sanders-Bush E, Friedman L, et al. Clozapine and other 5-hydroxytryptamine-2A receptor antagonists alter the subcellular distribution of 5-hydroxytryptamine-2A receptors in vitro and in vivo. Neuroscience. 1999;91:599–606. 10.1016/s0306-4522(98)00653-8.10366017 10.1016/s0306-4522(98)00653-8
202. Bhatnagar A Willins DL Gray JA Woods J Benovic JL Roth BL The dynamin-dependent, arrestin-independent internalization of 5-hydroxytryptamine 2A (5-HT2A) serotonin receptors reveals differential sorting of arrestins and 5-HT2A receptors during endocytosis J Biol Chem 2001 276 8269 77 10.1074/jbc.M006968200 11069907
Bhatnagar A, Willins DL, Gray JA, Woods J, Benovic JL, Roth BL. The dynamin-dependent, arrestin-independent internalization of 5-hydroxytryptamine 2A (5-HT2A) serotonin receptors reveals differential sorting of arrestins and 5-HT2A receptors during endocytosis. J Biol Chem. 2001;276:8269–77. 10.1074/jbc.M006968200.11069907 10.1074/jbc.M006968200
203. Berry SA Shah MC Khan N Roth BL Rapid agonist-induced internalization of the 5-hydroxytryptamine2A receptor occurs via the endosome pathway in vitro Mol Pharm 1996 50 306 13
Berry SA, Shah MC, Khan N, Roth BL. Rapid agonist-induced internalization of the 5-hydroxytryptamine2A receptor occurs via the endosome pathway in vitro. Mol Pharm. 1996;50:306–13.
204. Frecska E Szabo A Winkelman MJ Luna LE McKenna DJ A possibly sigma-1 receptor mediated role of dimethyltryptamine in tissue protection, regeneration, and immunity J Neural Transm (Vienna) 2013 120 1295 303 10.1007/s00702-013-1024-y 23619992
Frecska E, Szabo A, Winkelman MJ, Luna LE, McKenna DJ. A possibly sigma-1 receptor mediated role of dimethyltryptamine in tissue protection, regeneration, and immunity. J Neural Transm (Vienna). 2013;120:1295–303. 10.1007/s00702-013-1024-y.23619992 10.1007/s00702-013-1024-y
205. Carbonaro TM Gatch MB Neuropharmacology of N,N-dimethyltryptamine Brain Res Bull 2016 126 74 88 10.1016/j.brainresbull.2016.04.016 27126737
Carbonaro TM, Gatch MB. Neuropharmacology of N,N-dimethyltryptamine. Brain Res Bull. 2016;126:74–88. 10.1016/j.brainresbull.2016.04.016.27126737 10.1016/j.brainresbull.2016.04.016
206. Fontanilla D Johannessen M Hajipour AR Cozzi NV Jackson MB Ruoho AE The hallucinogen N,N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator Science 2009 323 934 7 10.1126/science.1166127 19213917
Fontanilla D, Johannessen M, Hajipour AR, Cozzi NV, Jackson MB, Ruoho AE. The hallucinogen N,N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator. Science. 2009;323:934–7. 10.1126/science.1166127.19213917 10.1126/science.1166127
207. Tsai SY Chuang JY Tsai MS Wang XF Xi ZX Hung JJ Sigma-1 receptor mediates cocaine-induced transcriptional regulation by recruiting chromatin-remodeling factors at the nuclear envelope Proc Natl Acad Sci USA 2015 112 E6562 70 10.1073/pnas.1518894112 26554014
Tsai SY, Chuang JY, Tsai MS, Wang XF, Xi ZX, Hung JJ, et al. Sigma-1 receptor mediates cocaine-induced transcriptional regulation by recruiting chromatin-remodeling factors at the nuclear envelope. Proc Natl Acad Sci USA. 2015;112:E6562–70. 10.1073/pnas.1518894112.26554014 10.1073/pnas.1518894112
208. Chuang SM Lu JH Lin KL Long CY Lee YC Hsiao HP Epigenetic regulation of COX2 expression by DNA hypomethylation via NFkappaB activation in ketamineinduced ulcerative cystitis Int J Mol Med 2019 44 797 812 10.3892/ijmm.2019.4252 31257475
Chuang SM, Lu JH, Lin KL, Long CY, Lee YC, Hsiao HP, et al. Epigenetic regulation of COX2 expression by DNA hypomethylation via NFkappaB activation in ketamineinduced ulcerative cystitis. Int J Mol Med. 2019;44:797–812. 10.3892/ijmm.2019.4252.31257475 10.3892/ijmm.2019.4252
209. Jhang JF Hsu YH Jiang YH Kuo HC Elevated serum IgE may be associated with development of ketamine cystitis J Urol 2014 192 1249 56 10.1016/j.juro.2014.05.084 24859443
Jhang JF, Hsu YH, Jiang YH, Kuo HC. Elevated serum IgE may be associated with development of ketamine cystitis. J Urol. 2014;192:1249–56. 10.1016/j.juro.2014.05.084.24859443 10.1016/j.juro.2014.05.084
210. Fan X Bian W Liu M Li J Wang Y MiRNA-429 alleviates ketamine-induced neurotoxicity through targeting BAG5 Environ Toxicol 2021 36 620 7 10.1002/tox.23066 33283947
Fan X, Bian W, Liu M, Li J, Wang Y. MiRNA-429 alleviates ketamine-induced neurotoxicity through targeting BAG5. Environ Toxicol. 2021;36:620–7. 10.1002/tox.23066.33283947 10.1002/tox.23066
211. Li H Li K Zhu Q Tang Z Wang Z Transcriptomic analysis of bladder tissue in a rat model of ketamine-induced bladder fibrosis Neurourol Urodyn 2022 41 765 76 10.1002/nau.24892 35170809
Li H, Li K, Zhu Q, Tang Z, Wang Z. Transcriptomic analysis of bladder tissue in a rat model of ketamine-induced bladder fibrosis. Neurourol Urodyn. 2022;41:765–76. 10.1002/nau.24892.35170809 10.1002/nau.24892
212. Zeng F Wu Q Song M Kang X Ou Z Yang Z Circ-SFMBT2 sponges miR-224-5p to induce ketamine-induced cystitis by up-regulating metadherin (MTDH) Hum Cell 2023 36 2040 54 10.1007/s13577-023-00972-w 37642831
Zeng F, Wu Q, Song M, Kang X, Ou Z, Yang Z, et al. Circ-SFMBT2 sponges miR-224-5p to induce ketamine-induced cystitis by up-regulating metadherin (MTDH). Hum Cell. 2023;36:2040–54. 10.1007/s13577-023-00972-w.37642831 10.1007/s13577-023-00972-w
213. Li X Ma G Zhang C Chen M Huang X Gu C miR-34a overexpression protects against hippocampal neuron damage caused by ketamine-induced anesthesia in immature rats through the Notch-1/NF-κB signaling pathway Am J Transl Res 2021 13 13452 61 35035687
Li X, Ma G, Zhang C, Chen M, Huang X, Gu C. miR-34a overexpression protects against hippocampal neuron damage caused by ketamine-induced anesthesia in immature rats through the Notch-1/NF-κB signaling pathway. Am J Transl Res. 2021;13:13452–61.35035687
214. Chen Q, Yan J, Xie W, Xie W, Li M, Ye Y. LncRNA LINC00641 Sponges miR-497-5p to Ameliorate Neural Injury Induced by Anesthesia via up-regulating BDNF. Front. Mol. Neurosci. 2020;13. 10.3389/fnmol.2020.00095
215. Zhao X, Shu F, Wang X, Wang F, Wu L, Li L, et al. Inhibition of microRNA-375 ameliorated ketamine-induced neurotoxicity in human embryonic stem cell derived neurons. Eur J Pharmacol. 2019;844:56–64. 10.1016/j.ejphar.2018.11.035
216. Huang C-H Chang M-C Lai Y-C Lin C-Y Hsu C-H Tseng B-Y Mitochondrial DNA methylation profiling of the human prefrontal cortex and nucleus accumbens: correlations with aging and drug use Clin Epigenetics 2022 14 79 10.1186/s13148-022-01300-z 35752846
Huang C-H, Chang M-C, Lai Y-C, Lin C-Y, Hsu C-H, Tseng B-Y, et al. Mitochondrial DNA methylation profiling of the human prefrontal cortex and nucleus accumbens: correlations with aging and drug use. Clin Epigenetics. 2022;14:79. 10.1186/s13148-022-01300-z.35752846 10.1186/s13148-022-01300-z
217. Koczor CA Ludlow I Hight RS 2nd Jiao Z Fields E Ludaway T Ecstasy (MDMA) alters cardiac gene expression and DNA methylation: implications for circadian rhythm dysfunction in the heart Toxicol Sci 2015 148 183 91 10.1093/toxsci/kfv170 26251327
Koczor CA, Ludlow I, Hight RS 2nd, Jiao Z, Fields E, Ludaway T, et al. Ecstasy (MDMA) alters cardiac gene expression and DNA methylation: implications for circadian rhythm dysfunction in the heart. Toxicol Sci. 2015;148:183–91. 10.1093/toxsci/kfv170.26251327 10.1093/toxsci/kfv170
218. Yu Y Quan J Zou M Zhao W Su Y Xu Y Effects of ketamine-induced H3K9 hypoacetylation during pregnancy on cardiogenesis of mouse offspring Birth Defects Res 2023 115 770 81 10.1002/bdr2.2168 36899481
Yu Y, Quan J, Zou M, Zhao W, Su Y, Xu Y. Effects of ketamine-induced H3K9 hypoacetylation during pregnancy on cardiogenesis of mouse offspring. Birth Defects Res. 2023;115:770–81. 10.1002/bdr2.2168.36899481 10.1002/bdr2.2168
219. Tagen M Mantuani D van Heerden L Holstein A Klumpers LE Knowles R The risk of chronic psychedelic and MDMA microdosing for valvular heart disease J Psychopharmacol 2023 37 876 90 10.1177/02698811231190865 37572027
Tagen M, Mantuani D, van Heerden L, Holstein A, Klumpers LE, Knowles R. The risk of chronic psychedelic and MDMA microdosing for valvular heart disease. J Psychopharmacol. 2023;37:876–90. 10.1177/02698811231190865.37572027 10.1177/02698811231190865
220. Gemmel M Rayen I van Donkelaar E Loftus T Steinbusch HW Kokras N Gestational stress and fluoxetine treatment differentially affect plasticity, methylation and serotonin levels in the PFC and hippocampus of rat dams Neuroscience 2016 327 32 43 10.1016/j.neuroscience.2016.03.068 27060483
Gemmel M, Rayen I, van Donkelaar E, Loftus T, Steinbusch HW, Kokras N, et al. Gestational stress and fluoxetine treatment differentially affect plasticity, methylation and serotonin levels in the PFC and hippocampus of rat dams. Neuroscience. 2016;327:32–43. 10.1016/j.neuroscience.2016.03.068.27060483 10.1016/j.neuroscience.2016.03.068
221. Silva AS Toffoli LV Estrada VB Veríssimo LF Francis-Oliveira J Moreira EG Maternal exposure to fluoxetine during gestation and lactation induces long lasting changes in the DNA methylation profile of offspring’s brain and affects the social interaction of rat Brain Res Bull 2018 142 409 13 10.1016/j.brainresbull.2018.09.007 30236534
Silva AS, Toffoli LV, Estrada VB, Veríssimo LF, Francis-Oliveira J, Moreira EG, et al. Maternal exposure to fluoxetine during gestation and lactation induces long lasting changes in the DNA methylation profile of offspring’s brain and affects the social interaction of rat. Brain Res Bull. 2018;142:409–13. 10.1016/j.brainresbull.2018.09.007.30236534 10.1016/j.brainresbull.2018.09.007
222. Boulle F Pawluski JL Homberg JR Machiels B Kroeze Y Kumar N Developmental fluoxetine exposure increases behavioral despair and alters epigenetic regulation of the hippocampal BDNF gene in adult female offspring Hormones Behav 2016 80 47 57 10.1016/j.yhbeh.2016.01.017
Boulle F, Pawluski JL, Homberg JR, Machiels B, Kroeze Y, Kumar N, et al. Developmental fluoxetine exposure increases behavioral despair and alters epigenetic regulation of the hippocampal BDNF gene in adult female offspring. Hormones Behav. 2016;80:47–57. 10.1016/j.yhbeh.2016.01.017.10.1016/j.yhbeh.2016.01.017
223. Cheung HM Yew DTW Effects of perinatal exposure to ketamine on the developing brain Front Neurosci 2019 13 138 10.3389/fnins.2019.00138 30853884
Cheung HM, Yew DTW. Effects of perinatal exposure to ketamine on the developing brain. Front Neurosci. 2019;13:138. 10.3389/fnins.2019.00138.30853884 10.3389/fnins.2019.00138
224. Oliveira CDRD Moreira CQ Spinosa HDS Yonamine M Neurobehavioral, reflexological and physical development of Wistar rat offspring exposed to ayahuasca during pregnancy and lactation Rev Brasileira de Farmacogn 2011 21 1065 76 10.1590/S0102-695X2011005000170
Oliveira CDRD, Moreira CQ, Spinosa HDS, Yonamine M. Neurobehavioral, reflexological and physical development of Wistar rat offspring exposed to ayahuasca during pregnancy and lactation. Rev Brasileira de Farmacogn. 2011;21:1065–76.10.1590/S0102-695X2011005000170
225. Li C Tu G Luo C Guo Y Fang M Zhu C Effects of rhynchophylline on the hippocampal miRNA expression profile in ketamine-addicted rats Prog Neuro-Psychopharmacol Biol Psychiatry 2018 86 379 89 10.1016/j.pnpbp.2018.02.009
Li C, Tu G, Luo C, Guo Y, Fang M, Zhu C, et al. Effects of rhynchophylline on the hippocampal miRNA expression profile in ketamine-addicted rats. Prog Neuro-Psychopharmacol Biol Psychiatry. 2018;86:379–89. 10.1016/j.pnpbp.2018.02.009.10.1016/j.pnpbp.2018.02.009
226. De Luca MT Badiani A Ketamine self-administration in the rat: evidence for a critical role of setting Psychopharmacology 2011 214 549 56 10.1007/s00213-010-2062-x 21069515
De Luca MT, Badiani A. Ketamine self-administration in the rat: evidence for a critical role of setting. Psychopharmacology. 2011;214:549–56. 10.1007/s00213-010-2062-x.21069515 10.1007/s00213-010-2062-x
227. Schenk S Gittings D Johnstone M Daniela E Development, maintenance and temporal pattern of self-administration maintained by ecstasy (MDMA) in rats Psychopharmacology 2003 169 21 7 10.1007/s00213-003-1407-0 12774185
Schenk S, Gittings D, Johnstone M, Daniela E. Development, maintenance and temporal pattern of self-administration maintained by ecstasy (MDMA) in rats. Psychopharmacology. 2003;169:21–7. 10.1007/s00213-003-1407-0.12774185 10.1007/s00213-003-1407-0
228. Cole JC Sumnall HR O’Shea E Marsden CA Effects of MDMA exposure on the conditioned place preference produced by other drugs of abuse Psychopharmacology 2003 166 383 90 10.1007/s00213-002-1374-x 12601504
Cole JC, Sumnall HR, O’Shea E, Marsden CA. Effects of MDMA exposure on the conditioned place preference produced by other drugs of abuse. Psychopharmacology. 2003;166:383–90. 10.1007/s00213-002-1374-x.12601504 10.1007/s00213-002-1374-x
229. Bisagno V Cadet JL Histone Deacetylases and Immediate early genes: key players in psychostimulant-induced neuronal plasticity Neurotox Res 2021 39 2134 40 10.1007/s12640-021-00420-3 34581974
Bisagno V, Cadet JL. Histone Deacetylases and Immediate early genes: key players in psychostimulant-induced neuronal plasticity. Neurotox Res. 2021;39:2134–40. 10.1007/s12640-021-00420-3.34581974 10.1007/s12640-021-00420-3
230. Wong CCY Mill J Fernandes C Drugs and addiction: an introduction to epigenetics Addiction 2011 106 480 9 10.1111/j.1360-0443.2010.03321.x 21205049
Wong CCY, Mill J, Fernandes C. Drugs and addiction: an introduction to epigenetics. Addiction. 2011;106:480–9. 10.1111/j.1360-0443.2010.03321.x.21205049 10.1111/j.1360-0443.2010.03321.x
231. Li H Li C Zhou Y Luo C Ou J Li J Expression of microRNAs in the serum exosomes of methamphetamine-dependent rats vs. ketamine-dependent rats Exp Ther Med 2018 15 3369 75 10.3892/etm.2018.5814 29545857
Li H, Li C, Zhou Y, Luo C, Ou J, Li J, et al. Expression of microRNAs in the serum exosomes of methamphetamine-dependent rats vs. ketamine-dependent rats. Exp Ther Med. 2018;15:3369–75. 10.3892/etm.2018.5814.29545857 10.3892/etm.2018.5814
232. Caputi FF Palmisano M Carboni L Candeletti S Romualdi P Opioid gene expression changes and post-translational histone modifications at promoter regions in the rat nucleus accumbens after acute and repeated 3,4-methylenedioxy-methamphetamine (MDMA) exposure Pharm Res 2016 114 209 18 10.1016/j.phrs.2016.10.023
Caputi FF, Palmisano M, Carboni L, Candeletti S, Romualdi P. Opioid gene expression changes and post-translational histone modifications at promoter regions in the rat nucleus accumbens after acute and repeated 3,4-methylenedioxy-methamphetamine (MDMA) exposure. Pharm Res. 2016;114:209–18. 10.1016/j.phrs.2016.10.023.10.1016/j.phrs.2016.10.023
233. Mithoefer MC Mithoefer AT Feduccia AA Jerome L Wagner M Wymer J 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial Lancet Psychiatry 2018 5 486 97 10.1016/S2215-0366(18)30135-4 29728331
Mithoefer MC, Mithoefer AT, Feduccia AA, Jerome L, Wagner M, Wymer J, et al. 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. Lancet Psychiatry. 2018;5:486–97. 10.1016/S2215-0366(18)30135-4.29728331 10.1016/S2215-0366(18)30135-4
234. Lyles J Cadet JL Methylenedioxymethamphetamine (MDMA, Ecstasy) neurotoxicity: cellular and molecular mechanisms Brain Res Brain Res Rev 2003 42 155 68 10.1016/s0165-0173(03)00173-5 12738056
Lyles J, Cadet JL. Methylenedioxymethamphetamine (MDMA, Ecstasy) neurotoxicity: cellular and molecular mechanisms. Brain Res Brain Res Rev. 2003;42:155–68. 10.1016/s0165-0173(03)00173-5.12738056 10.1016/s0165-0173(03)00173-5
235. Valvassori SS da Rosa RT Dal-Pont GC Varela RB Mastella GA Daminelli T Haloperidol alters neurotrophic factors and epigenetic parameters in an animal model of schizophrenia induced by ketamine Int J Dev Neurosci 2023 83 691 702 10.1002/jdn.10296 37635268
Valvassori SS, da Rosa RT, Dal-Pont GC, Varela RB, Mastella GA, Daminelli T, et al. Haloperidol alters neurotrophic factors and epigenetic parameters in an animal model of schizophrenia induced by ketamine. Int J Dev Neurosci. 2023;83:691–702. 10.1002/jdn.10296.37635268 10.1002/jdn.10296
236. Cao S-E Tian J Chen S Zhang X Zhang Y Role of miR-34c in ketamine-induced neurotoxicity in neonatal mice hippocampus Cell Biol Int 2015 39 164 8 10.1002/cbin.10349 25052764
Cao S-E, Tian J, Chen S, Zhang X, Zhang Y. Role of miR-34c in ketamine-induced neurotoxicity in neonatal mice hippocampus. Cell Biol Int. 2015;39:164–8. 10.1002/cbin.10349.25052764 10.1002/cbin.10349
237. Xu H Zhang J Zhou W Feng Y Teng S Song X The role of miR-124 in modulating hippocampal neurotoxicity induced by ketamine anesthesia Int J Neurosci 2015 125 213 20 10.3109/00207454.2014.919915 24825585
Xu H, Zhang J, Zhou W, Feng Y, Teng S, Song X. The role of miR-124 in modulating hippocampal neurotoxicity induced by ketamine anesthesia. Int J Neurosci. 2015;125:213–20. 10.3109/00207454.2014.919915.24825585 10.3109/00207454.2014.919915
238. Huang C Zhang X Zheng J Chen C Chen Y Yi J Upregulation of miR-137 protects anesthesia-induced hippocampal neurodegeneration Int J Clin Exp Pathol 2014 7 5000 7 25197371
Huang C, Zhang X, Zheng J, Chen C, Chen Y, Yi J. Upregulation of miR-137 protects anesthesia-induced hippocampal neurodegeneration. Int J Clin Exp Pathol. 2014;7:5000–7.25197371
239. Yan J Yu Y Sun Y Hu R Jiang H Ketamine induces neuronal apoptosis and cognitive disorder via miR-199a-5p/HIF-1α in neonatal rats Mol Cell Toxicol 2017 13 395 404 10.1007/s13273-017-0044-3
Yan J, Yu Y, Sun Y, Hu R, Jiang H. Ketamine induces neuronal apoptosis and cognitive disorder via miR-199a-5p/HIF-1α in neonatal rats. Mol Cell Toxicol. 2017;13:395–404. 10.1007/s13273-017-0044-3.10.1007/s13273-017-0044-3
240. Wang J Zhou M Wang X Yang X Wang M Zhang C Impact of ketamine on learning and memory function, neuronal apoptosis and its potential association with miR-214 and PTEN in adolescent rats PLoS ONE 2014 9 e99855 10.1371/journal.pone.0099855 24914689
Wang J, Zhou M, Wang X, Yang X, Wang M, Zhang C, et al. Impact of ketamine on learning and memory function, neuronal apoptosis and its potential association with miR-214 and PTEN in adolescent rats. PLoS ONE. 2014;9:e99855. 10.1371/journal.pone.0099855.24914689 10.1371/journal.pone.0099855
241. Jiang XL Du BX Chen J Liu L Shao WB Song J MicroRNA-34a negatively regulates anesthesia-induced hippocampal apoptosis and memory impairment through FGFR1 Int J Clin Exp Pathol 2014 7 6760 7 25400756
Jiang XL, Du BX, Chen J, Liu L, Shao WB, Song J. MicroRNA-34a negatively regulates anesthesia-induced hippocampal apoptosis and memory impairment through FGFR1. Int J Clin Exp Pathol. 2014;7:6760–7.25400756
242. Li X-J Yu J-H Wu X Zhu X-M Lv P Du Z Ketamine enhances dopamine D1 receptor expression by modulating microRNAs in a ketamine-induced schizophrenia-like mouse model Neurotoxicology Teratol 2022 91 107079 10.1016/j.ntt.2022.107079
Li X-J, Yu J-H, Wu X, Zhu X-M, Lv P, Du Z, et al. Ketamine enhances dopamine D1 receptor expression by modulating microRNAs in a ketamine-induced schizophrenia-like mouse model. Neurotoxicology Teratol. 2022;91:107079. 10.1016/j.ntt.2022.107079.10.1016/j.ntt.2022.107079
243. Yao Y Wang X Gao J LncRNA KCNQ1OT1 sponges miR-206 to ameliorate neural injury induced by anesthesia via up-regulating BDNF Drug Des Dev Ther 2020 14 4789 4800 10.2147/DDDT.S256319
Yao Y, Wang X, Gao J. LncRNA KCNQ1OT1 sponges miR-206 to ameliorate neural injury induced by anesthesia via up-regulating BDNF. Drug Des Dev Ther. 2020;14:4789–4800. 10.2147/DDDT.S256319.10.2147/DDDT.S256319
244. Li X Saiyin H Chen X Yu Q Ma L Liang W Ketamine impairs growth cone and synaptogenesis in human GABAergic projection neurons via GSK-3β and HDAC6 signaling Mol Psychiatry 2022 10.1038/s41380-022-01864-5 36577844
Li X, Saiyin H, Chen X, Yu Q, Ma L, Liang W. Ketamine impairs growth cone and synaptogenesis in human GABAergic projection neurons via GSK-3β and HDAC6 signaling. Mol Psychiatry. 2022. 10.1038/s41380-022-01864-5.36577844 10.1038/s41380-022-01864-5
245. Julie E Sarah LT Avin V Janette B Collin C Jeanine J HDAC6 regulates glucocorticoid receptor signaling in serotonin pathways with critical impact on stress resilience J Neurosci 2012 32 4400 10.1523/JNEUROSCI.5634-11.2012 22457490
Julie E, Sarah LT, Avin V, Janette B, Collin C, Jeanine J, et al. HDAC6 regulates glucocorticoid receptor signaling in serotonin pathways with critical impact on stress resilience. J Neurosci. 2012;32:4400. 10.1523/JNEUROSCI.5634-11.2012.22457490 10.1523/JNEUROSCI.5634-11.2012
246. Pang X Su Z Sun Y Zhang W Wang H Long noncoding RNA SNHG16 reduced ketamine-induced neurotoxicity in human embryonic stem cell-derived neurons J Chem Neuroanat 2018 94 39 45 10.1016/j.jchemneu.2018.08.005 30171995
Pang X, Su Z, Sun Y, Zhang W, Wang H. Long noncoding RNA SNHG16 reduced ketamine-induced neurotoxicity in human embryonic stem cell-derived neurons. J Chem Neuroanat. 2018;94:39–45. 10.1016/j.jchemneu.2018.08.005.30171995 10.1016/j.jchemneu.2018.08.005
247. Jiang JD Zheng XC Huang FY Gao F You MZ Zheng T MicroRNA-107 regulates anesthesia-induced neural injury in embryonic stem cell derived neurons IUBMB Life 2019 71 20 7 10.1002/iub.1911 30308117
Jiang JD, Zheng XC, Huang FY, Gao F, You MZ, Zheng T. MicroRNA-107 regulates anesthesia-induced neural injury in embryonic stem cell derived neurons. IUBMB Life. 2019;71:20–7. 10.1002/iub.1911.30308117 10.1002/iub.1911
248. Li X Saiyin H Zhou J-H Yu Q Liang W-M HDAC6 is critical for ketamine-induced impairment of dendritic and spine growth in GABAergic projection neurons Acta Pharmacol Sin 2021 42 861 70 10.1038/s41401-020-00521-3 32939037
Li X, Saiyin H, Zhou J-H, Yu Q, Liang W-M. HDAC6 is critical for ketamine-induced impairment of dendritic and spine growth in GABAergic projection neurons. Acta Pharmacol Sin. 2021;42:861–70. 10.1038/s41401-020-00521-3.32939037 10.1038/s41401-020-00521-3
249. Wang X-S Li L-C Zhang X Gao J Lipoxin A4 methyl ester protects PC12 cells from ketamine-induced neurotoxicity via the miR-22/BAG5 pathway Hum Exp Toxicol 2021 40 S519 S529 10.1177/09603271211051602 34670429
Wang X-S, Li L-C, Zhang X, Gao J. Lipoxin A4 methyl ester protects PC12 cells from ketamine-induced neurotoxicity via the miR-22/BAG5 pathway. Hum Exp Toxicol. 2021;40:S519–S529. 10.1177/09603271211051602.34670429 10.1177/09603271211051602
250. Huang J Xu Y Wang F Wang H Li L Deng Y Long Noncoding RNA SPRY4-IT1 modulates Ketamine-induced neurotoxicity in human embryonic stem cell-derived neurons through EZH2 Dev Neurosci 2021 43 9 17 10.1159/000513535 33827085
Huang J, Xu Y, Wang F, Wang H, Li L, Deng Y, et al. Long Noncoding RNA SPRY4-IT1 modulates Ketamine-induced neurotoxicity in human embryonic stem cell-derived neurons through EZH2. Dev Neurosci. 2021;43:9–17. 10.1159/000513535.33827085 10.1159/000513535
251. Zheng X Lin C Li Y Ye J Zhou J Guo P Long noncoding RNA BDNF-AS regulates ketamine-induced neurotoxicity in neural stem cell derived neurons Biomed Pharmacother 2016 82 722 8 10.1016/j.biopha.2016.05.050 27470416
Zheng X, Lin C, Li Y, Ye J, Zhou J, Guo P. Long noncoding RNA BDNF-AS regulates ketamine-induced neurotoxicity in neural stem cell derived neurons. Biomed Pharmacother. 2016;82:722–8. 10.1016/j.biopha.2016.05.050.27470416 10.1016/j.biopha.2016.05.050
252. Meng L Liu B Ji R Jiang X Yan X Xin Y Targeting the BDNF/TrkB pathway for the treatment of tumors Oncol Lett 2019 17 2031 9 10.3892/ol.2018.9854 30675270
Meng L, Liu B, Ji R, Jiang X, Yan X, Xin Y. Targeting the BDNF/TrkB pathway for the treatment of tumors. Oncol Lett. 2019;17:2031–9. 10.3892/ol.2018.9854.30675270 10.3892/ol.2018.9854
253. Zou Z Tao T Li H Zhu X mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges Cell Biosci 2020 10 31 10.1186/s13578-020-00396-1 32175074
Zou Z, Tao T, Li H, Zhu X. mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges. Cell Biosci. 2020;10:31. 10.1186/s13578-020-00396-1.32175074 10.1186/s13578-020-00396-1
254. Griffiths RR Johnson MW Carducci MA Umbricht A Richards WA Richards BD Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial J Psychopharmacol 2016 30 1181 97 10.1177/0269881116675513 27909165
Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol. 2016;30:1181–97.27909165 10.1177/0269881116675513
255. Holze F Gasser P Müller F Dolder PC Liechti ME Lysergic acid diethylamide–assisted therapy in patients with anxiety with and without a life-threatening illness: a randomized, double-blind, placebo-controlled phase II study Biol Psychiatry 2023 93 215 23 10.1016/j.biopsych.2022.08.025 36266118
Holze F, Gasser P, Müller F, Dolder PC, Liechti ME. Lysergic acid diethylamide–assisted therapy in patients with anxiety with and without a life-threatening illness: a randomized, double-blind, placebo-controlled phase II study. Biol Psychiatry. 2023;93:215–23.36266118 10.1016/j.biopsych.2022.08.025
256. Agin-Liebes GI Malone T Yalch MM Mennenga SE Ponté KL Guss J Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer J Psychopharmacol 2020 34 155 66 10.1177/0269881119897615 31916890
Agin-Liebes GI, Malone T, Yalch MM, Mennenga SE, Ponté KL, Guss J, et al. Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. J Psychopharmacol. 2020;34:155–66.31916890 10.1177/0269881119897615
257. Feinberg AP Gehrke CW Kuo KC Ehrlich M Reduced genomic 5-methylcytosine content in human colonic neoplasia Cancer Res 1988 48 1159 61 3342396
Feinberg AP, Gehrke CW, Kuo KC, Ehrlich M. Reduced genomic 5-methylcytosine content in human colonic neoplasia. Cancer Res. 1988;48:1159–61.3342396
258. Howard G Eiges R Gaudet F Jaenisch R Eden A Activation and transposition of endogenous retroviral elements in hypomethylation induced tumors in mice Oncogene 2008 27 404 8 10.1038/sj.onc.1210631 17621273
Howard G, Eiges R, Gaudet F, Jaenisch R, Eden A. Activation and transposition of endogenous retroviral elements in hypomethylation induced tumors in mice. Oncogene. 2008;27:404–8. 10.1038/sj.onc.1210631.17621273 10.1038/sj.onc.1210631
259. Schuebel KE Chen W Cope L Glöckner SC Suzuki H Yi J-M Comparing the DNA hypermethylome with gene mutations in human colorectal cancer PLoS Genet 2007 3 e157 10.1371/journal.pgen.0030157 17892325
Schuebel KE, Chen W, Cope L, Glöckner SC, Suzuki H, Yi J-M, et al. Comparing the DNA hypermethylome with gene mutations in human colorectal cancer. PLoS Genet. 2007;3:e157. 10.1371/journal.pgen.0030157.17892325 10.1371/journal.pgen.0030157
260. Wojtas A, Bysiek A, Wawrzczak-Bargiela A, Szych Z, Majcher-Maślanka I, Herian M, et al. Effect of psilocybin and ketamine on brain neurotransmitters, glutamate receptors, DNA and rat behavior. Int J Mol Sci. 2022;23.
261. Barnett BS Ziegler K Doblin R Carlo AD Is psychedelic use associated with cancer?: Interrogating a half-century-old claim using contemporary population-level data J Psychopharmacol 2022 36 1118 28 10.1177/02698811221117536 35971893
Barnett BS, Ziegler K, Doblin R, Carlo AD. Is psychedelic use associated with cancer?: Interrogating a half-century-old claim using contemporary population-level data. J Psychopharmacol. 2022;36:1118–28. 10.1177/02698811221117536.35971893 10.1177/02698811221117536
262. Simonsson O Hendricks PS Carhart-Harris R Kettner H Osika W Association between lifetime classic psychedelic use and hypertension in the past year Hypertension 2021 77 1510 6 10.1161/hypertensionaha.120.16715 33677982
Simonsson O, Hendricks PS, Carhart-Harris R, Kettner H, Osika W. Association between lifetime classic psychedelic use and hypertension in the past year. Hypertension. 2021;77:1510–6. 10.1161/hypertensionaha.120.16715.33677982 10.1161/hypertensionaha.120.16715
263. He G-N Bao N-R Wang S Xi M Zhang T-H Chen F-S Ketamine induces ferroptosis of liver cancer cells by targeting lncRNA PVT1/miR-214-3p/GPX4 Drug Des Dev Ther 2021 15 3965 78 10.2147/DDDT.S332847
He G-N, Bao N-R, Wang S, Xi M, Zhang T-H, Chen F-S. Ketamine induces ferroptosis of liver cancer cells by targeting lncRNA PVT1/miR-214-3p/GPX4. Drug Des Dev Ther. 2021;15:3965–78. 10.2147/DDDT.S332847.10.2147/DDDT.S332847
264. Jakovcevski M Akbarian S Di Benedetto B Pharmacological modulation of astrocytes and the role of cell type-specific histone modifications for the treatment of mood disorders Curr Opin Pharm 2016 26 61 6 10.1016/j.coph.2015.10.002
Jakovcevski M, Akbarian S, Di Benedetto B. Pharmacological modulation of astrocytes and the role of cell type-specific histone modifications for the treatment of mood disorders. Curr Opin Pharm. 2016;26:61–6. 10.1016/j.coph.2015.10.002.10.1016/j.coph.2015.10.002
265. Filošević Vujnović A Stanković Matić I Saftić Martinović L Dević Pavlić S Breaking the chains: advances in substance addiction research through single-cell sequencing, epigenetics, and epitranscriptomic Future Pharm 2024 4 115 38 10.3390/futurepharmacol4010009
Filošević Vujnović A, Stanković Matić I, Saftić Martinović L, Dević Pavlić S. Breaking the chains: advances in substance addiction research through single-cell sequencing, epigenetics, and epitranscriptomic. Future Pharm. 2024;4:115–38.10.3390/futurepharmacol4010009
266. Engelmann J Zillich L Frank J Wagner S Cetin M Herzog DP Epigenetic signatures in antidepressant treatment response: a methylome-wide association study in the EMC trial Transl Psychiatry 2022 12 268 10.1038/s41398-022-02032-7 35794104
Engelmann J, Zillich L, Frank J, Wagner S, Cetin M, Herzog DP, et al. Epigenetic signatures in antidepressant treatment response: a methylome-wide association study in the EMC trial. Transl Psychiatry. 2022;12:268. 10.1038/s41398-022-02032-7.35794104 10.1038/s41398-022-02032-7
267. Hartogsohn I Set and setting, psychedelics and the placebo response: an extra-pharmacological perspective on psychopharmacology J Psychopharmacol 2016 30 1259 67 10.1177/0269881116677852 27852960
Hartogsohn I. Set and setting, psychedelics and the placebo response: an extra-pharmacological perspective on psychopharmacology. J Psychopharmacol. 2016;30:1259–67. 10.1177/0269881116677852.27852960 10.1177/0269881116677852
268. Andersen PR Gibbs P Kubinski H Effects of neuropharmacological agents on in vitro formation of complexes between nucleic acids and proteins Neuropharmacology 1974 13 111 7 10.1016/0028-3908(74)90028-8 4595677
Andersen PR, Gibbs P, Kubinski H. Effects of neuropharmacological agents on in vitro formation of complexes between nucleic acids and proteins. Neuropharmacology. 1974;13:111–7. 10.1016/0028-3908(74)90028-8.4595677 10.1016/0028-3908(74)90028-8
